Xxxxxxxx Xxxxxx 2000/32/ES
ze xxx 19. xxxxxx 2000,
xxxxxx xx xx xxxxxxx xxxxx přizpůsobuje xxxxxxxxxxx xxxxxxx xxxxxxxx Xxxx 67/548/XXX x xxxxxxxxxx xxxxxxxx x xxxxxxxxx předpisů xxxxxxxxxx xx xxxxxxxxxxx, balení x označování xxxxxxxxxxxx xxxxx [1]
(Xxxx s xxxxxxxx xxx XXX)
XXXXXX XXXXXXXXXX XXXXXXXXXXXX,
x xxxxxxx xx Xxxxxxx x xxxxxxxx Evropského xxxxxxxxxxxx,
x xxxxxxx xx xxxxxxxx Xxxx 67/548/XXX ze xxx 27. xxxxxx 1967 o sbližování xxxxxxxx x správních xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx, balení x xxxxxxxxxx nebezpečných xxxxx [2], xxxxxxxxx xxxxxxxxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 1999/33/XX [3], a xxxxxxx xx xxxxxx 28 xxxxxxx směrnice,
vzhledem k xxxxx důvodům:
(1) Xxxxxxx X xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxxxxxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxx xxxxx x xxxxxxxxxxx x xxxxxxxxxx xxxxx xxxxx. Xxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxx, že xx xxx xxx xxxxxx xxxxxxxxxxxx xxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxx oddílů xxxxxxxxx x xxxxxxx X v xxxxxxx X.
(2) Xxxxxxx III xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx vět xxxxxxxxxxx xxxxxx zvláštních xxxxx xxxxxxxxx x nebezpečnými xxxxxxx x xxxxxxxxx. Xxxxxxx XX směrnice 67/548/XXX obsahuje xxxxxx xxx x bezpečnostními xxxxxx xxxxxxxxxx se xxxxxxxxxxxx xxxxx a xxxxxxxxx. Příloha XX xxxxxxxx 67/548/EHS xxxxxxxx xxxxx xx klasifikaci x x označování xxxxxxxxxxxx xxxxx a xxxxxxxxx. Xxxxxxx xxxxxxxx xxxxx směrnice xxxxxxxx xxxxxx xxxxxxxx xxxxxx xxxxxx XXX, IV x XX.
(3) X xxxxxxx V směrnice 67/548/XXX se stanoví xxxxxx pro xxxxxxxxx xxxxxxxxx-xxxxxxxxxx xxxxxxxxxx, toxicity x xxxxxxxxxxx xxxxx x xxxxxxxxx. Xx xxxxxxxx xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxx xxxxxxx.
(4) Xxxxxxx XX směrnice 67/548/XXX xxxxxxxx xxxxxxxx xxxxxxxx se uzávěrů xxxxxxxx xxxxx otevření xxxxx. Xxxx xxxxxxxx xx xxxx xxx xxxxxxxxxxxx x xxxxxxxxxxxxx. Xx xxxxxxxx rozšířit xxxxxx, xxx se xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxxxx.
(5) Xxxxxxxx xxxx xxxxxxxx xxxx x xxxxxxx xx stanoviskem Xxxxxx xxx přizpůsobení xxxxxxxxxxx xxxxxxx xxxxxxx pro xxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xx xxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxx,
XXXXXXX XXXX XXXXXXXX:
Xxxxxx 1
Xxxxxxxx 67/548/XXX xx xxxx xxxxx:
1. Xxxxxxx X xx xxxx takto:
a) odpovídající xxxxxxxx x předmluvě xx xxxxxxxxx xxxxxxxxx X v xxxxxxx 1X xxxx xxxxxxxx;
x) xxxxxxxxxxxx xxxxx v xxxxxxx X xx xxxxxxxxx xxxxx x xxxxxxx 1B této xxxxxxxx;
x) xxxxxxxxxxxx položky xx xxxxxxxxx xxxxxxxxx x xxxxxxx 1C xxxx xxxxxxxx;
x) xxxxxxxx xx xxxxxxx v xxxxxxx 1X xxxx xxxxxxxx.
2. Xxxxxxxxxxxx xxxx x xxxxxxx XXX xx nahrazuje xxxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxx 2 xxxx směrnice.
3. Xxxxxxx IV xx xxxx xxxxx:
x) xxxxxxxxxxxx xxxxxx x příloze XX xx xxxxxxxxx xxxxxxxxxxxx pokyny pro xxxxxxxx xxxxxxxxx x xxxxxxx 3X xxxx xxxxxxxx;
x) xxxxxxxxxxxx xxxxxx x xxxxxxx XX xx nahrazují xxxxxxxxxxxxx xxxxxxxxxxxx pokyny xxx xxxxxxxx zacházení v xxxxxxx 3X xxxx xxxxxxxx.
4. Xxxx X xxxxxxx V xx xxxx xxxxx:
x) xxxxxxxx X.10 xx nahrazuje xxxxxx v xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx B.11 xx xxxxxxxxx textem x xxxxxxx 4X xxxx xxxxxxxx;
x) kapitola X.12 xx xxxxxxxxx textem x xxxxxxx 4C xxxx směrnice;
d) kapitoly X.13 x X.14 xx xxxxxxxxx textem x xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx X.17 xx xxxxxxxxx xxxxxx v xxxxxxx 4X xxxx směrnice;
f) xxxxxxxx B.23 xx xxxxxxxxx xxxxxx v xxxxxxx 4X této xxxxxxxx. Xxxxx xxxxxxxx X.23 xx xxxxxxxxxxx xx xxxx odpovídajícím xxxxxxxx;
x) vkládá xx xxxx x xxxxxxx 4X této xxxxxxxx.
5. Xxxxxxx se xxxxxx xxxxxxx xxxxxxxx xxxxx x xxxxx X xxxxxxx X.
6. Xxxxxxxxxxxx xxxxx x příloze XX xx xxxxxxxxx xxxxx v xxxxxxx 5 této xxxxxxxx.
7. Xxxxxxx IX se xxxx xxxxxxxx xxxxxxxx x xxxxxxx 6 xxxx směrnice.
Článek 2
1. Členské xxxxx xxxxxx x xxxxxxxx xxxxxx a xxxxxxx xxxxxxxx xxxxxxxx xxx xxxxxxxx souladu x touto směrnicí xxxxxxxxxx xx 1. xxxxxx 2001. Xxxxxxxxxx x nich xxxxxxx Xxxxxx.
Xxxx xxxxxxxx xxxxxxx xxxxxxxxx státy xxxx xxxxxxxxx xxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxx xxxxx xxx xxxxxx při xxxxxx xxxxxxx vyhlášení. Xxxxxx xxxxxx xx xxxxxxx členské xxxxx.
2. Xxxxxxx xxxxx sdělí Xxxxxx xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx právních xxxxxxxx, xxxxx přijmou x xxxxxxx xxxxxxxxxx xxxx xxxxxxxx, x xxxxxxxxxx xxxxxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxx ustanoveními.
Xxxxxx 3
Tato xxxxxxxx xxxxxxxx x platnost xxxxxx dnem xx xxxxxxxxx v Xxxxxxx xxxxxxxx Evropských xxxxxxxxxxxx.
Xxxxxx 4
Tato xxxxxxxx xx xxxxxx xxxxxxxx xxxxxx.
X Xxxxxxx dne 19. května 2000.
Xx Xxxxxx
Xxxxxx Xxxxxxxöx
xxxxxx Komise
[1] Xxxxxxx xx xxxxxxxxxxxx xx xxxxxxx xxxxx.
[2] Xx. xxxx. 196, 16.8.1967, x. 1.
[3] Úř. věst. X 199, 30.7.1999, x. 57.
XXXXXXX 1X
XXXXXXXXX X XXXXXXX X
Xxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx, xxxxxxxxxxx a označování xxxxx
(Xxxxxx xx českého xxxxx)
XXXXXXX 1X
"XXXXXXX A
|
Z |
Symbol |
ES |
DA |
DE |
EL |
EN |
FI |
FR |
IT |
NL |
PT |
SV |
|
18 |
Ar |
Argón |
Argon |
Argon |
Αργό |
Argon |
Argon |
Argon |
Argon |
Argon |
Árgon |
Argon |
|
64 |
Gd |
Gadolinio |
Gadolinium |
Gadolinium |
Γαδολίνιο |
Gadolinium |
Gadolinium |
Gadolinium |
Gadolinio |
Gadolinium |
Gadolínio |
Gadolinium" |
PŘÍLOHA 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx k xxxxxx |
Xxxxx XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
|
006–011–00–7 |
xxxxxxxx (XXX) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. xxx. 3; X40 Xx; X22 X; R50 |
Xn; N X: 22–40–50 S: (2-)22–24–36/37–46–61 |
|||
|
006–013–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx |
205–293–0 |
137–42–8 |
Xx; X22 X31 X; X34 X43 X; X50–53 |
X; X R: 22–31–34–43–50/53 X: (1/2-)26–36/37/39–45–60–61 |
|||
|
006–015–00–9 |
diuron (XXX) 3-(3,4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
206–354–4 |
330–54–1 |
Xxxx. xxx. 3; R40 Xxxx. xxx. 3; R40 Xx; X22–48/22 X; X50–53 |
Xx; N X: 22–40–48/22–50/53 S: (2-)13–22–23–37–46–60–61 |
|||
|
006–016–00–4 |
propoxur (XXX) 2- isopropoxyfenyl-N-methylkarbamát |
204–043–8 |
114–26–1 |
T; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–017–00-X |
xxxxxxxx (ISO) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 X; X24 N; X50–53 |
X+; X X: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–018–00–5 |
aminokarb (XXX) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; X24/25 X; X50–53 |
X; X X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–019–00–0 |
di-allát (XXX) X-(2,3-xxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–961–1 |
2303–16–4 |
Xxxx. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
|
006–020–00–6 |
xxxxxx (XXX) 4-xxxxxxxx-2-xx-1-xx-X -(3-xxxxxxxxxx)xxxxxxxx |
202–930–4 |
101–27–9 |
Xx; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
|
006–023–00–2 |
xxxxxxxxxxxxxxxx (ISO) xxxxxxxxxx 3,5-xxxxxxxx-4-(xxxxxxxxxxxxxx)xxxxx-X -xxxxxxxxxxxxxx |
217–991–2 |
2032–65–7 |
X; X25 N; X50–53 |
X; X R: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
|
006–024–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; R22 Xx; X38 N; X51–53 |
Xx; X X: 22–38–51/53 X: (2-)13-61 |
|||
|
006–026–00–9 |
karbofuran (XXX) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; R26/28 N; X50–53 |
X+; X X: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–028–00-X |
xxxxxxxxx (XXX) 2-(1-xxxxxxxxxxxx)-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx 2-xxx-xxxxx-4,6-xxxxxxxxxxxx-xxxxxxxxx-xxxxxxxx |
213–546–1 |
973–21–7 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–029–00–5 |
dioxakarb (XXX) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; X25 N; X51–53 |
X; X R: 25–51/53 X: (1/2-)37–45–61 |
|||
|
006–033–00–7 |
xxxxxxxxx (XXX) 3-(3-chlor-4-methoxyfenyl)-1,1-dimethylmočovina |
243–433–2 |
19937–59–8 |
N; X50–53 |
X X: 5 0/ 5 3 S: 60-61 |
|||
|
006–034–00–2 |
xxxxxxx (ISO) X-xxxxxx-X-xxxxx-X-xxxxxxxxxxxxxxxxx |
214–215–4 |
1114–71–2 |
Xx; X22 X; X51–53 |
Xx; X R: 22–51/53 X: (2-)23-61 |
|||
|
006–035–00–8 |
xxxxxxxxxx (ISO) 2-(xxxxxxxxxxxxx)- 5,6-xxxxxxxx xxxxxxxxx-4-xx-X,X-xxxxxxxxxxxxxxxx |
245–430–1 |
23103–98–2 |
X; X25 X; R50–53 |
T; X X: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
|
006–037–00–9 |
xxxxxxxxx (XXX) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; R25 X; X50–53 |
X; N X: 25–50/53 X: (1/2-)24–37–45–60–61 |
|||
|
006–038–00–4 |
sulfallát (XXX) 2-xxxxxxxxxx-X,X-xxxxxxxxxxxxxxxxxxxxxx |
X |
202–388–9 |
95–06–7 |
Xxxx. xxx. 2; R45 Xn; X22 X; X50–53 |
X; X R: 45–22–50/53 X: 53–45–60–61 |
||
|
006–039–00-X |
xxx-xxxxx (XXX) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; X22–48/22 X43 X; X50–53 |
Xx; X X: 22–43–48/22–50/53 X: (2-)24–37–60–61 |
|||
|
006–042–00–6 |
xxxxxxx (XXX) 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
205–766–1 |
150–68–5 |
Xxxx. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; X R: 22–40–50/53 X: (2-)36/37–60–61 |
|||
|
006–043–00–1 |
xxxxxxx-XXX 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; X36/38 Xxxx. xxx. 3; X40 X; X50–53 |
Xx; X X: 36/38–40–50/53 S: (2-)36/37–60–61 |
|||
|
006–045–00–2 |
xxxxxxxx (XXX) methyl-N-[(N-methylkarbamoyl)oxy]thioacetimidát |
240–815–0 |
16752–77–5 |
T+; X28 X; R50–53 |
T+; X X: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–046–00–8 |
bendiokarb (XXX) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; R23/25 Xx; X21 N; X50–53 |
X; X R: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–047–00–3 |
bufenkarb (XXX) xxxx: 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx a 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; X24/25 X; X50–53 |
X; X R: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–048–00–9 |
xxxxxxxxxxxx (XXX) 2-[(ethylsulfanyl)methyl]fenyl-N-methylkarbamát |
249–981–9 |
29973–13–5 |
Xn; X22 X; R50–53 |
Xn; X X: 22–50/53 S: (2-)60-61 |
|||
|
006–050–00–X |
xxxxxxx-XXX 3-xxxxx-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
4482–55–7 |
Xx; R38 X; R50–53 |
Xi; X X: 38–50/53 X: (2-)60-61 |
|||
|
006–053–00–6 |
xxxxxxxxxx (XXX) 2-isopropylfenyl-N-methylkarbamát |
220–114–6 |
2631–40–5 |
Xn; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–054–00–1 |
xxxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; R28 Xx; X21 X; R50–53 |
T+; X R: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–057–00–8 |
xxxxxxxxxx (XXX) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; X22 N; X51–53 |
Xx; N X: 22–51/53 X: (2-)24-61 |
|||
|
006–060–00–4 |
oxykarboxin (XXX) 2-xxxxxx-4,4-xxxxx-5,6-xxxxxxx-4λ4-1,4-xxxxxxxx-3-xxxxxxxxxxxx |
226–066–2 |
5259–88–1 |
Xx; R22 X52–53 |
Xx X:22–52/53 X: (2-)61 |
|||
|
006–069–00–3 |
xxxxxxxxx-xxxxxx (ISO) 1,2-xx[3-(xxxxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx |
245–740–7 |
23564–05–8 |
Xxxx. xxx. 3; X40 X; X50–53 |
Xx; X X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–070–00–9 |
xxxxxxxxxxx X-xxxxxxxxxx-X-xxxxxxx-2,5-xxxxxxxx-3-xxxxxxx |
262–302–0 |
60568–05–0 |
Xxxx. kat. 3; R40 X; X50–53 |
Xx; X X: 40–50/53 S: (2-)36/37–60–61 |
|||
|
006–088–00–7 |
benfurakarb (XXX) xxxxx-X -[({[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy]karbonyl}methylamino)sulfanyl]-N-isopropyl-β-alaninát(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-N-({[2-(ethoxykarbonyl)ethyl]isopropylamino}sulfanyl)-N-methylkarbamát |
— |
82560–54–1 |
T; X23/25 X; R50–53 |
T; X R: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
007–012–00–5 |
N,N-dimethylhydrazin 1,1-xxxxxxxxxxxxxxxx |
X |
200–316–0 |
57–14–7 |
X; X11 Karc. xxx. 2; X45 T; X23/25 X; R34 X; X51–53 |
X; T; X R: 45–11–23/25–34–51/53 X: 53–45–61 |
||
|
007–013–00–0 |
N,N-dimethylhydrazin 1,2-dimethylhydrazin |
E |
— |
540–73–8 |
Karc. xxx. 2; X45 X; X23/24/25 X; X51–53 |
X; X X: 45–23/24/25–51/53 X: 53–45–61 |
X ≥ 25 %: X; X45–23/24/25 3 % &xx; C &xx; 25 %: X; X45–20/21/22 0,01 % &xx; X &xx; 3 %: X; X45 |
|
|
009–003–00–1 |
xxxxxxxx xxxxxxxxxxxxxx … % |
X |
231–634–8 |
7664–39–3 |
X+; X26/27/28 X; X35 |
X+; X X: 26/27/28–35 X: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: X+; C; X26/27/28–35 1 % ≤ X < 7 %: X; X23/24/25–34 0,1 % ≤ X < 1 %: Xx; X20/21/22–36/37/38 |
|
|
015–039–00–9 |
xxxxxxx-xxxxxx (XXX) O,O-dimethyl-S -[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
201–676–1 |
86–50–0 |
X+; X26/28 X; R24 R43 X; X50–53 |
X+; N X: 24–26/28–43–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–048–00–8 |
xxxxxxxx (XXX) X,X-xxxxxxxx-X-[3-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxx]-xxxxxxxxxxxxx |
200–231–9 |
55–38–9 |
Xxxx. xxx. 3; R40 X; X23–48/25 Xx; X21/22 X; R50–53 |
T; X X: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
015–056–00–1 |
azinfos-ethyl (XXX) X,X-xxxxxxx-X-[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
220–147–6 |
2642–71–9 |
X+; X28 X; R24 X; X50–53 |
X+; N X: 24–28–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
015–140–00–8 |
triazofos (XXX) O,O-diethyl-O-(1-fenyl-1 X- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; X23/25 Xx; X21 X; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
016–013–00-X |
xxxxxxx sirnatý |
234–129–0 |
10545–99–0 |
R14 X; X34 N; X50 |
X; N R: 14–34–50 S: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ X &xx; 10 %: Xx; X36/37/38 |
||
|
016–014–00–5 |
xxxxxxx xxxxxxxx |
— |
13451–08–6 |
X14 X; X34 X; X50 |
X; N R: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. xxx. 2; X45 Xxxx. xxx. 3; R40 X+; R26 X; X25 C; X34 X43 |
X+ R: 45–25–26–34–43 X: 53-4 5 |
X ≥ 25 %: X+; R45–25–26–34–43 10 % ≤ X &xx; 25 %: X+; X45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; X45–22–26–36/ 37/38–43 5 % ≤ X &xx; 7 %: T; R45–22–23–36/37/38–43 3 % ≤ X &xx; 5 %: X; X45–22–23–43 1 % ≤ X &xx; 3 %: X; R45–23–43 0,1 % ≤ X &xx; 1 %: X; X45–20 0,01 % ≤ X &xx; 0,1 %:X; X45 |
|
|
016–024–00-X |
xxxxxxxx (ISO) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; X22 N; X50–53 |
Xx; X R: 22–50/53 X: (2-)60-61 |
|||
|
016–071–00–6 |
3-xxxxx-6,13-xxxxxxx-10-[(3-{[4-xxxxx-6-(2-xxxxxxxxxxxxxxxx)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx xxxxxxxx |
410–130–3 |
136248–03–8 |
X43 |
Xx R: 43 X: (2-)22–24–37 |
|||
|
022–001–00–5 |
chlorid xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 X; X34 |
X X: 14-34 X: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: C; X34 5 % ≤ X &xx; 10 %: Xi; X36/37/38 |
||
|
030–004–00–8 |
xxxxxxxxxxxxx [1] xxxxxxxxxxxx [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; X17 X; X34 N; X50–53 |
X; X; N X: 14–17–34–50/53 X: (1/2-)16–43–45–60–61 |
|||
|
050–002–00–0 |
xxxxxxxxx (XXX) tricyklohexyl(hydroxy)stannan xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx |
236–049–1 |
13121–70–5 |
Xx; X20/21/22 X; X50–53 |
Xx; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
|
050–012–00–5 |
tetracyklohexylstannan [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] butyl(tricyklohexyl)stannan [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xn; R20/21/22 X; R50–53 |
Xn; N X: 20/21/22–50/53 S: (2-)26–28–60–61 |
X ≥ 1 %: Xn; X20/21/22 |
1 |
|
|
050–017–00–2 |
xxxxxxxxxxxxxx (XXX) 1,1,1,3,3,3-hexakis(2-fenyl-2-methylpropyl)distannoxan |
236–407–7 |
13356–08–6 |
T+; X26 Xx; R36/38 X; X50/53 |
X+; X R: 26–36/38–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
082–009–00–X |
xxxx (xxxxxxxxxxxx xxxxxxxx) XX Xxxxxxx Xxxxxx 34 (XX 77603) XX xxxxxxxxxx xxxx 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Karc. kat. 3; R40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 X33 N; X50–53 |
X; X R: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
082–010–00–5 |
xxxxxx (xxxxxxx-xxxxxxxxxx-xxxxx xxxxxxxx) XX Xxxxxxx Red 104 (XX 77605) XX xxxxxxxxxx červeň 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Xxxx. xxx. 3; R40 Xxxx. xxx. 1; X61 Xxxx. xxx. 3; X62 X33 X; X50–53 |
X; N R: 61–33–40–50/53–62 S: 53–45–60–61 |
1 |
||
|
601–024–00-X |
kumen [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
X10 Xx; X65 Xi; X37 X; X51–53 |
Xx; X R: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
|
601–032–00–3 |
xxxxx[x]xxxxx xxxxx[xxx]xxxxxxx |
200–028–5 |
50–32–8 |
Xxxx. xxx.2; X45 Muta. xxx. 2; R46 Xxxx. xxx. 2; X60–61 X; R50–53 |
T; X X: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
|
601–034–00–4 |
benzo[e]acefenanthrylen |
205–911–9 |
205–99–2 |
Karc. kat.2; X45 X; X50–53 |
X; X R: 45–50/53 X: 53–45–60–61 |
|||
|
602–035–00–2 |
1,4-xxxxxxxxxxxxx x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 X; X50–53 |
Xx; X X: 36–50/53 X: (2-)24/25–46–60–61 |
|||
|
602–054–00–6 |
3-xxxxxxx-1-xx allyljodid |
209–130–4 |
556–56–9 |
R10 X; X34 |
X X: 10-34 X: (1/2-)7–26–45 |
|||
|
603–076–00–9 |
xxx-2-xx-1,4-xxxx |
203–788–6 |
110–65–6 |
X; X23/25 Xx; R21–48/22 X; X34 |
X X: 21–23/25–34–48/22 S: (1/2-)26–36/37/39–45 |
C ≥ 50 %: X; X21–23/25–34–48/22 25 % ≤ C &xx; 50 %: X; X21–23/25–36/38–48/22 10 % ≤ C &xx; 25 %: Xx; X20/22–48/22 3 % ≤ C &xx; 10 %: Xx; R20/22 |
||
|
603–091–00–0 |
exo-4-isopropyl-1-methyl-7-oxabicyklo[2.2.1]heptan-2-ol |
402–470–6 |
87172–89–2 |
O; R8 Xx; R22 Xx; X36 |
X; Xx R: 8–22–36 X: (2-)26 |
|||
|
603–093–00–1 |
xxx-(±)-4-xxxxxxxxx-1-xxxxxx-2-[(2-xxxxxxxxxxxx)xxx]-7-xxxxxxxxxx[2.2.1]xxxxxx |
402–410–9 |
87818–31–3 |
Xx; X20 N; X51–53 |
Xx; X X: 20–51/53 X: (2-)23-61 |
|||
|
603–097–00–3 |
1,1', 1′′-xxxxxxxxxxxxxxxx-2-xx xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; X36 X52–53 |
Xx X:36–52/53 X: (2-)26-61 |
|||
|
603–117–00–0 |
xxxxxx-2-xx xxxxxxxxxxxxxxxx xxxxxxxxxxx |
200–661–7 |
67–63–0 |
X; X11 Xx; X36 R67 |
F; Xx X: 11–36–67 X: (2-)7–16–24/25–26 |
|||
|
604–020–00–6 |
xxxxxxx-2-xx 2-xxxxxxxxxxxxxx 2-xxxxxxxxxx (ISO) |
201–993–5 |
90–43–7 |
Xi; X36/37/38 X; X50 |
Xx; X X: 36/37/38–50 X: (2-)22-61 |
|||
|
604–021–00–1 |
2-xxxxxxxxxx, xxxxx sůl xxxxxxx-2-xxxxxxxxxxxx 2-bifenylát xxxxx xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; X22 Xx; X37/38–41 N; R50 |
Xn; X R: 37/38–41–50 X: (2-)22–26–61 |
|||
|
604–024–00–8 |
4,4'-(4-methylpentan-2,2-diyl)difenol 2,2-xxx(4-xxxxxxxxxxxx)-4-xxxxxxxxxxxx |
401–720–1 |
6807–17–6 |
Xxxx. xxx. 2; X60 Xx; X36 X; X50–53 |
X; X X: 60–36–50/53 S: 53–45–60–61 |
|||
|
604–041–00–0 |
xxxxxxxxxxx [1] xxxxxxxxxxx-xxxxxxx [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx kyselina [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xx; X22 Xx; X38–41 X; X50–53 |
Xx; X X: 22–38–41–50/53 X: (2-)24–39–60–61 |
|||
|
604–043–00–1 |
monobenzonbenzyl (4-xxxxxxxxxxxx)xxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx 4-(xxxxxxxxx)xxxxx |
203–083–3 |
103–16–2 |
Xx; X36 R43 |
Xi X: 36-43 X: (2-)24/25–26–37 |
|||
|
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx |
205–769–8 |
150–76–5 |
Xx; X22 Xx; R36 R43 |
Xn X: 22–36–43 X: (2-)24/25–26–37/39–46 |
|||
|
605–016–00–7 |
xxxxxxx… % xxxxxxxxx… % |
X |
203–474–9 |
107–22–2 |
Xxxx. xxx. 3; X40 Xx; R20 Xx; R36/38 R43 |
Xn X: 20–36/38–40–43 X: (2-)36/37 |
X ≥ 10 %: Xx; X20–36/38–40–43 1 % ≤ X < 10 %: Xn; X40–43 |
|
|
606–016–00-X |
xxxxxx (XXX) 2-(trimethylacetyl)indan-1,3-dion |
201–462–8 |
83–26–1 |
T; X25–48/25 X; X50–53 |
X; X X: 25–48/25–50/53 X: (1/2-)37–45–60–61 |
|||
|
606–018–00–0 |
xxxxxxx (XXX) 2,3-xxxxxxx-1,4-xxxxxxxxxxx |
204–210–5 |
117–80–6 |
Xx; X22 Xi; R36/38 X; X50–53 |
Xx; N X: 22–36/38–50/53 X: (2-)26–60–61 |
|||
|
606–019–00–6 |
xxxxxxxxxx (XXX) xxxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-xxxxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx |
205–601–3 |
143–50–0 |
Xxxx. xxx. 3; X40 T; X24/25 X; R50–53 |
T; X X: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
606–034–00–8 |
metribuzin (XXX) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 H)-on 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-4,5-xxxxxxx-1,2,4-xxxxxxx-5-xx |
244–209–7 |
21087–64–9 |
Xx; X22 N; R50–53 |
Xn; X R: 22–50/53 X: (2-)60-61 |
|||
|
606–035–00–3 |
xxxxxxxxxxx (XXX) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx xxxxxxx |
216–920–2 |
1698–60–8 |
X43 X; X50–53 |
Xx; X X: 43–50/53 S: (2-)24–37–60–61 |
|||
|
606–036–00–9 |
xxxxxxxxxxxxxx (XXX) 6-xxxxxx-2 H-[1,3]dithiolo[4,5-b]chinoxalin-2-on |
219–455–3 |
2439–01–2 |
Repr. xxx. 3; X62 Xx; X20/21/22–48/22 Xi; X36 R43 X; X50–53 |
Xx; X X: 20/21/22–36–43–48/22–50/53–62 X: (2-)24–37–60–61 |
|||
|
606–037–00–4 |
xxxxxxxxxxx (XXX) 1-(4-chlorfenoxy)- 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-on |
256–103–8 |
43121–43–3 |
Xn; X22 N; R51–53 |
Xn; X R: 22–51/53 X: (2-)61 |
|||
|
606–044–00–2 |
2,4,6-trimethylbenzofenon xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xi; X36 X; R50–53 |
Xn; X X: 22–36–50/53 S: (2-)26–60–61 |
|||
|
607–043–00-X |
xxxxxxx (ISO) 3,6-xxxxxxx-2-xxxxxxxxxxxxxxx xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; X22 Xx; X41 X52–53 |
Xx; X X: 22–41–52/53 X: (2-)26-61 |
|||
|
607–057–00–6 |
xxxxxxxxx (XXX) 3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxykumarin3-[1-(4-chlorfenyl)-3-oxobutyl]-4-hydroxy-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; X48/22 X52–53 |
Xx X:48/22–52/53 X: (2-)37-61 |
|||
|
607–058–00–1 |
xxxxxxxxx (XXX) xxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxxxxxxxxx (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 X -chromen-2-on 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 H -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; R25–48/25 X52–53 |
X X:25–48/25–52/53 X: (1/2-)37–45–61 |
|||
|
607–079–00–6 |
xxxxxxx (XXX) ethyl-4-oxo-5-(perchlor-5-hydroxypentacyklo[5.3.0.02,6.03,9.04,8]dekan-5-yl)pentanoát xxxxx-5-(1,2,3,5,6,7,8,9,10,10-xxxxxxxxx-4-xxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx)-4-xxxxxxxxxxxx xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; R24 Xn; X22 X; X51–53 |
X; X R: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
|
607–097–00–4 |
xxxxxx-1,2,4-xxxxxxxxx-1,2-xxxxxxxx 1,2-xxxxxxxx xxxxxx-1,2,4-xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxx |
209–008–0 |
552–30–7 |
Xx; X37–41 X42/43 |
Xx R: 37–41–42/43 X: (2-)22–26–36/37/39 |
|||
|
607–143–00–3 |
pentanová xxxxxxxx xxxxxxxx xxxxxxxx |
203–677–2 |
109–52–4 |
X; X34 X52–53 |
X R:34–52/53 X: (1/2-)26–36–45–61 |
|||
|
607–152–00–2 |
2,3,6-TBA (XXX) 2,3,6-xxxxxxxxxxxxxxxx xxxxxxxx |
200–026–4 |
50–31–7 |
Xx; X22 X; X51–53 |
Xx; X X: 22–51/53 X: (2-)61 |
|||
|
607–153–00–8 |
xxxxxxxxx (ISO) (4-xxxxx-2-xxx-2,3-xxxxxxx-1,3-xxxxxxxxxxxx-3-xx)xxxxxx xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; X36/38 X52–53 |
Xx X:36/38–52/53 X: (2-)22-61 |
|||
|
607–156–00–4 |
chlorfenson (XXX) 4-chlorfenyl-4-chlorbenzen-1-sulfonát |
201–270–4 |
80–33–1 |
Xn; R22 Xx; X38 X; X50–53 |
Xx; X X: 22–38–50/53 S: (2-)37–60–61 |
|||
|
607–158–00–5 |
xxxxx xxx chloroctové xxxxxxxx xxxxxxxxxx sodný |
223–498–3 |
3926–62–3 |
T; X25 Xx; X38 N; X50 |
X; N R: 25–38–50 S: (1/2-)22–37–45–61 |
|||
|
607–159–00–0 |
chlorobenzilát (XXX) xxxxx-2,2-xxx(4-xxxxxxxxxx)-2-xxxxxxxxxxxxx xxxxx-4,4'-xxxxxxxxxxxxxxx |
208–110–2 |
510–15–6 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
607–176–00–3 |
Xxxx: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propionyl}-ω-({3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}xxx)xxxx(xxxxxxxxxx) |
400–830–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)36/37–61 |
|||
|
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 X; X51–53 |
Xx; X R: 43–51/53 X: (2-)24/37–61 |
|||
|
607–209–00–1 |
Xxxx: O,O′-diisopropyl-trisulfanbis(karbothioát); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx) |
403–030–6 |
— |
Xx; R22 X43 N; X50–53 |
Xx; X X: 22–43–50/ 53 X: (2-)36/37–60–61 |
|||
|
607–213–00–3 |
xxxxx-3,3-xxx(xxxx-xxxxxxxxxxxx)xxxxxxxx |
403–320–2 |
67567–23–1 |
X; X2 X; X7 X10 X; X51–53 |
X; X R: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
|
607–217–00–5 |
2-xxxxxxxxxxx-[4-(7-xxxxx-2,6-xxxxx-2,6-xxxxxxx-1,5-xxxxx-x-xxxxxxx-3-xx)xxxxxx]xxxxxx |
403–960–2 |
— |
X43 X53 |
Xx X: 43-53 X: (2-)24–37–61 |
|||
|
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] xxxxxxx-3,6-xxxxxxx-x-xxxxxx [1] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [3] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 X: 61 |
|||
|
607–248–00–4 |
Xxxxxxxx-xxxxxxx Natrium-N-(1-naftyl)ftalamát |
205–073–4 |
132–67–2 |
Xn; R22 |
Xn X: 22 S: (2) |
|||
|
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx xxxxxxxxxxxxxxxxx-xxxxxxxxx XXXXX |
256–032–2 |
42978–66–5 |
Xx; X36/37/38 R43 X; X51–53 |
Xx; N X:36/37/38–43–51/53 X: (2-)24–37–61 |
C ≥ 10 %: Xx; X36/37/38–43 1 % ≤ C &xx; 10 %: Xx; X43 |
||
|
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Xxxx (1:1): (S)-[(3-fenoxyfenyl)kyanmethyl]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx |
415–130–7 |
91465–08–6 |
X+; X26 X; X25 Xn; X21 N; R50–53 |
T+; X X: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
|
607–255–00–2 |
fluroxypyr (ISO) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx kyselina |
— |
69377–81–7 |
R52–53 |
R: 52/53 X: 61 |
|||
|
608–003–00–4 |
akrylonitril |
D X |
203–466–5 |
107–13–1 |
X; Xxx Karc. kat. 2; R45 X; X23/24/25 Xi; R37/38–41 X43 N; X51–53 |
X; X; X R: 45–11–23-/24/25–37/38–41–43–51/53 X: 9–16–53–45–61 |
X ≥ 20 %: X; X45–23/24/25–37/38–41–43 10 % ≤ C &xx; 20 %: X; R45–23/24/25–41–43 5 % ≤ X &xx; 10 %: X; X45–23/24/25–36–43 1 % ≤ X &xx; 5 %:X; X45–23/24/25–43 0,2 % ≤ X &xx; 1 %:X; X45–20/21/22 0,1 % ≤ X &xx; 0,2 %: T; X45 |
43 |
|
608–016–00–5 |
2,3,5,6-xxxxxxxxxx-1,4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 X; R50–53 |
Xi; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
609–030–00–4 |
xxxxxxxx (XXX) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. xxx. 2; X61 X+; X28 X; X24 X44 X; X50–53 |
X+; X X: 61–24–28–44–50/53 X: 53–45–60–61 |
||
|
609–040–00–9 |
xxxxxxxx (XXX) (2,4-dichlorfenyl)(4-nitrofenyl)ether |
E |
217–406–0 |
1836–75–5 |
Karc. xxx. 2; R45 Xxxx. xxx. 2; X61 Xn; X22 X; X50–53 |
X; X X: 45–61–22–50/53 S: 53–45–60–61 |
||
|
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-xxxxxxxxxx-3-xxxxxxxxxxx |
204–178–2 |
117–18–0 |
Xx; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 S: (2-)24–37–60–61 |
|||
|
611–008–00–4 |
4-xxxxxxxxxxxxxx 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. kat. 2; X45 X; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
611–013–00–1 |
4-xxxxxxx-3-{4-[2-xxxxxxx-4-(3-xxxxxxxxxxxxxxxxx)xxxxxxxx]-3-xxxxxxxxxxxxxx}-6-(3-xxxxxxxxxxxxxxxx)xxxxxxxx-2-xxxxxxxx xxxxxxxxx |
403–650–7 |
117409–78–6 |
X; X2 N; X51–53 |
X; X X: 2–51/53 X: (2-)35-61 |
|||
|
611–031–00-X |
4,4'-[(4-xxxxxxxxxxxxxx-2,5-xxxx-1-xxxxxx)xxxxxxxx]xxxxxxxx-xxxxxxxxxxxx CI Xxxxx Xxx 9 XX basická xxxxxx 9 |
209–321–2 |
569–61–9 |
Xxxx. kat. 2; X45 |
X R: 45 X: 53-45 |
|||
|
612–035–00–4 |
2-xxxxxxxxxxxxx x-xxxxxxxx |
X |
201–963–1 |
90–04–0 |
Xxxx. xxx. 2; R45 Xxxx. kat. 3; X40 X; X23/24/25 |
X X: 45–23/24/25 S: 53-45 |
||
|
612–042–00–2 |
xxxxxxxx xxxxxxx-4,4'-xxxxxx 4,4'-diaminobifenyl xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xn; R22 X; R50–53 |
T; X X: 45–22–50/53 X: 53–45–60–61 |
X ≥ 25 %: T; X45–22 0,01 % ≤ X < 25 %: X; R45 |
|
|
612–051–00–1 |
4,4'-diaminodifenylmethan xxx(4-xxxxxxxxxx)xxxxxx 4,4'-xxxxxxxxxxxxxxxx |
X |
202–974–4 |
101–77–9 |
Xxxx. xxx. 2; R45 Muta. xxx. 3; R40 X; X39/23/24/25Xx; X48/20/21/22 X43 X; R51–53 |
T; X X: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
|
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, xxxx x-xxxxxxx, xxxx |
X X |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Xxxx. xxx. 2; R45 Xx; X22 X; X51–53 |
X; X R: 45–22–51/53 X: 53–45–61 |
||
|
612–099–00–3 |
4-xxxxxx-x-xxxxxxxxxxxxx4-xxxxxx-1,3-xxxxxxxxxxxxx4-xxxxxxxxxxxx-1,3-xxxxxx 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. xxx. 2; X45 X; X25 Xx; X21 Xx; X36 X43 N; X51–53 |
X; X X: 45–21–25–36–43–51/53 X: 53–45–61 |
||
|
612–105–00–4 |
2-(xxxxxxxxx-1-xx)xxxxxxxxx2-(xxxxxxxxx-1-xx)xxxxx-1-xxxx |
205–411–0 |
140–31–8 |
Xx; X21/22 X; X34 X43 X52–53 |
X R: 21/22–34–43–52/53 X: (1/2-)26–36/37/39–45–61 |
|||
|
612–111–00–7 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,3-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,3-xxxxxx 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. xxx. 3; X40 Xx; X21/22 X43 N; R51–53 |
Xn; X R: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
|
612–125–00–3 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,4-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,4-xxxxxx 2,5-toluendiamin |
202–442–1 |
95–70–5 |
T; X25 Xn; R20/21 X43 X; X51–53 |
X; X R: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
|
612–144–00–7 |
flumetralin (XXX) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; X36/38 X4 3 X; R50–53 |
Xi; X R: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
|
612–151–00–5 |
xxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx |
X |
246–910–3 |
25376–45–8 |
Xxxx. kat. 2; X45 X; X25 Xn; R20/21 Xx; X36 X43 X; X51–53 |
X; X X: 45–20/21–25–36–43–51/53 X: 53–45–61 |
||
|
613–018–00–4 |
xxxxxxxxxx (XXX) 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx |
— |
7411–47–4 |
Xx; X22 Xx; R36/37/38 X52–53 |
Xx X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–031–00–5 |
xxxxxxxxx trichlorisokyanurová xxxxxxxx xxxxxxxx-1,3,5-xxxxxxxxxxxx 1,3,5-xxxxxxxx-1,3,5-xxxxxxx-2(1X), 4(3X), 6(5X)-xxxxx |
201–782–8 |
87–90–1 |
X; R8 Xx; X22 X31 Xx; X36/37 X; X50–53 |
X; Xx; N X: 8–22–31–36/37–50/53 S: (2-)8–26–41–60–61 |
|||
|
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxx xxxxxxxxxxxxx |
202–095–6 |
91–76–9 |
Xx; X22 R52–53 |
Xn R:22–52/53 X: (2-)61 |
|||
|
613–042–00–5 |
imazalil (ISO) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 X-xxxxxxxx |
252–615–0 |
35554–44–0 |
Xx; X20/22 N; X41 X; X50–53 |
Xx; X X: 20/22–41–50/53 S: (2-)26–39–60–61 |
|||
|
613–043–00–0 |
xxxxxxxx-xxxxxx (XXX) 1-[2-(allyloxy)-2-(2,4-dichlorfenyl)ethyl]- 1X -xxxxxxxx-1-xxx-xxxxxxxxxxxxxx [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; X20/22 Xx; X41 N; X50–53 |
Xx; X X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–066–00–6 |
xxxxxxxxxx (XXX) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 S: (2-)60-61 |
|||
|
613–091–00–2 |
morfamkvat-dichlorid [1] xxxxxxxxxx-xxxxxx [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxx-xxxxxxxx [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xn; X22 Xx; X36/37/38 R52–53 |
Xn; X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-xxxxx-2-xxxxxxxxxx |
403–700–8 |
2687–94–7 |
X; R34 X; X51–53 |
X; X X: 34–51/53 S: (1/2-)23–26–36/37/39–45–61 |
|||
|
613–130–00–3 |
xxxxxxxxxxx (ISO) (RS)-2-(2,4-dichlorfenyl)-1-(1H-1,2,4-triazol-1-yl)hexan-2-ol |
— |
79983–71–4 |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–131–00–9 |
xxxxxxxxxx (XXX) 1,2,5,6-xxxxxxxxxx-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; X22 R52–53 |
Xn X:22–52/53 S: (2-)61 |
|||
|
613–134–00–5 |
xxxxxxxxxxxx (XXX) 2-(4-xxxxxxxxxx)-2-[(1 H-1,2,4-triazol-1-yl)methyl]hexannitril |
— |
88671–89–0 |
Repr. xxx. 3; X63 Xx; X22 Xx; X36 X; X51–53 |
Xx; X X: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
|
613–137–00–1 |
xxxxxxxxxxxxxxxxxx (ISO) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; X50–53 |
X R: 50/53 X: 60-61 |
|||
|
613–139–00–2 |
xxxxxxxxxxx-xxxxxx xxxxxx-2-{X —[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxxx]xxxxxxxxx}xxxxxxx |
— |
74223–64–6 |
X; R50–53 |
N X: 50/53 S: 60-61 |
|||
|
614–001–00–4 |
xxxxxxx (ISO) 3-(1-xxxxxxxxxxxxxxxx-2-xx)xxxxxxx |
200–193–3 |
54–11–5 |
X+; X27 T; X25 X; X51–53 |
X+; N X: 25–27–51/53 X: (1/2-)36/37–45–61 |
|||
|
614–006–00–1 |
xxxxxx 2,3-dimethoxystrychnidin-10-on |
206–614–7 |
357–57–3 |
T+; X26/28 X52–53 |
X+ X:26/28–52/53 X: (1/2-)13–45–61 |
|||
|
614–007–00–7 |
xxxxxx-xxxxxx [1] brucin-nitrát [2] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; X26/28 X52–53 |
X+ X: 26/28–52/53 X: (1/2-)13–45–61 |
|||
|
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [1] 4-methyl-m-fenylendiisokyanát [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] x-xxxxxxxxxxxxxxxxxxxx [3] 5-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [3] xxxxxx-2,6-xxxxxxxxxxx [1] toluen-2,4-diisokyanát [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
X |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. xxx. 3; X40 X+; X26 Xx; X36/37/38 X42/43 X52–53 |
X+ X: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
X320 %: X+; X26–36/37/38–40–42/43 7 % ≤ C &xx; 20 %: X+; X26–40–42/43 1 % ≤ C &xx; 7 %: X; X23–40–42/43 0,1 % ≤ X &xx; 1 %:Xx; X20–42 |
2 |
|
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx, xxxxx xxx |
204–854–7 |
127–65–1 |
Xx; X22 X31 X; X34 X42 |
X X: 22–31–34–42 X: (1/2-)7–22–26–36/37/39–45 |
|||
|
616–034–00-X |
xxxxxxxxxxxx (XXX) 6-xxxxxx-3,4-xxxxxxx-2X-xxxxx-5-xxxxxxxxxxxx |
246–419–4 |
24691–76–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
616–035–00–5 |
xxxxxxxxx X -[(xxxxxxxxxx)xxxxxxxx]-2-xxxx-2-(xxxxxxxxxxxx)xxxxxxxx 1-ethyl-3-[2-kyan-2-(methoxyimino)acetyl]močovina |
261–043–0 |
57966–95–7 |
Xn; X22 R43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)36/37–60–61 |
|||
|
617–004–00–9 |
(1,2,3,4-tetrahydro-1-naftyl)hydroperoxid xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; X7 Xx; X22 X; X34 X; R50–53 |
O; C; X R: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: C; X22–34 10 % ≤ X &xx; 25 %: X; X34 5 % ≤ X &xx; 10 %: Xi; X36/37/38 |
||
|
617–006–00-X |
xxx(α, α-xxxxxxxxxxxxxx)xxxxxxx xxx(2-xxxxxxxxxxx-2-xx)xxxxxxx xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx dikumylperoxid |
201–279–3 |
80–43–3 |
O; R7 Xx; X36/38 X; X51–53 |
X; Xx; N X: 7–36/38–51/53 X: (2-)3/7–14–36/37/39–61 |
|||
|
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; R2 Xx; X36 R43 |
E; Xx; X: 2–36–43 X: (2-)3/7–14–36/37/39 |
|||
|
650–007–00–3 |
xxxxxxxxxxxxx (XXX) X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. kat. 3; X40 Xx; X21/22 X; X50–53 |
Xx; X X: 21/22–40–50/53 X: (2-)22–36/37–60–61 |
|||
|
650–008–00–9 |
xxxxxxxxxx (XXX) 4-[(2-chlorfenyl)hydrazono]-3-methylisoxazol-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)22–24–36/37–45–60–61 |
|||
|
650–009–00–4 |
xxxxxxxxxxxxx-xxxxxxxxxxxx X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx N2-(4-chlor-o-tolyl)-N1,N1-dimethylformamidin-hydrochlorid |
243–269–1 |
19750–95–9 |
Karc. xxx. 3; X40 Xx; X22 X; X50–53 |
Xx; N R: 22–40–50/53 X: (2-)22–36/37–60–61 |
|||
|
650–033–00–5 |
xxxxxxxxxxxx (XXX) [(S)-(3-fenoxyfenyl)kyanmethyl]-(S)-2-(4-chlorfenyl)-3-methylbutanoát (S)-3-fenoxy-α-kyanbenzyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát |
— |
66230–04–4 |
T; X23/25 R43 X; X50–53 |
X; N X: 23/25–43–50/53 X: (1/2-)24–36/37/39–45–60–61 |
|||
|
650–041–00–9 |
triasulfuron (XXX) 1-[2-(2-xxxxxxxxxxx)xxxxxx-1-xxxxxxxx]-3-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxx |
— |
82097–50–5 |
X; X50–53 |
X X: 50/53 X: 60-61 |
XXXXXXX 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx x xxxxxx |
Xxxxx XX |
Xxxxx CAS |
Klasifikace |
Označení |
Koncentrační xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
|
006–090–00–8 |
2-[(3-xxxxxxx-2-xx-1-xx)xxx]xxxxx-X-xxxxxxxxxxxxx |
408–010–0 |
88558–41–2 |
Xx; X20 Xx; X41 X52–53 |
Xx X: 20–41–52/53 X: (2-)22–26–39–61 |
|||
|
014–016–00–0 |
Xxxx: 1,3-di(hex-5-en-1-yl)- 1,1,3,3-tetramethyldisiloxan x 1,3-di(hex-x-en-1-yl)- 1,1,3,3-tetramethyldisiloxan |
406–490–6 |
— |
N; X51–53 |
X X: 51/53 X: 61 |
|||
|
015–164–00–9 |
xxxxxxx-xxxxxxxxxx-(1-xxxxxxxxxxxxxx)xxxxxxxxxxx dihydrát |
400–480–5 |
36669–85–9 |
R52–53 |
R:52/53 X: 61 |
|||
|
015–165–00–4 |
Směs: S, X, X', S''-tetrafenyl-4,4'-sulfandiylbis(fenylsulfonium)-bis(hexafluorofosfát) x difenyl[4-(fenylsulfanyl)fenyl]sulfonium-hexafluorofosfát |
404–986–7 |
— |
Xi; R41 X; X50–53 |
Xx; X X: 41–50/53 X: (2-)15–26–39–60–61 |
|||
|
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 S: 61 |
|||
|
015–167–00–5 |
3-[xxxxxxx(xxxxx)xxxxxxxxx]xxxxxxxxx xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
601–050–00–1 |
X10-X13-xxxxxxxxxxxxx xxxxxxx |
267–051–0 |
67774–74–7 |
X; R50 |
N X: 50 X: 61 |
|||
|
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 N; X51–53 |
Xx; X X: 38–51/53 X: (2-)37-61 |
|||
|
602–083–00–4 |
xxxxxxxxxxxxxxxx difenyletheru xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; X48/21/22 X64 X; X50–53 |
Xx; X X: 48/21/22–50/53–64 X: (1/2-)36/37–45–60–61 |
|||
|
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; X52–53–59 |
X X: 52/53–59 S: 59-61 |
|||
|
603–128–00–0 |
2-(fenylmethoxy)naftalen |
405–490–3 |
613–62–7 |
R53 |
R:53 X: 61 |
|||
|
603–129–00–6 |
1-terc-butoxypropan-2-ol |
406–180–0 |
57018–52–7 |
R10 Xx; X41 |
Xx R: 10-41 X: (2-)26-39 |
|||
|
603–130–00–1 |
Xxxx xxxxxxx: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; X22 R52–53 |
Xn X:22–52/53 X: (2-)39-61 |
|||
|
603–131–00–7 |
Xxxx (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-deoxy-1-[methyl(1-oxotetradecyl)amino]-D-glucitol |
407–290–1 |
— |
Xi; R41 |
Xi X: 41 X: (2-)26-39 |
|||
|
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; X38–41 X52–53 |
Xx X:38–41–52/53 X: (2-)26–37/39–61 |
|||
|
603–133–00–8 |
Xxxx:3-(4-xxxxx-2-xxxxx-5-xxxxxxxxxxxx)xxxxxx-1,2-xxxx x 3,3'-[(2-xxxxx-5-xxxxx-1,4-xxxxxxx)xxxxxxx]xx(xxxxxx-1,2-xxxx) |
408–240–1 |
— |
Xx; R22 X52–53 |
Xx X:22–52/53 S: (2-)22–36–61 |
|||
|
603–134–00–3 |
Xxxx: xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxx x xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (xxxxxxx a xxxxxxxxxx nerozvětvené) |
410–450–3 |
— |
R53 |
R: 53 X: 61 |
|||
|
603–135–00–9 |
xxx[2-(2-xxxxxxxxxxxxx)xxxxxxxxxx]xxx(2,2', 2-xxxxxxxxxxxxxxx-1-xxxxx-X,X)xxxxxxxxxx xxxxxxx |
410–500–4 |
— |
Xx; R41 X; X51–53 |
Xx; N X: 41–51/53 X: (2-)26–39–61 |
|||
|
603–136–00–4 |
3-{4-[xxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxxx}xxxxxx-1-xx |
410–910–3 |
104226–19–9 |
X43 X52–53 |
Xx X:43–52/53 X: (2-)24–37–61 |
|||
|
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx x 1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx |
411–130–6 |
— |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–138–00–5 |
3-(2,2-xxxxxxxx-3-xxxxxxxxxxxxx)xxxxxx 2,2-xxxxxxxx-3-(3-xxxxxxxxxxx)xxxxxx-1-xx |
403–140–4 |
103694–68–4 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–050–00-X |
4-xxxxx-x-xxxxxx 4-xxxxx-2-xxxxxxxxxxx |
216–381–3 |
1570–64–5 |
X; X23 X; X 35 X; X50 |
X; X; N X: 23–35–50 X: (1/2-)26–36/37/39–45–61 |
X ≥ 25 %: X; C; X23–35 10 % ≤ X < 25 %: C;R20–35 5 % ≤ X &xx; 10 %: X;X20–34 3 % ≤ X &xx; 5 %: Xn;R20–36/37/38 1 % ≤ X &xx; 3 %:Xx;X36/37/38 |
||
|
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–052–00–0 |
2,2'-xxxxxxxxxxx[6-(2 X - benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)fenol] 6,6'-xxx(2X -xxxxxxxxxxxx-2-xx)- 4,4'-xxx(1,1,3,3-xxxxxxxxxxxxxxxx)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 X: 61 |
|||
|
604–053–00–6 |
4-xxxx - xxxxx-2-xxxxxx-6-(1-xxxxxxxxxxxxxxxx)xxxxx |
410–760–9 |
157661–93–3 |
Xx; X38 X43 X; X50–53 |
Xx; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
604–054–00–1 |
Směs:2-methoxy-4-(4-methylidentetrahydropyran-2-yl)fenol x 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -pyran-2-yl)fenol |
412–020–0 |
— |
R43 X52–53 |
Xx X:43–52/53 X: (2-)24–37–61 |
|||
|
604–055–00–7 |
4,4'-xxx[(2,3-xxxxxxxxxxx)xxx]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Xxx.3; X40 |
Xx X: 40 S: (2-)22–36–37 |
|||
|
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-6-karbaldehyd a 3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 N; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
|
606–051–00–0 |
4-xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx-1-xx |
4–406–670–4 |
61203–83–6 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
606–052–00–6 |
4-(X, X-xxxxxxxxxxxx)-2-xxxxxxx-2'-xxxxxxxxxxxxxxxxx 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx xxxxxxxx |
410–410–5 |
54574–82–2 |
X52–53 |
X:52/53 S: 61 |
|||
|
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (XXX) [1] xxxxxxxxxx-xxxxxxxxx (ISO) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-xxxxxx-1-xxxxxxxxxxx)-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
607–273–00–0 |
amonium-7-{2,6-dimethyl-8-[(2,2-dimethylbutanoyl)oxy]- 1,2,6,7,8,8x-xxxxxxxxx-1-xxxxxx}-3,5-xxxxxxxxxxxxxxxxxx |
404–520–2 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–274–00–6 |
{2-[xxxxxx(xxxxxx)xxxxx]xxxxx}-3-xxxxxxxx-2-xxxxx |
405–350–1 |
54527–73–0 |
X43 X; X51–53 |
Xx; X X: 43–51/53 S: (2-)24–37–61 |
|||
|
607–275–00–1 |
xxxxxxx-4-(xxxxxxxxxx)xxxxxx-1-xxxxxxxx |
405–450–5 |
66531–87–1 |
X43 |
Xx X: 43 S: (2-)24-37 |
|||
|
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) xxx(1-xxxxxxxxxxxxxx)]xxxxxxxxx xxxxxxx |
405–635–0 |
— |
Xx; X38–41 X; R50–53 |
Xi; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–277–00–2 |
Směs:2-(hexylsulfanyl)ethylamin-hydrochlorid x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; X22 Xi; X41 R43 X; X51–53 |
Xx; N X: 22–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–278–00–8 |
Xxxx:xxxxx(X7-X9 xxxxxxxxxx x xxxxxxxxxxxx)-3-[3-(2 X - xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
405–760–0 |
— |
Xx; X41 R43 X52–53 |
Xx X: 41–43–52/53 X: (2-)24–26–37/39–61 |
|||
|
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) x (oktadecylimino)diethylen-(hydrogen-ftalát)-(hydrogen-maleinát) |
405–960–8 |
— |
R43 X; R51–53 |
Xi; X X: 43–51/53 S: (2-)24–37–61 |
|||
|
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx sodný natrium-4-chlor-1-hydroxybutan-1-sulfonát |
406–190–5 |
54322–20–2 |
Xn; X22 Xx; R36 X43 |
Xx X: 22–36–43 X: (2-)22–26–36/37 |
|||
|
607–281–00–4 |
Xxxx:xxxxx(X7-X9 rozvětvené x xxxxxxxx)-3-[3-(2X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
407–000–3 |
127519–17–9 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 S: 61 |
|||
|
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; R21/22 Xx; X38–41 R43 X; X50–53 |
Xx; X X: 21/22–38–41–43–50/53 X: (2-)26–36/37/39–60–61 |
|||
|
607–284–00–0 |
Směs (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) x xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) |
410–040–4 |
136213–76–8 |
X; X51–53 |
X R: 51/53 X: 61 |
|||
|
607–285–00–6 |
Směs:7-(3-aminobenzensulfonamido)naftalen-1,3-disulfonová kyselina, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx a xxxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx |
410–065–0 |
— |
X43 |
Xx X: 43 S: (2-)22–24–37 |
|||
|
607–286–00–1 |
Xxxx:xxxxxx- x xxxxxxx-7-[4-({4-[(2-xxxxxxx-1-xxxxxx)xxx]xxxxx}xxx)xxxxxxxxxxxxxxxxx]xxxxxxxx-1,3-xxxxxxxxxx |
410–070–8 |
141880–36–6 |
X43 X52–53 |
Xx X:43–52/53 X: (2-)22–24–37–61 |
|||
|
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–288–00–2 |
[x-(X -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -xxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxxx xxxxxxx, xxxxxxxxxx sůl; x = 15, 16, 17 xxxx 18, x = 1, 2, 3 nebo 4, x = 8, 9, 10 xxxx 11, x = 22, 23, 24 nebo 25 |
410–160–7 |
148732–74–5 |
Xi; X36 X43 R52–53 |
Xi X: 36–43–52/53 X: (2-)22–26–36/37–61 |
|||
|
607–288–00–8 |
3-[(3-{X —[4-(2,4-di-terc-pentylfenoxy)butyl]karbamoyl}-4-hydroxy-1-naftyl)sulfanyl]propanová xxxxxxxx |
410–370–9 |
105488–33–3 |
X53 |
X:53 X: 61 |
|||
|
607–290–00–3 |
Xxxx (o xxxxxxxx xxxxxx):xxxxxxx-1-xxxxx(X14-X18)-4-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx x xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; R38 R43 X; R50–53 |
Xi; X X: 38–43–50/53 S: (2-)24–37–60–61 |
|||
|
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx cyklohexyl)alkanoát |
410–630–1 |
104051–92–5 |
R53 |
R: 53 X: 61 |
|||
|
607–292–00–4 |
Xxxx:[2-(xxxxx(X12)xxx)-1-(xxxxxxxxxxxxx)xxxxxx]xxxxxx xxxxxxxx x [2-(alkyl(C14)oxy)-1-(methoxymethyl)]octová xxxxxxxx |
410–640–6 |
— |
Xx; X38–41 X; X50–53 |
Xx; X R: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–293–00-XXxxx: |
1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx x 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; X41 X43 X; R51–53 |
Xi; X X: 41–43–51/53 X: (2-)26–36/37/39–61 |
|||
|
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
607–295–00–0 |
Směs:tetranatrium-fosfonobutandioát x xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 N; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
|
607–296–00–6 |
Směs:tetraestery xxxxxxxxxxxxxxxx, xxxxxxxxx kyselina x 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
|
607–297–00–1 |
3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(2-xxxxxxxxx-10-xxxxxxxxx kyselina)2,2'-dioxo-3,3'-(1,4-fenylendimethyliden)bis(1,7,7-trimethylbicyklo[2.2.1]heptan-1-methansulfonová xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; X41 |
Xx R: 41 S: (2-)26-39 |
|||
|
607–298–00–7 |
[2-(trimethylamonio)ethyl]-4-sulfonatobenzoát |
411–010–3 |
— |
R43 |
Xi X: 43 S: (2-)22–36/37 |
|||
|
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; X22 X43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, x-xxxxxxxxxxxxxxxxxxxx]xxxxxxx xxxxxxx, xxxxxxxx xxx; x = 1,2,3 xxxx 4, b = 8, 9, 10 xxxx 11, c = 15, 16, 17 xxxx 18, x = 22, 23, 24 xxxx 25 |
411–430–7 |
— |
X43 |
Xx R: 43 X: (2-)22–24–37 |
|||
|
607–301–00–1 |
Směs:dodekanová xxxxxxxx x xxxxxxxxxxx oligo(1-7)laktátů |
411–860–5 |
— |
Xi; X38–41 R43 X; X51–53 |
Xx; X X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx x tetradekanoáty xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; X38–41 X43 X; R51–53 |
Xi; X X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx xxxxxxxx |
413–760–7 |
93107–30–3 |
Xxxx. kat.3; X62 R52–53 |
Xn R: 62–52/53 S: (2-)22–36/37–61 |
|||
|
608–023–00–3 |
4-(4-xxxxxxxxxx)-2-xxxxx-2-[(1X- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; X50–53 |
X R: 50/53 X: 60-61 |
|||
|
608–024–00–9 |
2-{4-[xxxxx(xxxxxxxx)xxxxx]xxxxx}xxxxx-1,1,2-xxxxxxxxxxxxxx |
407–650–8 |
97460–76–9 |
X53 |
X:53 X: 61 |
|||
|
608–025–00–4 |
[2-xxxxx-4,5-xxx(xxxxxxxxx)xxxxx]xxxxxxxxxxx |
410–970–0 |
117568–27–1 |
X53 |
X:53 X: 61 |
|||
|
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; R3 O; X8 Xxxx. kat. 2; X45 X; X23/25 X43 |
X; X X: 45–3–8–23/25–43 S: 53-45 |
|||
|
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; R22–48/22 X; X34 X43 X; X50–53 |
X; N X: 22–34–43–48/22–50/53 X: (1/2-)22–26–36/37/39–45–60–61 |
|||
|
611–043–00–5 |
Xxxx (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx, [xxx{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- nebo 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx trisodný x[{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx R: 41–52/53 X: (2-)26–39–61 |
|||||
|
611–044–00–0 |
Xxxx:[xxx(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [bis(4-nitrobenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan terc-alkyl(C12-C14)amonný, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx terc-alkyl(C12-C14)amonný, [(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx x[(4(5)-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx) (3-nitro-5-pentylbenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; X51–53 |
Xx; X41 X52–53 |
|||
|
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 X: 61 |
N X: 51/53 X: 61 |
||
|
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; X25 Xn; X48/22 R43 X; X50–53 |
X; X X: 25–43–48/22–50/53 S: (1/2-)22–28–36/37–45–60–61 |
|||
|
611–047–00–7 |
Xxxx (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx a 2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–890–3 |
111381–11–4 |
X53 |
X: 53 X: 61 |
|||
|
611–048–00–2 |
Xxxx (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx a 2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–900–6 |
111381–12–5 |
X53 |
X: 53 X: 61 |
|||
|
611–049–00–8 |
Směs (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, xxxxxxxx xxxxxx x xxxxxx xxxxxxxx (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; R48/22 R43 X52–53 |
Xx X: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
|
611–051–00–9 |
2-({4-[xxxxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxx}xxx)-6-xxxxxxx-3-xxxxxxxxxxxxxxxxxxxxx-xxxxxxx |
411–110–7 |
136213–74–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) xxx]-6-[(6-xxxxxxxxx-1-xxxxxx)xxx]xxxxxx-1,3-xxxxxxx}]xxxxxxxxx xxxxxxx, xxxxx xxx |
400–720–9 |
— |
X52–53 |
X: 52/53 X: 61 |
|||
|
612–156–00–2 |
Směs:trihexadecyl(methyl)amonium-chlorid a xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; X41 X; X50–53 |
Xx; X X: 41–50/53 X: (2-)26–39–60–61 |
|||
|
612–157–00–8 |
(Z)-1-(1-benzothiofen-2-yl)ethan-1-on-oxim-hydrochlorid |
410–780–8 |
— |
Xn; X22–48/22 Xx; R41 X43 X; R51–53 |
Xn; X R: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
|
612–158–00–3 |
Xxxx:[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxx-2-xxxxxxxxxxxxxxxxxx[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
|
612–159–00–9 |
xxxxxxx xxxxxxxx xxxxx 2,2,4-xxxxxxxxx- x 2,4,4-xxxxxxxxxxxxxx-1,6-xxxxxxx (x xxxxxxx XXXXXX), xxxxxxxx [(xxxxx(X10-X16)xxx)xxxxxx]xxxxxxx (Xxxxxx 8) a 4-xxxxxxxxxxxx-1-xxxxxxxxx xxxxxxxx |
410–880–1 |
— |
Xx; X22 X; X34 X; R50–53 |
C; X X: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
|
613–149–00–7 |
2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx |
405–700–3 |
96489–71–3 |
X; X23/25 X; X50–53 |
X; X X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 S: 61 |
|||
|
613–151–00–8 |
1-(2-xxxxx-3-X-xxxxx-5-X-xxxxxx-β-X-xxxxx-xxxxxxxxxxxxxx)-5-xxxxxxxxxxxxxxx-2(1X), 4(3 X)-xxxx |
406–360–9 |
104218–44–2 |
X53 |
X:53 X: 61 |
|||
|
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 X; X51–53 |
Xx; X R: 43–51/53 X: (2-)24–37–61 |
|||
|
613–153–00–9 |
2,3,5-xxxxxxxxxxxxxxx |
407–270–2 |
16063–70–0 |
X52–53 |
X:52/53 X: 61 |
|||
|
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; X22 |
Xx X: 22 X: (2-)22 |
|||
|
613–155–00-X |
5-chlor-2,3-difluorpyridin |
410–090–7 |
89402–43–7 |
R10 Xx; R22 X52–53 |
Xx X: 10–22–52/53 X: (2-)23–36–61 |
|||
|
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-xxxxx-5-xxxxxxxxxxxxx-4-xxxxxxxxxxx |
410–260–0 |
83857–96–9 |
X43 N; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–157–00–0 |
2,4-diamino-5-(methoxymethyl)pyrimidin 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xi; X36 |
Xx X: 22–36–48/22 X: (2-)22–26–36 |
|||
|
613–158–00–6 |
2,3-xxxxxxx-5-(xxxxxxxxxxxxxx)xxxxxxx |
410–340–5 |
69045–84–7 |
Xx; R20/22 Xx; X41 X43 X; X51–53 |
Xx; X X: 20/22–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; R25 Xn; X20 X; X50–53 |
X; X R: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
|
613–160–00–7 |
2-xxxxxx-2,5-xxxxxxxxxxxx[2.2.1]xxxxxx-xxxxxxxxxxxxx |
411–000–9 |
125224–62–6 |
X43 |
Xx X: 43 S: (2-)24-37 |
|||
|
615–022–00–1 |
xxxxxx-3-(xxxxxxxxxxxxxxxxxx)xxxxxxx-2-xxxxxxxxxx |
410–550–7 |
79277–18–2 |
X; X2 R14 Xx; X48/22 X42/43 |
X; Xx X: 2–14–42/43–48/22 X: (2-)22–30–35–36/37 |
|||
|
615–023–00–7 |
xxxxxxxxxxx 2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxxx xxxxxxxxxxxxxx-2-[(xxxxxxxxxxxxxxxxxx)xxxxxx]xxxxxxx |
410–900–9 |
83056–32–0 |
X10 X14 Xxxx. xxx. 3; X40 Xx; X20–48/22 Xx; X41 X42 |
Xx X: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
|
616–044–00–4 |
X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)-2-(3-xxxxxxxxxxxxxxxx)xxxxxxxxx |
402–510–2 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(diethylamino)-2-methoxyacetanilid |
405–190–2 |
122371–93–1 |
R43 R53 |
Xi X: 43-53 S: (2-)22–24–37–61 |
|||
|
616–046–00–5 |
X -[2-(6-xxxxx-7-xxxxxxxxxxxxxx[1,5-x][1,2,4]xxxxxxx-4-xx)xxxxxx]-2-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxxxxxx |
406–390–2 |
— |
X; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - tetraalkyl(C16)-2,2′, 2″, 2′′′ (xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx x X, X′,X″,X′′′ - xxxxxxxxxx(X18)- 2,2′, 2′′, 2′′′-(xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx |
406–640–0 |
— |
X43 |
Xx X: 43 S: (2-)24-37 |
|||
|
616–048–00–6 |
3'-(trifluormethyl)isobutyranilid |
406–740–4 |
1939–27–1 |
Xn; X48/22 N; X51–53 |
Xx; X R: 48/22–51/53 X: (2-)22–36–61 |
|||
|
616–049–00–1 |
2-(2,4-xx-xxxx-xxxxxxxxxxx)-X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxx |
408–150–2 |
99141–89–6 |
X53 |
X:53 X: 61 |
|||
|
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 X; X50–53 |
Xx; X R: 43–50/53 X: (2-)24–37–60–61 |
|||
|
616–051–00–2 |
Směs:3,3'-bis(4-methylfenyl)- 1,1'-(4-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx x 3,3'-xxx(4-xxxxxxxxxxx)-1,1'-(2-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx Xxxx:2,4-xxx[3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx x 2,6-bis[(3-(4-methylfenyl)ureido]toluen |
411–070–0 |
— |
R53 |
R: 53 X: 61 |
|||
|
617–015–00–9 |
bis(4-methylbenzoyl)peroxid |
407–950–9 |
895–85–2 |
E; X2 X; X7 X; X50–53 |
X; X R: 2–7–50/53 S: (2-)7–14–36/37/39–47–60–61 |
|||
|
650–032–00-X |
cyprokonazol (XXX) (2R, 3R)-, (2 S, 3 X)-, (2 R, 3 X)-, (2 X, 3 X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxx-1-(1X- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. kat. 3; X63 Xx; R22 X; X50–53 |
Xx; N X: 22–50/53–63 X: (2-)36/37–60–61 |
XXXXXXX 2
XXXXXX SPECIFICKÝCH XXXXX XXXXXXXXX S XXXXXXXXXXXX LÁTKAMI X XXXXXXXXX
Xxx směrnice Xxxxxx 2001/59/XX,
Xx. xxxx. L 332, 28.12.2000, s. 81.
PŘÍLOHA 3A
STANDARDNÍ POKYNY XXX XXXXXXXX ZACHÁZENÍ X XXXXXXXXXXXX XXXXXXX X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/ES,
Úř. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 3B
STANDARDNÍ XXXXXX XXX XXXXXXXX ZACHÁZENÍ X NEBEZPEČNÝMI XXXXXXX X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 4X
"X.10 XXXXXXXXXX — XXXXXXX NA XXXXXXXXXXXX ABERACE U XXXXX XX XXXXX
1. XXXXXX
Xxxx metoda je xxxxxxxx xxxxxx XXXX XX 473 — Xxxxxxx na xxxxxxxxxxxx xxxxxxx x savců xx vitro (1997).
1.1 XXXX
Xxxxxxx xx chromozomové xxxxxxx x savců xx xxxxx má xxxxxxxxxxxxx činitele, xxxxx xxxxxxxxx xxxxxxxxxx chromozomové xxxxxxx v xxxxxxxxxxxxx xxxxxxx xxxxx (1, 2, 3). Xxxxxxxxx xx xxx typy xxxxxxxxxxxx xxxxxxx: xxxxxxxxxxxx x chromatidové. X xxxxxxx xxxxxxxxxx xxxxxxxx xxxx indukované xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx aberace xx xxxxxx vyskytují. Xxxxxx xxxxxxxxxxx může xxxxxxxx, xx xxxxxxxx látka xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxx však xxxx xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx x xxxx x tomuto xxxxx rutinně xxxxxxxxx. Xxxxxxxxxxxx xxxxxx x xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx chorob x xxxxxxx a existuje xxxxx xxxxxx x xxx, že xxxxxxxxxxxx xxxxxx x x xxxx související jevy xxxxxxxxxxx xxxxx v xxxxxxxxxx a x xxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxx na xxxxxxx xxxxxxxx x xxxxxxx x x xxxxxxxxx xxxxxx.
Xx zkoušce na xxxxxxxxxxxx xxxxxxx in xxxxx mohou xxx xxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx, xxxxxxx xxxxx xxxx xxxxxxxx buněčné xxxxxxx. Použité buňky xxxx xxxxxxx na xxxxxxx xxxxxxxxxx xxxxx x kultuře, stálosti xxxxxxxxx, xxxxx chromozomů, xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
Xxxxxxx prováděné xx xxxxx xxxxxx vyžadují xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxx aktivační xxxxxx xxxxxx xxxxx napodobit xxxxxxxx xx xxxx x savců. Xx xxxxx xx xxxxx xxxxxxxxx xxxxxxxx, xxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxx, jež xxxxxxxxxx xxxxxxx mutagenitu x xxxx x xxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx xxxxxxxx xxxxxx cytotoxicity (4, 5).
Xxxx zkouška xx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxxxx xxx xxxxx. Mnoho xxxxxxxxx, xxx xxx xx xxxx zkouška xxxxxxxxx, xxxx xxx xxxxx xxxxxxxxxxx; mezi xxxxx xxxxxxxx a xxxxxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxxxxx xx chemické xxxxx x přibývají xxxxxx x xxx, xx xxxxxxxx karcinogeny, xxxxx xxxxxx zjištěny xxxxx xxxxxxxx, neboť xxxxxx xxxxxx jinými xxxxxxxxxx xxx xxxxxx xxxxxxxxxx XXX.
Xxx xxxx Xxxxxx xxxx, část X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx aberace : xxxxxxxxxx poškození xxxxxxxxxx v xxxxxx xxxxx xxxx xxxxx x xxxxxxx xxxx xxxxxxxxx v xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx kterém x xxxxx po X-xxxx xxxxxxxxx XXX nedojde x mitóze, xxxxx xxxxxxxxx další X-xxxx. Xxxxxxxxx xxxx chromozomy xx 4, 8, 16… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx léze xxxxx xxx xxxxx xxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxx : xxxxx xxxxx, xxxxx xx xxxxxxxxx x metafázi, x celkového xxxxx xxxxx x xxxxxxxx; xxxxx xxxxxx xxxxxxxxxxx xxxx populace.
Numerická xxxxxxx : odchylka xxxxx xxxxxxxxxx xx xxxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxxx xxxx buněk.
Polyploidie : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), jiný xxx xxxxxxxxx (tj. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx změny xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx xxxxxxxx; xxxx xx xxxx delece x fragmenty, xxxxxxxxxxxxxxxxxx xxxx interchromozomální xxxxx.
1.3 XXXXXXXX XXXXXXXX METODY
Buněčné xxxxxxx jsou xxxxxxxxx xxxxxxxx xxxxx, x xx x xxxxxxxxxxxx xxxxxxxx a xxx xx. X předem xxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxx látce xx xx xxxxxxxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® xxxx kolchicin), xxxxxxx xx xxxxxx, xxxxxx x xxxxxxxxxx chromozomových xxxxxxx xx zjistí xxxxxxxxxxxxxx pozorováním xxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxxxx xxx xxxxxxx xxxxx buněčné xxxxx, xxxxx nebo xxxxxxxx buněčné xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxx (např. fibroblasty xxxxxx xxxxxxxx, xxxxxxxxx xxxxxxxxx krve xxxxxxx xxxx xxxxxx savců).
1.4.1.2 Xxxxx x xxxxxxxxxx xxxxxxxx
Xxx xxxxxxxxx xxxxxx xx xxxx xxx xxxxxxx vhodná kultivační xxxxx x inkubační xxxxxxxx (kultivační nádoby, xxxxxxxxxxx XX2, teplota x xxxxxxx). X xxxxxxxxxxxxxxx buněčných xxxxx x xxxxx xx xxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxx modální xxxxxxx počtu xxxxxxxxxx x xxxx xx xxx xxxxxxxxxxxx, xxx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxxx; x xxxxxxx xxxxxxxxxxx xx neměly xxx xxxxxxx. Pro xxxxxxx xxxxx a xxxxxxxxx xxxxxxxx by měla xxx xxxxx normální xxxxx buněčného xxxxx.
1.4.1.3 Xxxxxxxx kultur
Stabilizované buněčné xxxxx a kmeny: xxxxx xx xxxxxxx x xxxxxxxxx kultur, xxxxxx xx do xxxxxxxxxxxx xxxxx v xxxxxx xxxxxxx, aby xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx, x inkubují xx xxx 37 °X.
Xxxxxxxxx: xxxx ošetřená xxxxxxxxxxxxxxx (např. xxxxxxxxx) xxxx xxxxxxxx lymfocyty xxxxxxxx xxxxxxxx se xxxxxxx xx xxxxxxxxxxxx xxxxx obsahujícího xxxxxxx (xxxx. fytohemaglutinin) x xxxxxxxx se xxx 37 °C.
1.4.1.4 Metabolická xxxxxxxx
Xxxxx by xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, a xx x xxxxxxx xxxxxxxxxxxx xxxxxxxx x xxx xx. Xxxxxxxxxx používaným xxxxxxxx je kofaktorem xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Aroclor 1254 (6, 7, 8 x 9), xxxx xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (10, 11 x 12).
Postmitochondriální xxxxxx je x xxxxxxxx xxxxxxxxxx xxxxx xxxxxxx používána x xxxxxxxxxxxxx 1 — 10 % obj. Xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxx xx třídě xxxxxxxx xxxxx, která xx xxxxxxxx. X některých xxxxxxxxx xxxx být xxxxxx použít xxxx xxx jednu xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx výsledků xxxxxx, xxxxxx xxxxxxxx xxxxxxxxx modifikovaných xxxxxxxxx xxxxx xxxxxxxxxxxxx specifické xxxxxxxxx enzymy, xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxx xxxxxxxxx linií xx xxxx xxx xxxxxxx xxxxxxxxxx (xxxx. důležitostí xxxxxxxxx xxxxxxxxxx X450 xxx metabolismus xxxxxxxx xxxxx).
1.4.1.5 Zkoušená xxxxx/xxxxxxxx
Xxxxx xxxxxxxx xxxxx by xxxx xxx xxxx xxxxxxxx na buňky xxxxxxxxxx nebo xxxxxxxxxxxx xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Kapalné xxxxxxxx xxxxx xxxxx xxx xxxxxxx přímo x xxxxxxxxxx systémům x/xxxx xxxxx xxx xxxx xxxxxxxx zředěny. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx o stálosti xxxxxxxxxxx xxxxxxx skladování.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx mělo xxx xxxx xxxxxxxxx, že xxxxxxx xx xxxxxxxxx xxxxxx, a xxxx xx xxx xxxxxxxxxx x xxxxxxxx xxxxx x s aktivitou X9. Xxxx-xx použita xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, mělo xx xxx jejich zařazení xxxxxxxxx údaji x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx zvážit xxxxxxx xxxxxxx rozpouštědel/vehikul. Xxx xxxxxxxx xxxxx xxxxxxxxx xx xxxx xx xxxx být použita xxxxxxxxx xxxxxxxxxxxx neobsahující xxxx. Xxxx lze xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Expoziční koncentrace
Mezi xxxxxxxx, která mají xxx xxxxxxxxxx při xxxxxxxxx xxxxxxxx koncentrace, xxxxx cytotoxicita, xxxxxxxxxxx x xxxxxxxxxx xxxxxxx x xxxxx xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx xxx stanovena x xxxxxxxxxxxx xxxxxxxx x xxx xx x hlavním xxxxxxxxxxx xx xxxxxxx vhodných xxxxxxxxxx buněčné xxxxxxxxx x růstu, jako xxxx stupeň xxxxxxxxxx, xxxxx xxxxxxxxxxxxxxx xxxxx xxxx mitotický index. Xxxx xxx xxxxxxx xxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxx xxxxxxxxxxxxxx xxxxxxxxxxx. X xxxxxxx cytotoxicity by xxxx tyto koncentrace xxxxxxxx xxxxxxx xxxx xxxxxxxxx xx xxxxxxxxx xxxxxxxxx, případně xxxxxx xxxxxxxxx, což xxxxxxx xxxxxxx, že xx xx xxxxxxxxxxx neměly xxxxx více xxxxx xxxxxxxx 2 až Ö10. X okamžiku xxxxxxx xx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxxx, xxxxx buněk xxxx xxxxxxxxxxx xxxxxx (xxx x xxxx xxx 50 %). Xxxxxxxxx xxxxx xx xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxxxx xxxxxx a závisí xx době, xxxxx xxxxxxxx od xxxxxxxx. Xxxxxxxxx index xx xxxx xxxxxxxxxx x xxxxxxxxxxx kultur, u xxxxx xxxxx xxx xxxx xxxxxx stanovení xxxxxxxx xxxxxxx a xxxxxxxxxxx. Informace o xxxxxxxx xxxxxxxxx cyklu, xxxxxxxxx xxxxxxxx xxxxxxxxx xxxx (XXX), xxxxx xxx xxxxxxx xxxx xxxxxxxxx xxxxxxxxx. V xxxxxxx AGT xxxx xxx o xxxxxxxx xxxxxxxxx hodnotu, x xxx xxxxx usoudit xx existenci xxxxxxxxxx xxxxxxxxxxx, x x xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx xxxx xxxx xxx xx xxxxxxxx xxxxx podstatné xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
X xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx látek xx xxxx xxx maximální xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 xx/xx xxxx 0,01 X, xxxxx xxxx, xxxxx x nich je xxxxxxxx.
X xxxxxxx relativně xxxxxxxxxxxxx látek, které xxxxxx xxxxxxx xxx xxxxxxxxxxxxx xxxxxxx, než xx xxxxxx rozpustnost, xx měla xxx xxxxxxx xxxxxxxx xxxxx x koncentraci, xxx xx xxx xxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxxx médiu xx xxxxx doby xxxxxxxx. X xxxxxxxx xxxxxxxxx (xxxx. xxxxxxx-xx xx xxxxxxxx xxxxx při xxxxxxx xxxxxxxxxxxxx, než xx xxxxxxxxxxx) xx xxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxxx, při xxxxx xxxxxxx ke srážení. Xxxx být xxxxxxxx xxxxxxxx rozpustnost xx xxxxxxx x xx xxxxx xxxxxxxx, neboť xxxxxxxxxxx x testovacím xxxxxxx xx xxxx x průběhu xxxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx buněk, séra X9 xxx. Nerozpustnost xxx xxxxxxx xxxxxxxx. Xxxxxxxxx by xxxxxx xxxxx při vyšetřování.
1.4.2.3 Xxxxxxxxx a xxxxxxxxx xxxxxxxx
Xxxxxxxx každého xxxxxxxxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxx xxxxxxxx (kontroly rozpouštědla xxxx vehikula). Xxx xxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxx xxx xxx xxxxxxxxx kontrolu xxxxxxx chemická xxxxx, xxxxx k xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx.
X xxxxxxxxx xxxxxxxx xx xxx xxx xxxxxx xxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx, které xxxxxxxx poskytnou reprodukovatelný x xxxxxxxxxxxxx nárůst xxx pozadí, xxxx xx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxxxxxxxx xxxxxxxxxxx xxxxxxx by xxxx xxx xxxxxxx xxx, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx xxxxxx nevyšla xxxxx najevo xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx:
|
Xxxx xxxxxxxxxxx aktivace |
Látka |
Číslo XXX |
Xxxxx xxxxx XXXXXX |
|
Xxx xxxxxx xxxxxxxxxxx aktivace |
methyl-methansulfonát |
66–27–3 |
200–625–0 |
|
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
|
|
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
|
|
mitomycin X |
50–07–7 |
200–008–6 |
|
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
|
X vnější xxxxxxxxxxxx xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx x xxxx xxxxxx xxxxx. Xxx xxxxxxxxx kontrolu by xxxx xxx xxxxx xxxxx vzato x xxxxx xxxxxxx xxxxxxxxxx xxxxx ze xxxxxx xxxxxxxx xxxxx.
X xxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx negativní xxxxxxxx xxxxxxxxxx xx xx samotného xxxxxxxxxxxx xxxx xxxxxxxx v xxxxxxxxxxx xxxxx x xxxxxxxxxx xxxxxxx xxxxxxxx xxxx xxxxxxx. Xxxxx xxxx xx xxxx xxx neexponované xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx xxxxx xxxxx xxxxxxxxx údaje xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx mutagenní účinky.
1.4.3 Xxxxxx
1.4.3.1 Expozice zkoušené xxxxx
Xxxxxxxxxxxxx buňky xx xxxxxxx zkoušené látce xxx xx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxx xxx něho. Xxxxxxxx xxxxxxxxx by xxxx být zahájena xxx 48 xxxxx xx mitogenní xxxxxxxxx.
1.4.3.2 Xxx každou koncentraci xx xxxx být xxxxxxx xxxxxxx duplicitní xxxxxxx, x xxxxx xx xxxxxxx doporučuje x xxxxxx xxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxxxx. Xxxxxxxx xxx xx xxxxxxx xxxxxxxxxxx xxxxx prokázat (13, 14), že xxxx duplicitními xxxxxxxxx xx minimální xxxxxx, xxxx být přípustné xxxxxxx xxxxxx xxxxxxx.
Xxxxxx xxxx těkavé xxxxx xx xxxx být xxxxxxxx vhodnými xxxxxxxx, xxxx. v xxxxx xxxxxxxxxx kultivačních xxxxxxxx (15, 16).
1.4.3.3 Doba xxxxxxx xxxxxx
X xxxxxx xxxxxxxxxxx xx xxxx xxx buňky xxxxxxxxx xxxxxxxx látce, xxx x xxxxxxxxxxxx aktivací, xxx bez xx, xx dobu 3 — 6 hodin, x měly by xxx xxxxxxxx po xxxxxx době od xxxxxxxx aplikace, která xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx (12). Jestliže xxxxx xxxxxx dává xxxxxxxxx xxxxxxxx xxx x xxxxxxxx, xxx xxx xxxxxxxx, xxx xx xxx xxxxxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx x xxxxxxxxxxxx expozicí xx xx odběru x době, xxxxx xxxxxxxx 1,5xxxxxxx normální xxxxx buněčného xxxxx. Xxxxxx xxxxxxxx látky xxx xxxxx xxxxxxxxx xxx xxxxxx aplikace xxxx xxxxxx xxxxxxx xxx 1,5xxxxxxx délky xxxxx. Negativní xxxxxxxx xxx metabolické xxxxxxxx xxxx být xxxxxxxxx xxxxxx od xxxxxxx. X xxxxxxxxx, xxx xx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx výsledků za xxxxxxxx, by mělo xxx xxxxxx zdůvodnění.
1.4.3.4 Xxxxxxxx preparátů xxx xxxxxxx chromozomů
Do xxxxxxx xxxxxxx xx xxxxxxx 1-3 hodiny xxxx xxxxxxxxx xxxxx Colcemid® xxxx xxxxxxxxx. Xxx xxxxxxxx xxxxxxxxx pro xxxxxxx chromozomů se xxxxx xxxxxxx xxxxxxx xxxxxx a zpracovává xxxxxx. Xxxxxxxx preparátů xxx analýzu xxxxxxxxxx xxxxxxxx hypotonizaci buněk, xxxxxx a xxxxxxxx xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx preparáty, xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx xxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx xxx fixaci xxxxx xxxxxxx ke xxxxx části xxxxx x metafázi x xx ztrátě chromozomů, xxxx by xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx xxxxxx xxxxxxx hodnotě ± 2 xxx všechny xxxx xxxxx. Na xxxxxx xxxxxxxxxxx x xxxxxxxx by xxxx xxx xxxxxxxxx alespoň 200 xxxxx xxxxxxxxxxxxxx xxxxxxxx, případně xxxxxxxxxx xxxxxxxxxxx mezi xxxxxxxxxx xxxxxxx. Xxxxx xxxxx xxx snížit, je-li xxxxxxxxx xxxxx počet xxxxxxx.
Xxxxxx je xxxxxx xxxxxxx xxxxxxxxx strukturní xxxxxxxxxxxx xxxxxxx, je xxxxxxxx xxxxxxxxxx xxxxxxxxxxx x endoreduplikace, xxxx-xx xxxxxxxxxx.
2. ÚDAJE
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxxxx xxxxxxxxx je xxxxx a xxxx xx tedy xxx xxxxxxxxxxx množství xxxxx xx strukturní xxxxxxxxxxxxx xxxxxxx (aberacemi) vyjádřené x procentech. Xxx xxxxxxxxx a experimentální xxxxxxx by xxxx xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx chromozomových xxxxxxx x jejich xxxxxx x xxxxxxxx. Xxxx xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx xx, xxx xxxxxxxxxx xx xx celkové xxxxxxxx xxxxxxx.
Xxxx by xxx xxxx zaznamenána xxxxxxxx, xxxxx byla xxxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx x všech xxxxxxxxxxxx xxxxxx x xxxxxxxxxxx kultur x xxxxxxxx xxxxxxxxxxxxx x xxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx. Xxxx xx xxxx xxx xxxxxxx xxxxx xxxxxxx xx xxxxx tabulky.
Ověření xxxxx xxxxxxxxx odpovědi xx nepožaduje. Xxxxxxxxxx xxxxxxxx by xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx byla xxxxxxxxxxx x xxxx 1.4.3.3. Xxxxx parametrů studie x xxxxx xxxxxxxx xxxxxx posuzovaných podmínek xx xxxx xxx xxxxxxx x následných xxxxxxxxxxxxx. X parametrům xxxxxx, xxxxx xx xxxxx být xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx x podmínky metabolické xxxxxxxx.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxxx počtu buněk x chromozomovými xxxxxxxxx x závislosti na xxxxxxxxxxx, xxxx reprodukovatelný xxxxxx tohoto xxxxx. Xxxxxxxx xx xxxx xxx xxxxxxx biologická xxxxxxxxx výsledků. Xxx xxxxxxxxx xxxxxxxx zkoušky xxxxx být použity xxxx xxxxxxx prostředek xxxxxxxxxxx metody (3, 13). Statistická xxxxxxxxxx xx neměla xxx xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx odpověď.
Nárůst xxxxx polyploidie xxxxx xxxx xxxxxxxx, že xxxxxxxx xxxxx xx xxxxxxxxx potlačit xxxxxxxxx xxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxx počtu xxxxx x xxxxxxxxxxxxxxxxxxx chromozomy xxxx xxxxxxxx, že xxxxxxxx xxxxx má xxxxxxxxx xxxxxxxx progresi xxxxxxxxx xxxxx (17, 18).
Xxxxxxxx látka, jejíž xxxxxxxx xxxxxxxxx výše xxxxxxx xxxxxxxx, xx x tomto systému xxxxxxxx za nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx pozitivní xxxx xxxxxxxxx xxxxxxxx, v xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx vyslovit xxxxxxx výrok x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx zůstat xxxxxxxxxx nebo xxxxxx xxx ohledu xx xx, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx xxxxxxxxx, xx xxxxxxxx látka xxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx aberace. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx za xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxxxxxx somatických xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx aberace.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- rozpustnost x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- typ x xxxxx xxxxx,
- xxxxxxxxxx xxxxxxxxx a xxxxxxxx xxxxxxxxx typu xxxxx,
- xxxxxxxxx nepřítomnost xxxxxxxxxxx,
- xxxxxxxxx o xxxxx xxxxxxxxx xxxxx,
- xxxxxxx dárce xxxx, xxx xxxx použita xxxx xxxx xxxx xxxxxxxxxx lymfocyty, xxxxxxx xxxxxxx,
- případně počet xxxxxx,
- xxxxxxxx xxxxxx xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxx hodnota počtu xxxxxxxxxx.
Xxxxxxxx xxxxxxxx:
- identifikace xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx a xxxxx expozice buněk,
- xxxxxxxxxx výběru xxxxxxxxxxx x xxxxx xxxxxx, xxxxxx xxxx. údajů x xxxxxxxxxxxx x xxxxxx rozpustnosti, xxxx-xx x dispozici,
- xxxxxxx xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- xxxxxxxxxxx zkoušené xxxxx,
- xxxxx xxxxxxxx x přidané xxxxxxxx xxxxx,
- xxxxxxxxx xxxxxxx,
- xxxxxxxxx xxxx,
- délka xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx xxx xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx kontroly,
- xxxxxx xxxxxxxx preparátů,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx, xxxx. xxxxxx konfluence, xxxxx o xxxxxxxx xxxxx, xxxxx xxxxx, xxxxxxxxx index,
- známky xxxxxxx,
- xxxxx o xX x xxxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxx xxxxxxx, xxxxxx xxxx,
- xxxxx buněk s xxxxxxxxxxxxxx xxxxxxxxx x xxxx aberací xxxxxx xxx xxxxxx xxxxxxxxxxx x xxxxxxxxx kulturu,
- xxxxx xxxxxxx, pokud xxxx pozorovány,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx,
- xxxxxxxxx údaje x negativní (rozpouštědlo/vehikulum) x xxxxxxxxx xxxxxxxx x rozpětími, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx výsledků.
Závěry.
4. XXXXXXXXXX
1) Xxxxx, X. X. (1976), Cytological Xxxxxxx xxx Detecting Xxxxxxxx Xxxxxxxx, xx: Xxxxxxxx Xxxxxxxx, Principles and Xxxxxxx for xxxxx Xxxxxxxxx, Xxx. 4, Xxxxxxxxxx, X. (xx) Xxxxxx Xxxxx, Xxx Xxxx and Xxxxxx, 1-29.
2) Xxxxxxxx, M. Xx., Xxxxxx, X. (1985), Xxx Xx xxxxx Chromozomal Aberration Xxxx Xxxxx Xxxxxxx Xxxxxxx Xxxx (XXX) Xxxxxxxxxx Xxxxx xx Xxxxxxx, xx: Xxxxxxxx xx Xxxxxxxxxx Research, Xxx. 5, Ashby, X. xx xx., (xxx) Xxxxxxxx Xxxxxxx Xxxxxxxxxx, Amsterdam-New Xxxx-Xxxxxx, 427-432.
3) Xxxxxxxx, X. X., Xxxxxxxxx, X. X., Xxxxxx, C., Xxxxxx, X., Brown, X., Cannon, X., Xxxxx, A. D., Xxxxxxxx, F., Ahmed, X., Duk, X., Xxxxx, J., Xxxxxxxx, X. X., Xxxxxxx, X. A., Xxxxxxxx, X., Xxxxxx X. (1978), Xxxxxxxxxx aberration xxx xxxxxx chromatic xxxxxxxxx xx Chinese xxxxxxx ovary cells: Xxxxxxxxxx xx 108 xxxxxxxxx, Xxxxxxx. Xxxxx. Xxxxxxx. 10 (xxxxx. 10), 1-175.
4) Xxxxx, X., Galloway, X. X., Xxxxxxxx, X. X., Ishidate, M. Xx., Brusick, X., Xxxxx, X., Myhr, X. X. (1991), Xxxxxxxxxxxx xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. A xxxxxx xxxx ICPEMC Xxxx Group 9, Xxxxxxxxxx Res., 257, 147-204.
5) Xxxxxx, T., Xxxxxx, T., Fukuda, X., Okumura, X., (1992), Clastogenicity xx xxx pH xx Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 268, 297-305.
6) Ames, X. N., XxXxxx, X., Xxxxxxxx, X. (1975), Xxxxxxx xxx Xxxxxxxxx Carcinogens xxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxx Xxx., 31, 347-364.
7) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Methods for xxx Salmonella Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Res., 113, 173-215.
8) Natarajan, X. X., Tates, X. D., xxx Xxxx, X. X. X., Xxxxxxx, X., xx Xxxxx, N. (1976), Xxxxxxxxxxx Xxxxxxx xx Xxxxxxx/Xxxxxxxxxxx xxxxx Xxxxxxxxxx xx x Xxxxxxxxxxx Xxxxxx Xx xxxxx, I. Induction xx Chromozome Xxxxxxxxxxx xxx Xxxxxx Chromatid Xxxxxxxx xx Xxxxxxxxxxxxxxxxxx (XXX) xxx Xxxxxxxxxxxxxxxxxxx (XXX) in XXX Xxxxx xx the Xxxxxxxx xx Xxx-Xxxxx Xxxxxxxxxx, Xxxxxxxxxx Res., 37, 83-90.
9) Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, X. Xx. (1979), Xxxxxxxxxxx Xxxxxxxxxx Xxxxx xx 29 Xxxxxxxxx Combined with X9 Xxx In xxxxx, Xxxxxxxx Xxx., 66, 277-290.
10) Xxxxxx, X. X., Combes, X. X., Xxxxxxx, X. X., Gatehouse, X. X., Gibson, X. X., Xxxxxx, X. M., Wolf, X. X. (1992), Xxxxxx xx XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Party. Alternative xx Aroclor 1254-xxxxxxx X9 in In xxxxx Genotoxicity Assays, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, T. (1976), X. Xxxx Substitute xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Xxxxxxx of Xxxxxxxxx Xxxxxxxxxx Xxxxxxx, in: xx Xxxxxx, X. X., Fouts, X. X. Bend, X. X., Xxxxxxx, R. X. (eds), In xxxxx Metabolic Xxxxxxxxxx xx Mutagenesis Xxxxxxx, Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
12) Xxxxxxxx, X. X., Xxxxxxx, M. J., Xxxxxxxx, M. Xx., Xxxxx, J. X., Xxxxxxxx, X. J., Xxxxxx, T., Xxxxxxx, X., Xxxxxx, X. (1994), Xxxxxx xxxx Xxxxxxx Xxxxx xx Xx xxxxx Xxxxx xxx Xxxxxxxxxxx Xxxxxxxxxxx, Xxxxxxxxxx Xxx., 312, 241-261.
13) Xxxxxxxxxx, X., Xxxxxxxx, X. A., Xxxxx, X. X., Xxxxxxxx, G., Xxxxxxx, X. X., Xxxxxxxx, X. (1989), Xxxxxxxx xx Xxxx from Xx vitro Xxxxxxxxxxx Xxxxxx, xx: Statistical Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, Xxxxxxxx, X. X., (xx) Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, 141-154.
14) Xxxxx, X. X., Galloway, X. X. (1994), Xxxxxxxxx Xxxxxx xxx xxx Xxxxxxxxx xxx Xx vitro Xxxxxxxxxx Xxxxxxxxxx Xxxxxx in XXX Xxxxx, Xxxxxxxxxx Xxx., 312, 139-149.
15) Xxxxx, D. X., Xxxxxx, X. C., XxXxxxx, K. X. (1982), XXX/XXXXX Mutation Xxxxx: Evaluation xx Xxxxx xxx Xxxxxxxx Xxxxxxx, in: Xxxx, X. X., Costa, X. X., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Effects xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Plenum, 91-103.
16) Xxxxxx, X. X., Xxxxxx, X. X., Xx, A. X., Xxxxxx, X. X. (1983), Xxxxxxxxxx xx xx Xxxxxxxx System Xxxxx Xxxxx Xxxxx xx Collagen Xxxx xxx Detecting Xxxxxx Xxxxxxxx Xxxxxxxx xx xxx CHO/HGPRT Mutation Xxxxx, Xxxxxxxxxxxxx Xxxxxxx., 5, 795-801.
17) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx hamster xxxxx during xxxxx-xxxxxxxxx xxxxxxx G2 xxxxxx, Xxxxxxxxxx Res., 119, 403-413.
18) Huang, X., Xxxxxx, X., Trosko, X. X. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication xx Xxxxxxx hamster cells, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4X
"X.11 XXXXXXXXXX–XXXXXXX XX CHROMOZOMOVÉ XXXXXXX X XXXXXXX XXXXXX XXXXX XXXXX XX XXXX
1. XXXXXX
Xxxx metoda xx xxxxxxxx xxxxxx XXXX TG 475 — Zkouška na xxxxxxxxxxxx xxxxxxx v xxxxxxx xxxxxx xxxxx xxxxx (1997).
1.1 ÚVOD
Zkouška xx xxxxxxxxxxxx xxxxxxx x xxxxx xx xxxx xx používána xxx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx indukovaných xxxxxxxxx xxxxxx v xxxxxxx kostní xxxxx xxxxx, xxxxxxx xxxxxxxx (1, 2, 3, 4). Xxxxxxxxx se xxx xxxx xxxxxxxxxxxx xxxxxxx — xxxxxxxxxxxx x chromatidové. Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xx chemická xxxxx xx xxxxxxxxx indukovat xxxxxxxxx aberace. V xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxx vyskytují. Xxxxxxxxxxxx mutace a xxxxxxxxxxx xxxx jsou xxxxxxxx xxxxx geneticky xxxxxxxxxxx xxxxxx x xxxxxxx x xxxxxxxx xxxxx xxxxxx o xxx, xx xxxxxxxxxxxx xxxxxx x xxxxxxxxxxx xxxx způsobující xxxxx x xxxxxxxxxx a x xxxxxx somatických xxxxx xxxxxxxxx nádory, xxxx xxxxx xx xxxxxxx rakoviny u xxxxxxx x x xxxxxxxxxxxxxxxx xxxxxxxxx.
Xxx této xxxxxxx xxxx rutinně xxxxxxxxx hlodavci. Xxxxxxx xxxxx xx v xxxx zkoušce kostní xxxx, xxxxxxxx xx xxxxxx xxxxxxxxxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx s xxxxxxx xxxxxx, xxxxx xx xxxxxx izolují x xxxxxxxxxxxx. Jiné druhy x cílové xxxxx xxxxxx xxxxxxxxx xxxx xxxxxx.
Xxxx xxxxxxx xx xxxxxxxxxxxx aberace xx xxxxxxx xxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx x xxxxxxx reparace XXX, xxxxxxx xx xxxxx x xxxxxxx xxxxx x xxxxx xxxxx. Xxxxxxx xx xxxx xx xxxxxx xxxxxxxx xxx xxxxx výzkum xxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxx xx xxxxx.
Xxxxxxxx xxxxxxxx xxxxx o xxx, xx se xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xx xxxxxx tkáně, xxxx vhodné xxxx xxxxxxx xxxxxx.
Xxx xxxx Xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : strukturní xxxxxxxxx xxxxxxxxxx v xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx zlomu x xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxx xxxxx x spojení xxxx xxxxxxxxx x xxxxxx místě.
Endoreduplikace : xxxxxx, při xxxxxx x jádře po X-xxxx xxxxxxxxx XXX xxxxxxx x mitóze, xxxxx následuje další X-xxxx. Xxxxxxxxx jsou xxxxxxxxxx se 4, 8, 16,… chromatidami.
Gap : xxxxxxxxxxxx léze xxxxx xxx xxxxx xxxxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx chromozomů xx xxxxxxxx xxxxxxx xxxxxxx x použitých xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (n), xxxx xxx xxxxxxxxx (tj. 3 x, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx pozorovatelné xxxxx xxxxxxxxx chromozomů xxx xxxxxxxx xxxxxx xx stadiu xxxxxxxx; xxxx se xxxx xxxxxx x fragmenty, xxxxxxxxxxxxxxxxxx nebo interchromozomální xxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx jsou xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxxxx a xx xxxxxxx okamžiku xx xxxxxxxx se xxxxxx. Xxxx xxxxxxxxx se xxxxxxxx xxxx látka xxxxxxxxxxx metafázi (xxxx. xxxxxxxxx nebo Xxxxxxxx®). X buněk xxxxxx xxxxx se xxxx xxxxxxxx preparáty xxxxxxxxxx, xxxxxx xx x xxxxxxxxx xx xxxxxxxxxxxx xxxxxxx buněk x xxxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Výběr xxxxx xxxxxxx
Xxxxx xx xxxxxxxx xxxxxx, xxx x xxxxxx xxxxxx, xxxxxx xxx xxxxxx xxxxxxxx xxxxxx savčí xxxx. Xxxx xx xxx použity xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx zvířat. X xxxxxxxx xxxxxxxx xxxxxx xx měla xxx xxxxxxxx x xxxxxxxxx xxxxxx minimální x xxxxxx xx x xxxx pohlaví překročit ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx chovu x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx obecného úvodu x části X, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx pohlavně xxxxxxx xxxxxxx xx xxxxxxxx výběrem xxxxxxx xx kontrolní xxxxxxx x skupinu, xxxxx xx xxxxxxx xxxxxxxx xxxxx. Xxxxx xx xxxx být xxxxxxxxxx xxx, xxx byl xxxx jejich polohy xxxxxxxxxxxxx. Zvířata xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx x laboratorních xxxxxxxxxx xxxxxxx xxx xxx aklimatizovat.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx měly být xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx suspendovány xx xxxxxxxx xxxxxxxxxxxxxx xxxx vehikulech x xxxxxxxxx xxxxxxx. Kapalné xxxxxxxx látky xxxxx xxx podávány xxxxx xxxx mohou xxx xxxx podáním xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx údaje x xxxxxxxx neprokazují xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx při xxxxxxxxx xxxxxxxx dávek xxxxxxx xxxxxx x xxxx xx xxx xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx použita jiná xxx xxxxx rozpouštědla/vehikula, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí každého xxxxxxxxxxx by xxxx xxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx obě pohlaví. X výjimkou xxxxxxxx xxxxxxxx xxxxx xx xxxx zvířata xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xx xxxxxxxxx, x xxxxx xxxxx k xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx poskytovat xxxxxxxxxx xxxxxxx xx vivo xxx expozičních úrovních, x nichž se xxxxxxx, xx xxxxxxxxx xxxxxxxxxxxxx nárůst xxx xxxxxx. Xxxxx pozitivní xxxxxxxx xx xxxx xxx xxxxxxx tak, xxx byl účinek xxxxxxxx, ale aby xxx xxxxxx nevyšla xxxxx najevo xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx byla xxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxxxxx než xxxxxxxx xxxxx x xxx xxx xxxxx x xxxxx xxxxxxx xxxxxxxx xxx jednou. Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxx xxxxx xx xxxxxx chemické třídy, xxxx-xx x xxxxxxxxx. Xxxxxxxx látek pro xxxxxxxxx kontrolu:
|
Látka |
Číslo XXX |
Xxxxx xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-triazin |
51–18–3 |
200–083–5 |
V okamžiku xxxxxxx odběru xx xxx xxx xxxxxxxx xxxxx x xxxxxxxxxxx xxxxxxx, xxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxx xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx skupiny, xxxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxx xxxxx x xxxxxxxxx přijatelné údaje x xxxxxxxxxxx xxxxxx x xxxxxxxx xxxxx x chromozomovými xxxxxxxxx. Xxxxxxx-xx xx xxx xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxx. Kromě toho xx xxxx xxx xxxxxxxxxxxx kontroly xxxxxxx xxxx tehdy, xxxxxxxxxx-xx xxxxx kontrolní xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
1.5 POSTUP
1.5.1 Xxxxx x xxxxxxx zvířat
Každá xxxxxxxxxx a kontrolní xxxxxxx se xxxxxx x xxxxxxx pěti xxxxxxxxxxxxxxxx xxxxxx xxx xxxxx xxxxxxx. Xxxxxxxx xxxx x xxxx xxxxxx k dispozici xxxxx ze xxxxxx xx stejným xxxxxx x xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx xxxx xxxxxxxxx xxxxxx x xxxxxxxx, xxxx xxxxxxxxxxx zkoušení xxxxxxx xxxxxxx. Je-li xxxxxxxx xxxxxxx specifická xxx xxxxxx xxxxxxx, xxxx je xxxx xxxxxxxxx x některých xxxxxxxxxxxxxxx xxxxx, xxxx xx být zkouška xxxxxxxxx xx zvířaty xxxxxxxxxxxxxx pohlaví.
1.5.2 Plán xxxxxxxx
Xxxxxxxx látky by xxxx být xxxxx xxxxx podávány jednorázově. Xxxxxxxx xxxxx xxxxx xxx xxxxxxxx xxxx xx dvou dávkách, xxx. dvě dávky x xxx den x rozmezí xx xxxx xxx několika xxxxx, aby bylo xxxxxxxxx xxxxxxxx velkých xxxxxx materiálu. Xxxx xxxxxx xxxxxxxx xx xxxx být vědecky xxxxxxxxxx.
Xxxxxx xx xxxx xxx xxxxxxxx xx xxxx různých intervalech xx xxxxxxxx podané x xxxxxx dni. X xxxxxxxx xx xxxxx xxxxxxx po xxxxxx době xx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx (xxxx xxxx obvykle 12 — 18 h). Xxxxxxxx xxxx xxxxxxxx xxx xxxxxx x xxxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx pro xxxxxx xx xxxxxxxx xxxxxxxxx xxxxx může xxx vliv xx xxxxxxxxx xxxxxxx pro xxxxxxxxx xxxxxxxxxxxxxx xxxxxxx, xxxxxxxxxx xx provést xxxxx odběr xx 24 x xx xxxxxxx xxxxxx. Xx-xx xxxxxxxx xxxxxxxxx do xxxx než xxxxxxx xxx, měl xx xxx xxxxx xxxxxxxx xx xxxxxx xxxx xx poslední xxxxxxxx, xxxxx xxxxxxxx 1,5násobku xxxxxxxx xxxxx xxxxxxxxx xxxxx.
Xxxx xxxxxxxxx se xxxxxxxx xxxxxxxxxxxxxxxxx xxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (např. Xxxxxxxx® xxxx kolchicin). Xxxx xx xx xxxxxx době xxxxxxx x xxxxxx xxxxx. X xxxx xx xxxx xxxx xxxxxxxxx 3 — 5 x; x xxxxxx xxxxxxxx je xxxx xxxx přibližně 4 — 5 x. X xxxxxx xxxxx xx odeberou xxxxx x xxxxxxxxx xx xx chromozomové aberace.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx dostupných xxxxx studie pro xxxxxxxx rozsahu dávek, xxxx by xxx xxxxxxxxx xx stejné xxxxxxxxxx, se xxxxxxx xxxxxx, xxxxxx, xxxxxxxx x za xxxxxxxx xxxxxx xxxxxxxx, xxx xx xxxxxxx x xxxxxx xxxxxx (5). X xxxxxxx xxxxxxxx xx xxx xxxxx xxxxx xxxxxxx xxx xxxxxx dávky. Xxxx xxxxxx xxxxx by xxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx x xxxxxxxxx toxicitou, případně xxxxxx xxxxxxxxx. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx použita xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx je xxxxxxxxxx jako dávka xxxxxxxxxxxx xxxxxx xxxxxx xxxxxxxx, xx vyšší xxxxx xx xxxxx xxx stejném režimu xxxxxxxxx podle xxxxxxxxx x letalitě. Xxxxx xx xxxxxxxxxxx biologickou xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx kritériím xxxxxxxxx xxxxx xxxxxxxxx x xxxx by být xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx xxxxx xxxx xxx xxxx xxxxxxxxxx xxxx dávka xxxxxxxxxxxx x xxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx (xxxx. více xxx 50 % xxxxxxx xxxxxxxxxxx indexu).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx dávkou xxxxxxx 2000 mg/kg xxxxxxx hmotnosti xxxxxxx xxxxxxxxxxx xxxx xx xxxx dávkách v xxxxxx xxx nevykazuje xxxxx pozorovatelné xxxxxxx xxxxxx x není-li xx základě xxxxx x xxxxxxx, xxxxx xxxx podobnou xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxxxxxx xx xxxxx studie xx třemi xxxxxxxx xxxxx za nezbytnou. X xxxx xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx/xxx a xxx delší než 14xxxxx xxxxxxxx xx xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x limitní xxxxxxx xxxxx úroveň xxxxx.
1.5.5 Podávání xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx nebo xxxxxxx xxxxxxxxx kanylou, xxxx xxxxxxxxxxxxxxxxx injekcí. Xxxx xxxxxxx podávání jsou x odůvodněných xxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx xxxxxx, xxx xx uvedený xxxxx, xxxx xxx xxxxxxxxxx. Xx xx xxxxxxxx x žíravé látky, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxxx minimalizována xxxxxxxxxx koncentrace zajišťující xxxxxxxxxx xxxxx při xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxx
Xxxxx xx xxxxxxxx xx xxxxxxx xxxxxx xxxx, xxxxxxxxxxxx xx x xxxxxx. Xxxxx xx nanesou xx xxxxxxxx sklíčka x obarví se.
1.5.7 Xxxxxxx
Xxxx xxxxxxx xxxxxxxxxxxx xx měl xxx x všech exponovaných xxxxxx (xxxxxx xxxxxxxxxxx xxxxxxx) x x xxxxxxxxxxxxxx zvířat xxx xxxxxxxxx xxxxxxxx stanoven xxxxxxxxx xxxxx, x xx xxxxxxx u 1000 xxxxx na xxxxx xxxxx.
X xxxxxxx xxxxxxx xx mělo xxx xxxxxxxxxxx alespoň 100 xxxxx. Tento xxxxx xxx xxxxxx, xx-xx pozorován xxxxx xxxxx aberací. Xxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx xx xxxx xxx před xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Protože při xxxxxx často xxxxxxx xx xxxxxxxxxxxxxx xxxxxx xxxx xx ztrátě xxxxxxxxxx u xxxxx xxxxx v xxxxxxxx, xxxx xx xxxxxxxxxxx xxxxx obsahovat centromery x xxxxx xxxxxxxxxxxxxx xxxxx 2 x ± 2.
2. ÚDAJE
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx pro xxxxxxxxxx zvířata xx xxxx xxx zpracovány xx xxxxx tabulky. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Xxx xxxxx xxxxx by xxx xxx vyhodnocen xxxxx xxxxx, xxxxx xxxxxxx xx xxxxx x xxxxx buněk x xxxxxxxxxxxxx aberací (xxxxxxxxxxxxxx xxxxxxxxx) xxxxxxxxx x xxxxxxxxxx. Xxx xxxxxxxxxx x kontrolní xxxxxxx xx měly být xxxxxxx xxxxx typy xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x xxxxxx počtem x xxxxxxxx. Gapy xx xxxxxxxxxxxxx odděleně x xxxxxxx xx, xxx xxxxxx xx xxxxxxxxxx xx celkové xxxxxxxx aberací. Xxxxxxxxxx-xx xxxxx x xxxxxxx x odpovědi xxxx xxxxxxxxx, xxxxx být xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 HODNOCENÍ X INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx výsledku xxxxxxxx několik xxxxxxxx, xxxx. xxxxxx relativního xxxxx buněk x xxxxxxxxxxxxxx aberacemi v xxxxxxxxxx xx xxxxx xxxx jasný xxxxxx xxxxx xxxxx s xxxxxxxxx pro xxxxxxx x xxxxxxx xxxxxx x x určitému xxxxxxxx xxxxxx. Xxxxxxxx xx měla být xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx mohou xxx použity xxxx xxxxxxx xxxxxxxxxx statistické xxxxxx (6). Statistická xxxxxxxxxx xx neměla xxx xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx. Dvojznačné xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx zkoušením, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxxxxx xxxx znamenat, xx xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxx xxxxx buněk x xxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx, že xxxxxxxx xxxxx má xxxxxxxxx xxxxxxxx xxxxxxxx buněčného xxxxx (7, 8).
Xxxxxxxx xxxxx, jejíž xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, se xxxxxxxx x xxxxx systému xx xxxxxxxxxxx.
Xxxxxx většina xxxxxxxxxxx poskytne xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, v ojedinělých xxxxxxxxx xxxxxxxx xxxxxx xxxxx vyslovit xxxxxxx xxxxx x xxxxxxxx xxxxxxxx látky. Výsledky xxxxx zůstat xxxxxxxxxx xxxx sporné xxx xxxxxx xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx výsledky zkoušky xx xxxxxxxxxxxx xxxxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx x kostní xxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx látka xx xxxxxxxx zkoušky neindukuje x kostní dřeni xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx xx xxx xxxxxxxxxxx pravděpodobnost, x xxxxx xx xxxxxxxx xxxxx nebo xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx xxxxxx xxxxx (xxxx. systémová xxxxxxxx).
3. XXXXXX
XXXXXXXX O XXXXXXX
Xxxxxxxx o zkoušce xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx volby xxxxxxxx,
- rozpustnost x xxxxxxx zkoušené látky x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- počet, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx zvířat xx xxxxxxx xxxxxxx, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxx xxx xxxxxx skupinu.
Zkušební xxxxxxxx:
- xxxxxxxxx x xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- xxxxx xx studie xxx xxxxxxxx xxxxxxx, xxxxx xxxx provedena,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx látky,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- zdůvodnění způsobu xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, xxx xx xxxxxxxx xxxxx xxxxxxx xx krevního oběhu xxxx xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx zkoušené xxxxx x krmivu xxxx xxxx (xxx) xx xxxxxxxxxxxx dávku (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx údaje o xxxxxxx xxxxxx a xxxx,
- podrobný popis xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxxxxx látky xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx x délka xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- kritéria xxxxxxxxx xxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxx xx jedno xxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx pozitivní, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx,
- xxx x xxxxx xxxxxxx xxxxxxx xxxxxxxxxx pro xxxxx xxxxx,
- celkový počet xxxxxxx ve xxxxxxx xx středními hodnotami x směrodatnými odchylkami,
- xxxxx buněk x xxxxxxxxx ve xxxxxxx xx xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxx, pokud xxxx pozorovány,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx negativní xxxxxxxx,
- xxxxxxxxx xxxxx x negativní xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx x směrodatnými xxxxxxxxxx,
- údaje o xxxxxxxx xxxxxxxxx kontrole.
Rozbor xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Adler, X. X. (1984), Xxxxxxxxxxx Xxxxx xx Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: x Practical Xxxxxxxx, S. Venitt, X. X. Xxxxx (xxx), IRL Xxxxx, Xxxxxx, Washington X. X., 275-306.
2) Xxxxxxx, X. X., Xxxx, X. J., Xxxxxxxx, X., Holden, H., XxXxx, X. F., Xxxxxx, X. (1987), Xxxxxxxxx In vivo Xxxxxxxxxxx Xxxxxx: Xxxxxxxx xx Xxxxxxxxxx Aberrations xx Xxxx Marrow Xxxxx, Xxxxxxxxxx Xxx., 189, 157-165.
3) Xxxxxxx, X., Xxxxxxxx, X., Xxxxx, X., Xxxxxxxxx, X. G., Xxxxxxx, X., Xxxxxxxxx, X. (1990), In xxxx Xxxxxxxxxxx Xxxxxx, in: X. X. Kirkland (xx.), Basic Xxxxxxxxxxxx Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Sub-Committee xx Guidelines xxx Xxxxxxxxxxxx Testing. Xxxxxx, Xxxx X xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, New Xxxx, Xxxx Chester, Xxxxxxxxx, Xxxxxx, 115-141.
4) Tice, X. X., Hayashi, X., XxxXxxxxxx, X. X., Xxxxxxxx, X., Xxxxxx, X. H., Xxxxxx, H. E., Xxxxxx-Xxxxxxx, M., Oleson Xx., X. X., Xxxxxxxxxxxx, F., Xxxxxxx, X. X., Romagna, X., Xxxxxxx, X., Xxxxx, S., Xxxxxxx, X. (1994), Xxxxxx xxxx xxx Xxxxxxx Xxxxx xx the xx vivo Xxxxxxxxx Xxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 312, 305-312.
5) Xxxxxxx, R. X., Xxxxx, J. X., Xxxxxx, A. X., Xxxxxx, X. A., Xxx, J., Xxxxxxx, X. J., Gatehouse, X. X., Hodson-Walker, X., Xxxxxx, X. X., Kirkland, D. X., Richold, X. (1992), Xxxxxx of Xxxxxxx Xxxxxxxxxx Society/UK Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Xxxx Xxxxxxx xx In xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, X. X., Xxxxxxxx, X., Albanese, X., Amphlett, G. X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, D. X., Xxxxxx, X. X. X. (1989), Xxxxxxxxxxx Xxxxxxxx xx Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx Part III. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx, X. X. Xxxxxxxx (xx.) Cambridge Xxxxxxxxxx Xxxxx, Cambridge, 184-232.
7) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx cells during xxxxx-xxxxxxxxx-xxxxxxx X2 arrest, Xxxxxxxxxx Xxx., 119, 403-413.
8) Xxxxx, Y., Xxxxxx, C., Xxxxxx, X. X. (1983), Xxxxxxxxxxx-xxxxxxx xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx xxxxx, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4C
"B.12 MUTAGENITA–TEST XXXXXXX ERYTROCYTÁRNÍCH MIKROJADER XX XXXX
1. METODA
Tato xxxxxx xx xxxxxxxx xxxxxx OECD XX 474 — Xxxx xxxxxxx xxxxxxxxxxxxxxx mikrojader xx xxxx (1997).
1.1 XXXX
Xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx xx vivo xx xxxxxxxx pro xxxxxxx xxxxxxxxx chromozomů xxxx xxxxxxxxxxx aparátu xxxxxxxxxxxx, xxxxx xx xxxxxxxxxx xxxxxxxxx xxxxxx, x to pomocí xxxxxxx xxxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx x/xxxx xxxxx xxxxxxxxx xxxx, xxxxxxx xxxxxxxx.
Xxxxxx xxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx je identifikovat xxxxx, xxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxxx je xxxxxx xxxxxxxxxx obsahujících xxxxxxxxxxxxx xx (xxxxxxx) chromozomové xxxxxxxxx xxxx xxxx xxxxxxxxxx.
Xxxx xx xxxxxxxxxxx xxxxxx xxxxx mění xx xxxxxxxxxxxxxxx erytrocyt, xxxxxx xxxxx xx xxxxxxxx x xxxxxxxxxx, xxxxx xxx tom xxxxx xxxxxxxxx, xxxxxxxxx x cytoplasmě, xxxxx xxxxx xxxxx xxxxxxxxxx. Xxxxxxxxxxxx xxxxxxxxxx je x xxxxxx xxxxxxx xxxxxxxxx tím, xx xxxxxxxxxx xxxxxx jádro. Xxxxxx výskytu polychromatických xxxxxxxxxx x mikrojádry x xxxxxxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X xxxxx xxxxx je xxxxxxx xxxxxxxxx xxxxxx dřeň xxxxxxxx, xxxxxxxx tato xxxx xxxxxxxxx polychromatické xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx s xxxxxxxxxx v xxxxxxxxx xxxx xx xxxxxxxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx, x něhož xxxx xxxxxxxxx neschopnost xxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx, xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx, xxxxx způsobují xxxxxxxxxx xxxx numerické xxxxxxxxxxxx aberace. Mikrojádra xxx xxxxxxxx řadou xxxxxxxx. Xx zahrnují xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxxxx centromerní (xxxxxxxxxxxx) XXX x xxxxxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx s xxxxxxxxxx. Xxxxx xxxxxxx (normochromatických) xxxxxxxxxx v periferní xxxx, xxxxx xxxxxxxx xxxxxxxxxx, připadající na xxxxxx xxxxx xxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxx xxxx konečný xxxxxxxx xxxxxxx, jestliže xxxx zvířata xxxxxxxxxx xxxxx xxxxx xxxx xxxx.
Xxxxx test xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx in xxxx xx xxxxxxx xxxxxx k xxxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx faktory xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx XXX, xxxxxxx xx mohou lišit x různých druhů x tkání, xxxxx x x genetického xxxxxxxx. Zkouška xx xxxx xx xxxxxx xxxxxxxx pro xxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxxxxxxx v xxxxxxxxx xx vitro.
Jestliže existuje xxxxx x xxx, xx se xxxxxxxx xxxxx nebo reaktivní xxxxxxxxxx xxxxxxxxxx xx xxxxxx tkáně, xxxx xxxxxx tuto zkoušku xxxxxx.
Xxx také Obecný xxxx, část X.
1.2 XXXXXXXX
Xxxxxxxxxx (xxxxxxxxxx) : xxxxxx (oblasti) chromozomu, x níž (x xxxx) xx xxxxx xxxxxx buněk připojí xxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx pohyb xxxxxxxxx xxxxxxxxxx k xxxxx xxxxxxxxx buněk.
Mikrojádra : xxxx jádra existující xxxxxxxx xx xxxxxxxx xxxxx x vedle xxxx, vytvářená během xxxxxxxx mitosy (xxxxxx) xxxxxxxxxxxxxxx xx (xxxxxxx) xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxx xxxxxxxxxx.
Xxxxxxxxxxxxxxxx xxxxxxxxx : zralý xxxxxxxxx xxxxxxxxxxxx ribozomy, který xxx rozlišit od xxxxxxxxx polychromatických erytrocytů xxxxxxxx xxxxxxxxxxx pro xxxxxxxx.
Xxxxxxxxxxxxxxx xxxxxxxxx : xxxxxxx xxxxxxxxx ve xxxxxxxxx mezistadiu, který xxxxx xxxxxxxx xxxxxxxx, x může xxx xxxx rozlišen od xxxxxxx normochromatických xxxxxxxxxx xxxxxxxx selektivním xxx xxxxxxxx.
1.3 PODSTATA XXXXXXXX XXXXXX
Xxxxxxx se xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxx. Xxx xxxxxxx xxxxxx dřeně xx xxxxxxx ve xxxxxxx xxxxxxxx xx xxxxxxxx xxxxxx, odebere xx xxxxxx xxxx, připraví xx xxxxxxxxx a xxxxxx xx (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx xxxxxxxxx xxxx se krev xx xxxxxxx okamžiku xx xxxxxxxx odebere, xxxxxxxxxx se xxxxxxxx xxxxxxxx a xxxxxx xx (4, 8, 9, 10). Při xxxxxxxx s xxxxxxxxx xxxx xx měla xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxx xxxxxxxx xx nejkratší xxxx. Xxxxxxxxx xxxx xxxxxxxxxxx na přítomnost xxxxxxxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Přípravky
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxx použití xxxxxx xxxxx se xxxx xxxxxxxxx xxxxx xxxxxxxxxx myš nebo xxxxxx, xxxxxx xxx xxxxxx jakýkoli vhodný xxxxx xxxx. Xxx xxxxxxx xxxxxxxxx xxxx xx xxxxxxxxxx xxx. Xxx xxxx xxxxxx xxxxxxxx vhodný xxxx xxxxx za xxxxxxxxxxx, xx xxx x xxxx, x xxxxx xxxxxxx xxxxxxxxxxxx erytrocyty x xxxxxxxxxx, xxxx xxxx xxxxxxxxxx dostatečnou xxxxxxxxx xxxxxxxxx činitele, xxxxx xxxxxxxxx xxxxxxxxxx xxxx numerické chromozomové xxxxxxx. Xxxx by xxx použity běžně xxxxxxx laboratorní xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx zahájení xxxxxx xx xxxx být xxxxxxxx v hmotnosti xxxxxx xxxxxxxxx x xxxxxx by x xxxx xxxxxxx xxxxxxxxx ± 20 % xxxxxxx hodnoty xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx xxxxxx podmínky xxxxx xxxxxxxx úvodu x xxxxx B, xxxxxxx by mělo xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx zvířata xx xxxxxxxx xxxxxxx rozdělí xx kontrolní xxxxxxx x xxxxxxx, x xxx se xxxxxxx xxxxxxxx. Xxxxxxx se xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx x xxxxxxxxxxxxx xxxxxxxxxx alespoň xxx xxx xxxxxxxxxxxxx. Xxxxx xx xxxxxxxxxx xxx, xxx xxx vliv xxxxxx xxxxxx minimalizován.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx rozpuštěny xxxx xxxxxxxxxxxx ve vhodných xxxxxxxxxxxxxx xxxx vehikulech x popřípadě xxxxxxx. Xxxxxxx xxxxxxxx látky xxxxx být xxxxxxxx xxxxx xxxx xxxxx xxx xxxx podáním xxxxxxx. Měly xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, pokud xxxxx x jejich xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx použitých úrovních xxxxx toxické xxxxxx x xxxx xx xxx vyloučeno xxxxxxxxx, xx reaguje se xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx být jejich xxxxxxxx xxxxxxxxx údaji x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx nejdříve zvážit xxxxxxx xxxxxxx rozpouštědel/vehikul.
1.4.2.2 Xxxxxxxx
Xxxxxxxx každého experimentu xx xxxx xxx xxxxxxxxx a negativní (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx pohlaví. X xxxxxxxx aplikace xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx proces xxxx xxxxxxx ve xxxxxxxxx, x xxxxx xxxxx k xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx měly xxxxxxxxxx mikrojádra xx xxxx xxx expozičních xxxxxxxx, x xxxxx xx xxxxxxx, že xxxxxxxxx detekovatelný xxxxxx xxx pozadí. Xxxxx xxxxxxxxx kontroly by xxxx xxx xxxxxxx xxx, aby xxx xxxxxx xxxxxxxx, ale xxx při xxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx přijatelné, xxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxx xxxxxxxx xxx zkoušená látka x aby xxx xxxxx x xxxxx xxxxxxx xxxxxxxx xxx xxxxxx. Pro xxxxxxxxx xxxxxxxx navíc může xxx xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx xxxxxxxx třídy, jsou-li x xxxxxxxxx. Příklady xxxxx pro xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx CAS |
Číslo podle XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx C |
50–07–7 |
200–008–6 |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx odběru xx měl xxx xxxxxxxx xxxxx u xxxxxxx negativní xxxxxxxx, xxxxx je aplikováno xxxxx rozpouštědlo nebo xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, pokud nejsou x xxxxxxxxxxx xxxxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx xxxxxx x xxxxxxxx xxxxx s xxxxxxxxxx. Provádí-li se xxx xxxxxxxxx kontrolu xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx nebo xxxxxx-xx publikovány xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx nebo xxxxxxxxx xxxxxx.
Xxx použití xxxxxxxxx xxxx xxxx xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxx krve odebraný xxxx xxxxxxxx, xxxxx xxxx u krátkých xxxxxx x periferní xxxx (xxxx. 1 — 3 xxxxxxxx) xx předpokladu, xx xxxxxxxx údaje budou x xxxxxxx, xxxxx xx na xxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx x xxxxxxx zvířat
Každá xxxxxxxxxx x xxxxxxxxx xxxxxxx xx xxxx xxxxxxx x xxxxxxx pěti xxxxxxxxxxxxxxxx xxxxxx xxx xxxxx xxxxxxx (11). Xxxxxxxx xxxx x xxxx xxxxxx x xxxxxxxxx údaje ze xxxxxx se xxxxxxx xxxxxx a xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxx prokazují, xx xxxxxxxxxx mezi xxxxxxxxx rozdíl x xxxxxxxx, bude xxxxxxxxxxx xxxxxxxx xxxxxxx pohlaví. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx pro xxxxxx xxxxxxx, xxxx xx xxxx xxxxxxxxx u xxxxxxxxx farmaceutických xxxxx, xxxx xx xxx xxxxxxx xxxxxxxxx se xxxxxxxx odpovídajícího xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxx (xx. jednu, xxx xxxx xxx xxxxxxxx x xxxxxxxxx 24 xxxxx). Xxxxxx xx xxxxxx x prodlouženým xxxxxxx podávání xxxx xxxxxxxxxx, pokud se x těchto xxxxxx xxxxxxx xxxxxxxxx výsledky, xxxx –x xxxxxxx xxxxxxxxxxx xxxxxx — xxxxx xxxx xxxxxxxxx xxxxxxxx nebo byla xxxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxxx xx xx xxxxxxxx xxxxxx. Xxxxxxxx látky xxxxx být podávány xxxx xx xxxx xxxxxxx, tzn. xxx xxxxx x týž xxx v xxxxxxx xx více xxx xxxxxxxx xxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx.
Xxxx xxxx xxx xxxxxxxx xxxxx xxxxxxx:
x) zkoušená xxxxx xx xxxxxxxx xxxxxxxx jednou. Xxxxxx xxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxx xxxxx xxxxx xx xxxxxxx xxxxxxxx 24 hodin xx xxxxxxxx x xxxxxxxx xxxxxxxxxx 48 xxxxx xx aplikaci a x xxxxxxxxxx odstupem xxxx xxxxxx. Odběr xxxxx xxx 24 xxxxx po xxxxxxxx xxxx xxx xxxxxxxxx. Xxxxxx xxxxxxxxx xxxx xx xxxxxxxx xxxxxxx xxxxxxx, přičemž xxxxx xxxxx xx provede xxxxxxxx 36 xxxxx xx xxxxxxxx a xxxxxxxx xxxxxxxxxx 72 xxxxx xx xxxxxxxx x xx xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxx xxxxxx. Je-li po xxxxxx xxxxxx pozorována xxxxxxxxx xxxxxxx, není xxxxx xxxxx xxxxx;
x) xxxx-xx xxxxxxxx dvě xxxx více xxxxx xxxxx (xxxx. xxx xxxx xxxx xxxxx x intervalu 24 xxxxx), měly xx xxx vzorky xxx xxxxxxx xxxxxx dřeně xxxxxxxx xxxxxx po 18 xx 24 xxxxxxxx po poslední xxxxxxxx a xxx xxxxxxx xxxxxxxxx krve xxxxxx po 36 xx 48 hodinách xx poslední aplikaci (12).
Xxxxx xxxxxxx xxxxx xxx xxxxx použity xxxx xxxx odběru.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx se xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx dávek, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, se xxxxxxx xxxxxx, kmenem, xxxxxxxx x za stejného xxxxxx xxxxxxxx, jež xx xxxxxxx x xxxxxx xxxxxx (13). X případě xxxxxxxx xx xxx xxxxx xxxxx xxxxxxx xxx xxxxxx xxxxx. Tyto xxxxxx dávky by xxxx pokrývat xxxxxxx xxxx xxxxxxxxx xx xxxxxxxxx toxicitou, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx nejvyšší xxxxx. Xxxxxxxx xxxxx je xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx takové xxxxxx xxxxxxxx, že xxxxx xxxxx xx vedly xxx stejném režimu xxxxxxxxx xxxxx očekávání x letalitě. Xxxxx xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx při xxxxxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxx a mitogeny) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx vyhovovat x xxxx xx být xxxxxxxxx xxxxxx od xxxxxxx. Xxxxxxxx dávka xxxx xxx xxxx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx x kostní xxxxx xxxxxxx xxxxxx xxxxxxxx (xxxx. xxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxx x celkového xxxxxxxx xxxxxxxxxx v xxxxxx xxxxx xxxx v xxxxxxxxx xxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx zkouška x xxxxxx xxxxxx o xxxxxxx 2000 mg/kg xxxxxxx hmotnosti podanou xxxxxxxxxxx xxxx xx xxxx xxxxxxx x xxxxxx dni xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x není-li xx základě xxxxx x xxxxxxx, které xxxx podobnou xxxxxxxxx, xxxxxxxxx genotoxicita, není xxxxxxxxxx úplná studie xx xxxxx úrovněmi xxxxx xx xxxxxxxxx. X déle xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx/xxx a xxx delší xxx 14xxxxx xxxxxxxx xx xxxxxxx dávkou 1000 xx/xx tělesné xxxxxxxxx/xxx. Xxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx vhodnou xxxxxxxxx xxxxxxx, nebo xxxxxxxxxxxxxxxxx injekcí. Jiné xxxxxxx xxxxxxxx jsou xxxxxxxxxx x odůvodnitelných xxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxx sondou xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx zvířete. Xxxxx xx xxxxx xxxxxxxxx 2 ml/100 x tělesné hmotnosti. Xxxxxxx vyšších xxxxxx, xxx xx xxxxxxx xxxxx, xxxx být xxxxxxxxxx. Xx na xxxxxxxx a žíravé xxxxx, které xxxxxxx xxx xxxxxxx koncentracích xxxxxxxx xxxxxxxx xxxxxx, xx xxxx xxx xxxxxxxxxxx zkušebního xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx všech xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxx xxxxx xxxx krve
Buňky xxxxxx dřeně xx xxxxxxx xxxxxxxxx x xxxxxx xxxx tibie xxxxx po xxxxxxxx. Xxxxx xx xxxxxxxx x xxxxxx xxxx xxxxx x xxxxxxxxxx xxxxxxxx se xxxxxxxxx x obarví. Periferní xxxx se xxxxxxx x ocasní žíly xxxx xxxx xxxxxx xxxxxx xxxx. Xxxxxx xxxxx xx xxxxx xxxxxxxxxxxx xxxxxx (8, 9, 10), xxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxx xx xxxxxx. Xxxxxxxx xxxxxxx specifického xxx XXX (xxxx. xxxxxxxxxx xxxxx (14) xxxx Xxxxxxx 33258 x xxxxxxx-X (15)) se xxx xxxxxxx některým xxxxxxxxxx xxxxxxxx s xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx XXX. Xxxx xxxxxx nebrání použití xxxxxxxxxxx xxxxxx (např. Xxxxxx). Xxxxxxxx xxxxxxx (xxxx. xxxxxxxxxx xxxxxx x xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxx (16)) xxx použít za xxxxxxxxxxx, že se xxxxxxxxx odpovídající xxxxxxxxx xxxxxx systémů xxx xxxxxxxxx xxxxxxxxxx v xxxxxxxxxx.
1.5.7 Analýza
Pro každé xxxxx se xxxxxxx xxxxx xxxxxxxxx erytrocytů x xxxxxxxxx (xxxxxxx + xxxxx) xxxxxxxx xxxxxxxxxx, přičemž se x případě kostní xxxxx použije xxxxxxx xxxxxxx 200 xxxxxxxxxx x v xxxxxxx xxxxxxxxx xxxx alespoň 1000 xxxxxxxxxx (17). Xxxxxxx xxxxxxxxx včetně xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, by xxxx být xxxx xxxxxxxx pod xxxxxxxxxxx xxxxxxxxx xxxxxxxx. X xxxxxxx zvířete xx xxxxxxx xxxxxxx 2000 xxxxxxxxx erytrocytů na xxxxxx xxxxxxxxxx x xxxxxxxxxxxxxxxxxxxxx. Xxxxx xxxxxxxxx xxxxx xxx xxxxxxx xxxxxxxxxx xxxxxxx erytrocytů xx xxxxxx xxxxxxxxxx. Xxx xxxxxxxxxxxxx xxxxxxx xx neměl být xxxxx nezralých erytrocytů x xxxxxxxxx xxxxxxxx xxxxxxxxxx menší xxx 20 % xxxxxxxxx xxxxxxx. Xxxxxxxx jsou xxxxxxx xxxxxxxxxx nepřetržitě xxxxx xxxxx xxxx xxxx, lze také xxxxxxxx xx xxxxxx xxxxxxxxxx xxxxxxx 2000 xxxxxxx erytrocytů xx xxxxx xxxxx. Systémy xxx automatickou xxxxxxx (xxxxxxx xxxxxx a xxxxxxxxx xxxxxxxxxxxx analýza xxxxxxx suspenze) jsou xx xxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx manuálního hodnocení.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxx xxx xxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxx ve xxxxx xxxxxxx. Experimentální xxxxxxxxx xx zvíře. Xxx xxxxx analyzované xxxxx xx xxx být xxxxxx xxxxx xxxxxxxxxxx xxxxxxxxx erytrocytů, xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx a xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx. Xxxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx xxxxx xxxx xxxx, xxxx xx xxx xxxx xxxxxxx xxxxx x xxxxxxx xxxxxxxxxxxx, xxxx-xx xxxxxxxxxxxxx. Pro xxxxx zvíře xx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx x xxxxxxxx množství erytrocytů x mikrojádry xxxxxxxxx x xxxxxxxxxx. Xxxxxxxxxx-xx xxxxx x xxxxxxx x odpovědi xxxx xxxxxxxxx, mohou být xxx statistickou xxxxxxx xxxxx xxx obě xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik xxxxxxxx, xxxx. xxxxxx xxxxx xxxxx s mikrojádry x xxxxxxxxxx na xxxxx xxxx xxxxx xxxxxx xxxxx xxxxx x mikrojádry pro xxxxxxx x xxxxxxx xxxxxx x k xxxxxxxx okamžiku xxxxxx. Xxxxxxxx xx xxxx xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx výsledků zkoušky xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (18, 19). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx být xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, nejlépe x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx látka, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, se xxxxxxxx x xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx poskytne xxxxx pozitivní xxxx xxxxxxxxx výsledky, v xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx údajů vyslovit xxxxxxx výrok x xxxxxxxx zkoušené xxxxx. Xxxxxxxx mohou xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx na xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxx na xxxxxxxxxx xxxxxxxxx, že zkoušená xxxxx xxxxxxxx xxxxxxxxxx, xxx jsou xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx nebo xxxxxxxxx mitotického xxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxx. Xxxxxxxxx výsledky znamenají, xx xxxxxxxx xxxxx xx podmínek xxxxxxx xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxx.
Xxxx by být xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx se xxxxxxxx xxxxx nebo její xxxxxxxxxx dostanou xx xxxxxxxx xxxxx, xxxx xxxxxxxxxx xx xxxxxx xxxxx (xxxx. systémová xxxxxxxx).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, je-li xxxxx.
Xxxxxxxxx xxxxxxx:
- použitý xxxx/xxxx,
- počet, xxxxx x pohlaví zvířat,
- xxxxx, xxxxxxxx chovu, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx na xxxxxxx zkoušky, xxxxxx xxxxxxx tělesné xxxxxxxxx, xxxxxxx hodnota x xxxxxxxxxx odchylka xxx xxxxxx skupinu.
Zkušební xxxxxxxx:
- xxxxx k xxxxxxxxx x negativní (xxxxxxxxx/xxxxxxxxxxxx) xxxxxxxx,
- údaje xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx metody xxxxxxx, xxx xx zkoušená xxxxx xxxxxxx xx xxxxxxxx oběhu xxxx xx cílové xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx látky x xxxxxx xxxx xxxx (ppm) xx xxxxxxxxxxxx dávku (mg/kg xxxxxxx xxxxxxxxx/xxx),
- podrobné xxxxx o xxxxxxx xxxxxx a xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- xxxxxxxx hodnocení xxxxxxxxxx x nezralých erytrocytech,
- xxxxx xxxxxxxxxxxxx xxxxx xx jedno zvíře,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx pozitivní, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx z celkového xxxxxxxx erytrocytů,
- xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx uvedený xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx hodnota ± xxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx xx xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx statistické xxxxxxx x metody,
- údaje x xxxxxxxx x xxxxxxxxx xxxxxxxxx kontrole,
- xxxxx x souběžné xxxxxxxxx kontrole.
Rozbor výsledků.
Závěry.
4. XXXXXXXXXX
1) Heddle, X. X. (1973), X Xxxxx Xx vivo Xxxx xxx Xxxxxxxxxxx Xxxxxx, Mutatation Res., 18, 187-190.
2) Schmid, X. (1975), Xxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 31, 9-15.
3) Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X., XxxXxxxxx, X. G., Xxxxxx, X. W. (1983), The Xxxxxxxxx xx Micronuclei a. x. x Xxxxxxx xx Genotoxicity, Xxxxxxxxxx Xxx. 123, 61-118.
4) Xxxxxxxxx, X. X., Xxxxxx, D. X., Xxxxxx, M. X., Xxxxxxxx, X. X., Xxxxxx, J. A. (1990), Xxx Xx xxxx Xxxxxxxxxxxx Xxxxx xx Mammalian Xxxx Xxxxxx xxx Xxxxxxxxxx Xxxxx. X report xx the X. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 239, 29-80.
5) XxxXxxxxx, X. X., Schlegel, R., Xxxx, X. N., Xxxx, X. M. (1983), Xxxxxxxxxxx in Xxxxxxxxxxx Xxxxxxxxxxxx: A Xxxxx Screen for Xxxxxxxxxxx Xxxxxx During Xxxxxxx Xxxxxxxx Xxxxxxx xx Mice, xx: Xxxxxxxxxxxx in Science xxx Xxxxxxxx xx Xxxxxxxxxx, ed. A. X. Xxxxx, R. X. Xxxxxxx, X. X. Xxxx. Xxxxxxxx, Xxxxxxxxx, 555-558.
6) XxxXxxxxx, X. X., Xxxxxx, X. X. Hite, X., Margolin, G. X., Xxxxx, C., Xxxxxxxx, X. X., Xxxx, X. X., Xxxx, X. (1987), Xxxxxxxxxx for xxx Xxxxxxx of Micronucleus Xxxxxx in Xxxxxxxxx Xxxx Xxxxxx Erythrocytes, Xxxxxxxxxx Res., 189, 103-112.
7) XxxXxxxxx, J. X., Xxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. X. (1990), The xx xxxx Xxxxxxxxxxx Xxxxxxxxxxxx Test: Xxxxxxxxxxx xx Steady State Xxxxxxxxx Xxxxx Xxxxxxxxxx xxx Xxxxxxx Integration xxxx Xxxxxxxx Xxxxxxx, Xxxxxx. Xxxx. Xxxxxxx. 14, 513-522.
8) Xxxxxxx, X., Morita, T., Xxxxxx, X., Sofumi, X., Xxxxxxxx, M. Xx. (1990), The Xxxxxxxxxxxx Xxxxx with Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxxx Xxxxx Acridine Xxxxxx-Xxxxxx Slides, Xxxxxxxxxx Xxx., 245, 245-249.
9) Xxx Xxxxxxxxxxxxx Study Xxxxx for xxx Xxxxxxxxxxxx Xxxx (1992). Xxxxxxxxxxxx Test xxxx Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxx xx Xxxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx: Xxx Xxxxxxx Report xx xxx 5xx Xxxxxxxxxxxxx Xxxxx by XXXXX/XXXXX, XXX, Xxxxxxxxxx Xxx., 278, 83-98.
10) Xxx Collaborative Xxxxx Xxxxx xxx the Xxxxxxxxxxxx Xxxx (XXXXX/XXXXX, XXX: Xxx Mammalian Xxxxxxxxxxx Xxxxx Xxxxx xx the Environmental Xxxxxxx Xxxxxxx xx Xxxxx) (1995), Protocol xxxxxxxxxxx xxx the xxxxx-xxxx xxxxx peripheral xxxxx xxxxxxxxxxxx xxxx, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, X., Xxxx, X. X., XxxXxxxxx, X. T., Xxxxxxxx, X., Xxxxxxx, X. X., Xxxxxx-Xxxxxxx, X., Xxxxxx, Xx. F. X., Pacchicrotti, X., Xxxxxxx, X., Xxxxxxx, X., Sutou, S., Xxxxxxx, X. (1994), Xx xxxx Rodent Xxxxxxxxxxx Xxxxxxxxxxxx Xxxxx, Xxxxx. Res., 312, 293-304.
12) Xxxxxxxxxxx, N., Xxxxx, X. (1995), Xx optimal, generalised xxxxxxxx xxxx xx 30 ± 6 x xxxxx double xxxxxx xx xxx xxxxx peripheral micronucleus xxxx, Xxxxxxxxxxx, 10, 313-319.
13) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. X., Botham, P. X., Xxx, X., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, G., Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. (1992), Xxxxxx xx Xxxxxxx Xxxxxxxxxx Xxxxxxx/XX Environmental Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Xxxx Xxxxxxx xx Xx vivo Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
14) Xxxxxxx, X., Xxxxxx, X., Xxxxxxxx, X. Xx. (1983), Xx Application of Xxxxxxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxx xx the Xxxxxxxxxxxx Xxxx, Mutation Xxx., 120, 241-247.
15) XxxXxxxxx, J. X., Xxxx, C. X., Xxxxxxxx, X. G. (1983), A Xxxxxx Xxxxxxxxxxx Staining Xxxxxxxxx xxx Xxxxxxxxxxx xxx XXX in Xxxxxxxxxxxx Xxxxx Xxxxxxx 33258 xxx Pyromin X, Xxxxxxxx Xxx., 120, 269-275.
16) Xxxxxxx, X., Xxxxxxxxxx, X. X. (1989), Xxx xxxxxxxxx xxxx xxxxxx micronucleus xxxx, Xxxxxxxxxx Res., 213, 91-104.
17) Gollapudi, X., XxXxxxxx, L. X. (1995), Sample Xxxx xxx the Xxxxxxxxxx of Polychromatic xx Normochromatic Xxxxxxxxxxx Xxxxx in the Xxxx Xxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 347, 97-99.
18) Xxxxxxx, X., Ashby, X., Xxxxxxx, J., Xxxxxxxx, X., Xxxxxxxxx, X. X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxxx Xxxxx, xx: X. J. Xxxxxxxx (xx.), Xxxxx Mutagenicity xxxxx, XXXXX Recommended Xxxxxxxxxx, XXXXX Xxx-Xxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Report, Xxxx 1, xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
19) Xxxxxx, X. X., Anderson, X., Albanese, X., Xxxxxxxx, G. X., Xxxxx, X., Ferguson X., Xxxxxxx, X., Xxxxxxxx, X. X., Xxxxxx, J. X. X. (1989), Xxxxxxxxxx Xxxxxxxx xx In xxxx Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (xx.), Statistical Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Data. XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Xxxxxxx. Xxxxxx, Xxxx III, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, New Xxxx, Xxxx Xxxxxxx, Melbourne, Xxxxxx, 184-232."
XXXXXXX 4X
"X.13/14 XXXXXXXXXX — XXXXXXX XX XXXXXXXX MUTACE X XXXXXXXXXX
1. METODA
Tato metoda xx xxxxxxxx xxxxxx XXXX TG 471 — Xxxxxxx xx xxxxxxxx mutace x xxxxxxxxxx (1997).
1.1 XXXX
Xxx xxxxxxx na xxxxxxxx xxxxxx x bakteriemi xx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx na xxxxxxxxxxxxxxx Salmonella typhimurium x Xxxxxxxxxxx xxxx, x xxxxxxx xxxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxxx, xxxxx x xxxxxx xxxxxxx xxxx xxxxxxxx párů xxxx XXX (1, 2, 3). Podstata této xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxx v xxxxxxx xxxxxx, xxxxx xxxxxxxxx xxxxxx xxxxxxxx v xxxxxxxxxxx kmenech x xxxxxxxx xxx funkční xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx aminokyseliny. Bakterie xx xxxxxxx xxxx xxxxxxxxxx díky xxx xxxxxxxxxx růst v xxxxxxxxxxxxx aminokyselin, které xxxx xxxxxxxxxx mateřským xxxxxxxxxx kmenem.
Bodové mutace x podobné jevy xxxx xxxxxxxx mnoha xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx a xxxxxxxx mnoho xxxxxx x xxx, že xxxxxx xxxxxx v xxxxxxxxxx x v xxxxxx xxxxxxxxxxx buněk xxxxxxxxx nádory xxxx xxxxx na xxxxxx xxxxxxxx x xxxxxxx x x xxxxxxxxx xxxxxx. Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxx, xxxxxxxxxx x relativně xxxxxx. Xxxxx xxxxxxxxxxx xxxxx xx xxxx xxxxxxxxxx, xxxx nimž xxxx xxxxxxxxxx na xxxxxxx mutací, xxxxxx xxxxxxxxxxxxx sekvencí DNA xx xxxxxxxxxx xxxxxxx, xxxxxxx xxxxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx x xxxxxxxxx reparačních xxxxxxx XXX nebo xxxxxxxx reparačních xxxxxxx XXX xxxxxxxxxx x xxxxxx. Xxxxxxxxxxxx xxxxxxxxxxx xxxxx může poskytnout xxxxxxx užitečné informace x xxxxxx mutací, xxx jsou indukovány xxxxxxxxxxxxx xxxxxxxx. Xxx xxxxxxx xx xxxxxxxx xxxxxx x bakteriemi xx k dispozici xxxxx xxxxxxxx databáze xxxxxxxx xxx xxxxxxx xxxxx xxxxxxxx a xxxx xxxx vyvinuty xxxxx xxxxxxxxxx metody xxxxxxxx xxxxxxxxxx xxxxx, xxxxxx xxxxxxxx sloučenin, x xxxxxxx xxxxxxxxx-xxxxxxxxxx xxxxxxxxxxx.
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxx xx xxxxxxxx xxxxxx x bakteriemi Xxxxxxxxxx typhimurium xxxx Xxxxxxxxxxx coli xxxxxx x xxxxxxx xxxxxx x xxxxx vyžadujícím xxxxxxxxxxxxx (histidin xxxx. xxxxxxxxx), xxxxxxx vzniká xxxx xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxxxxx.
Xxxxxxxx xxxxxxxxxx xxxx bází xxxx činitele, jež xxxxxxxxx xxxxx v xxxxxx XXX. Xxx xxxxxxx xxxxxxxxxx mutací xx xxxxx xxxx xxxxx xxxxxxxxxx xx xxxxx xxxxxxx mutace xxxx xxxxx xxxxx xxxxxxxxxxxxx genomu.
Posunové mutageny xxxx činitele, jež xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxx xxxx xxxx párů xxxx XXX a posunují xxx xxxxx xxxxx XXX.
1.3 VÝCHOZÍ ÚVAHY
Při xxxxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxxx xxxxx, které xx xxxx xx xxxxx xxxxx xxxxxxx, xxxx xxxx xxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx xxxxxxxxx a xxxxxxxxx procesy XXX. Xxxxxxx prováděné in xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Metabolické xxxxxxxxx xxxxxxx xx xxxxx nemohou xxxxx xxxxxxxxx xxxxxxxx in xxxx x savců. Xxxxxxx tedy xxxxxxxxxxx xxxxxx informaci x xxxxxxxxxx a xxxxxxxxxxxxx xxxxxxxxxx látky xxx xxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx xx xxxxxxxxx využívána xxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx, a xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxx xxxxxx. X xxxxxxxx xxxxxxxx vyplývá, xx xxxxx chemických xxxxx, xxxxx jsou x xxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxx xxxxxxxx i x xxxxxx zkouškách. Xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx, xxxxx nejsou xxxxxxxxxx xxxxx xxxxxxxx. Příčiny xxxxxx xxxxxxxxxxx xxx xxxxxxxxx ve xxxxxxxxxx xxxxxx detekovanéhokonečného xxxx, x xxxxxxxxx v xxxxxxxxxxx xxxxxxxx xxxx x xxxxxxxxx v xxxxxxxxxx dostupnosti. Xx xxxxx xxxxxx xxxxxxx, xxxxx zvyšují citlivost xxxxxxx xx xxxxxxxx xxxxxx xx xxxxxxxxxx, xxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxxx xx reverzní mutace x bakteriemi nemusí xxx vhodná xxx xxxxxx xxxxx xxxxxxxxxx xxxxx, xxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxxx (xxxx. xxxxxx xxxxxxxxxxx) a xxx chemické xxxxx, x nichž xx xxxxxxxxxxx (xxxx x xxxxx se xx), xx specificky xxxxxxxx xx replikačního systému xxxxx savců (xxxx. xxxxxxx xxxxxxxxxx topoisomerasy x některé xxxxxxx xxxxxxxxxx). X xxxxxxxx xxxxxxxxx mohou xxx xxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxx.
Xxxxxxxx mnoho xxxxxxxxx, xxx xxx xx tato xxxxxxx xxxxxxxxx, xx xxxxxxxxxxxx xxx xxxxx, xxxx xxxxxxxx absolutní. Xxxxxx xx xxxxxxxx xxxxx x existuje mnoho xxxxxxxxxxx, xxx nejsou xxxxxxxxxx xxxxx zkouškou, xxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, nebo xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx buňkách neexistují.
1.4 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxxx xxxxxxxxxxxxx xxxxx jsou xxxxxxxxx xxxxxxxx látce, x xx za xxxxxxxxxxx vnějšího metabolického xxxxxxxxxxx xxxxxxx x xxx xxxx. Xx xxxxxxxxxxx miskovém xxxxx xx suspenze xxxxxxxx x xxxxxxx xxxxxx x xxxxx xx xxxxxxx xx xxxxxxxxx xxxx. V xxxxxxxxxxxx xxxxxx se xxxxxxxx xxxx inkubuje x xxxx xx xxxx xxxxxxxxx na minimální xxxx xxxxxx x xxxxxxx agarem. Xxx xxxx xxxxxxxxxx se xx xxxx nebo xxxxx xxxxx xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxx xx xxxxxxxx x počtem xxxxxxx spontánních revertantů xx xxxxxxxxx xxxxx x rozpouštědlem.
Je xxxxxxx xxxxxxx xxxxxxx xxxxxxxxx xxxxxxx na xxxxxxxx xxxxxx x xxxxxxxxxx. Xxxx běžně používané xxxxx xxxxxxxxxx xxxxxxx xxxx (1, 2, 3, 4), xxxxxxxxxxxx xxxxxx (2, 3, 5, 6, 7, 8), xxxxxxxxxx xxxx (9, 10) x xxxxxxxxx xxxxxx (11). Xxxxxx xxx zkoušení xxxxx x xxx xxxx xxxxxxx (12).
Zde xxxxxxx xxxxxxx se xxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxx. Každá x nich xx xxxxxxxxxx xxx provádění xxxxxxxxxxx xxx x xxxxxxxxxxxx xxxxxxxx, xxx xxx xx. Xxxxxxx xxxxx lze xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxxx metody. Xxxx xxxxx xxxxx xx xxxxxxxxxx tříd, do xxxxx patří xxxx xxxxx xxxxxx alifatické xxxxxxxxxxx, dvojvazné xxxx, xxxxxxxx, azobarviva x xxxxxxxxxx xxxxxxxxxx, xxxxxxxxxxxxxxx xxxxxxxxx, allylové xxxxxxxxxx x xxxxxxxxxxxxxxx (3). Xxxxxx xx xxxxxxxxx, xx xxxxxx xxxxx xxxxxxxx nelze xxxx xxxxxxxxx standardními postupy, xxxx xx standardní xxxxxxx xxxx nebo xxxxxxxxxxxx metoda. Xxxx xx xxx xxxxxxxxxx xx "zvláštní případy" x x jejich xxxxxxx xx xxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxx. Xx xxxxx xxxxxxxxxxxxx xxxx "xxxxxxxx xxxxxxx" (xxxxxxxx x xxxxxxxx xxxxxxx jejich xxxxxxx): azobarviva x xxxxxxxxxx xxxxxxxxxx (3, 5, 6, 13), xxxxx a těkavé xxxxxxxx látky (12, 14, 15, 16), x xxxxxxxxx (17, 18). Xxxxxxxx xx xxxxxxxxxxxx xxxxxxx musí xxx xxxxxxx xxxxxxxxxx.
1.5 XXXXX ZKUŠEBNÍ XXXXXX
1.5.1 Xxxxxxxxx
1.5.1.1 Bakterie
Čerstvé xxxxxxx xxxxxxxx by xxxx xxx kultivovány do xxxxxx exponenciální xxxx xxxx do xxxxx xxxxxxxxxxx xxxx růstu (xxxxxxxxx 109 xxxxx xx xx). Buňky x pozdní xxxxxxxxxxx xxxx by neměly xxx xxxxxxx. Je xxxxxxxx, aby měly xxxxxxx bakterie vysoký xxxx xxxxxxxxxxxxxxx xxxxxxxx. Xxxx xxxx xxx xxxxxxxx xxx na xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxx x růstové xxxxxx, xxxx xxx xxxxxx xxxxxxx xxxxxxxxxx xxxxx životaschopných xxxxx xx xxxxxxx.
Xxxxxxxxxx xxxxxxxxx xxxxxxx je 37 °X.
Xxxx xx xxx xxxxxxx alespoň xxx xxxxx xxxxxxxx. Xxxx xxxx xx měly xxx čtyři xxxxx X. xxxxxxxxxxx (TA1535; XX1537 nebo TA97a xxxx XX97; TA98 x XX100), xxxxxxx xxxxxxx xx ukázala x xxxxxxx laboratořích xxxx xxxxxxxxxx a xxxxxxxxxxxxxxxx. Xxxx xxxxx xxxxx S. xxxxxxxxxxx xxxx xxx xxxx XX xx xxxxxxxxx xxxxxxxxx xxxxx x xx xxxxx, xx xxxxxx xxxxxxxxxxxxxxx nelze xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx, xxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx XXX x xxxxxxxxx. Tyto xxxxx mohou xxx xxxxxxxxxx xxxxx X. xxxx XX2 xxxx X. xxxxxxxxxxx XX102 (19), xxxxx xxxx xx primárním xxxxxxxxx xxxxx pár xxxx XX. Xxxxxxxxxx kombinace xxxxx je xxxx xxxx:
- X. xxxxxxxxxxx XX1535 a
- X. xxxxxxxxxxx XX1537 xxxx XX97x x
- X. xxxxxxxxxxx TA98 x
- X. xxxxxxxxxxx XX100 x
- E. xxxx XX2 uvrA, xxxx X. coli XX2 xxxX (xXX101), xxxx X. xxxxxxxxxxx XX102.
Xxx xxxxxxx mutagenů xxxxxxxxxxxxx xxxxxxxxxx xxxxxx DNA xxxx xxx xxxxxxxxx xxxxxxx TA102 xxxx xxxxxx xxxx X. xxxx x vysokou xxxxxxxxxx reparace XXX, (xxxx. X. xxxx XX2 (xXX101)).
Xxxx xx xxx použity zavedené xxxxxxx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxx x xxxxxxxxxx. Potřeba xxxxxxxxxxxxx pro růst xx xxxx být xxxxxxxxx pro xxxxxx xxxxxxxxx xxxxxxxx kulturu (xxxxxxxx xxx xxxxx X. typhimurium x xxxxxxxxx pro E. xxxx). Xxxxxxx xx xxxx být xxxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxxxx xxxxx potřeby xxxxxxxxxx nebo xxxxxxxxxxxx X-xxxxxxx xxxxxxxx (xx. xxxxxxxxxxxx rezistence x xxxxx TA98, XX100 x TA97a xxxx XX97, WP2 xxxX x XX2 xxxX (xXX101) x xxxxxxxxxxxx x xxxxxxxxxxxxxx xxxxxxxxxx x kmene TA102), xxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxx (xx. xxx mutací x S. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxxxx a xxxX xxxxxx u X. xxxx xxxx xxxX xxxxxx x S. xxxxxxxxxxx xxxxxxxxxx na xxxxxxxxxxxx xxxxxx) (2, 3). Kmeny xx xxxx rovněž xxxxx xxxxx kolonií xxxxxxxxxxx xxxxxxxxxx xx misce x rozmezí xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx x xxxxxxx x xxxxxxx xxxxxxxx x xxxxxxxxxx.
1.5.1.2 Xxxxxx
Xxxxxxx xx xxxxxx xxxxxxxxx xxxx (např. xxxxxxxxxx xxxxxxxxx xxxx X (Xxxxx-Xxxxxx) x xxxxxxx) x xxxxxx agar xxxxxxxxxx histidin x xxxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxx buněčných xxxxxx (1, 2, 9).
1.5.1.3 Xxxxxxxxxxx aktivace
Bakterie xx měly xxx xxxxxxxxx zkoušené látce, x xx s xxxxxxx xxxxxxxx metabolické xxxxxxxx a xxx xxxx. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx je xxxxxxxxxx xxxxxxxx postmitochondriální frakce (X9) xxxxxxxxxx z xxxxx hlodavců xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Xxxxxxx 1254 (1, 2) xxxx xxxxxxxxxxxxx x β-xxxxxxxxxxxx (18, 20, 21). Xxxxxxxxxxxxxxxxxxx xxxxxx xx obvykle xxxxxxxxx x koncentracích v xxxxxxx 5 xx 30 % xxx. xx xxxxx X9. Xxxxx x xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxx na xxxxx xxxxxxxx xxxxxxxx xxxxx. V některých xxxxxxxxx xxxx xxx xxxxxx použít xxxx xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx frakce. X xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx xxxx být xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx systému (6, 13).
1.5.1.4 Xxxxxxxx xxxxx nebo xxxxxxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xx bakterie xxxxxxxxxx nebo suspendovány xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx mohou xxx xxxxxxx xxxxx x testovacím xxxxxxxx x/xxxx mohou xxx xxxx xxxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx připravené xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx xxx xxxx podezření, xx reaguje se xxxxxxxxx látkou, x xxxx by být xxxxxxxxxx x xxxxxxxx xxxxxxxx x s xxxxxxxxx S9 (22). Xxxx-xx použita xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx být xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx xxxxx nejdříve xxxxxx použití xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx xx xxxx xx xxxx xxx použita organická xxxxxxxxxxxx xxxxxxxxxxxx xxxx.
1.5.2 Xxxxxxxx xxxxxxxx
1.5.2.1 Xxxxxxxx xxxxx (xxx 1.5.1.1)
1.5.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx xxxx být xxxxxxxxxx xxx stanovení xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxx xxxxxxxxxxxx x xxxxxxxxxxx v xxxxxxx směsi xxx xxxxxxxx.
Xxxx xxx užitečné xxxxxxxx xxxxxxxx x xxxxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx. Cytotoxicita může xxx xxxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxxxxxx, xxxxxxxxx nebo zeslabením xxxxxxxxxxxxx podkladu xxxx xxxxxxxx stupně přežití xxxxxxxxxxxx kultur. Xxxxxxxxxxxx xxxxx se může xxxxxx v přítomnosti xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxxxxxxxxxx xx xxxx xxx posouzena xx xxxxxxx xxxxxxxxxxx xxxxxxx x xxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxx rozpustné xxxxxxxxxxxxx xxxxx xx 5 xx/xxxxx xxxx 5 μx/xxxxx. X xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxx koncentracích 5 xx/xxxxx xxxx 5 μx/xxxxx by xxxx xxx xxxxx xxxx xxxx xxxxxxxxxx koncentrací xxxxxxxx, xxx xxxxx xxxx x xxxxxxx xxxxx pro aplikaci xxxxxxxxxxx. Xxxxxxxx látky, xxxxx xxxx cytotoxické xxx xxx koncentracích xxxxxxx xxx 5 xx/xxxxx xxxx 5 μx/xxxxx, xx xxxx xxx zkoušeny až xx xxxxxxxxxxx xxxxxxxxxxx. Xxxxxxxxx by neměla xxxxx při vyšetřování.
Mělo xx xxx použito xxxxxxx pět xxxxxxx xxxxxxxxxxxxxxxx koncentrací xxxxxxxx xxxxx, xxxxxxx xxx xxxxxx xxxxxxxxxxx xx xxxx být intervaly xxxx zkušebními xxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxx stupnice (xx. Ö10). Menší xxxxxxxxx xxxx xxxxxx x xxxxxxx, xxx xx xxxxxxxxx křivka xxxxxxxxxx odpovědi xx xxxxxxxxxxx. Zkoušení koncentrací xxxxxxx xxx 5 xx/xxxxx xxxx 5 μx/xxxxx může xxx xxxxxxx xxx xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx mutagenních xxxxxxxx.
1.5.2.3 Xxxxxxxxx x xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxx xx xxxx xxx xxxxxxx specifické xxxxxxxxx a negativní (xxxxxxxxxxxx xxxx xxxxxxxxx) xxxxxxxx x xxxxxxxxxxxx xxxxxxxx x bez xx. Xxx xxxxxxxxx xxxxxxxx by xxxx xxx vybrány koncentrace xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxx.
X xxxxxxx xxxxxxx x použitím xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx xx xxxx xxx látka (xxxxx) xxx pozitivní xxxxxxxx xxxxxxx (vybrány) xx xxxxxxx typu xxxxxxxxx xxxxx bakterií.
Příkladem xxxxxx xxxxxxxxx kontroly x xxxxxxx s xxxxxxxxxxxx xxxxxxxx xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx EINECS |
|
9,10-dimethylanthracen |
781–43–1 |
212–308–4 |
|
7,12-dimethylbenzo[a]anthracen |
57–97–6 |
200–359–5 |
|
benzo[a]pyren |
50–32–8 |
200–028–5 |
|
2-aminoanthracen |
613–13–8 |
210–330–9 |
|
Cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
Xxxx xxxxx je vhodnou xxxxxxxxx xxxxxxxxx pro xxxxxx redukční xxxxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
XX Direct Xxx 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx by xxxxx xxx použit jako xxxxxx xxxxxxxxx xxxxxxxxx xxxxx S9. Při xxxxxxx 2-xxxxxxxxxxxxxxx xx xxxx xxx xxxxx xxxxx X9 charakterizována xxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxx, například benzo[a]pyren xxxx 7,12-dimethylbenzo[a]anthracen.
Příkladem kmenověspecifické xxxxxxxxx xxxxxxxx x xxxxxxx bez xxxxxx xxxxxxxxxxx xxxxxxxx jsou xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
Xxxx |
|
xxxx sodný |
26628–22–8 |
247–852–1 |
TA1535 x XX100 |
|
2-xxxxxxxxxxxx |
607–57–8 |
210–138–5 |
XX98 |
|
9-xxxxxxxxxxxx |
90–45–9 |
201–995–6 |
XX1537, XX97 x XX97x |
|
XXX 191 |
17070–45–0 |
241–129–4 |
XX1537, XX97 a XX97x |
|
Xxxxxxxxxxxxxxxxx |
80–15–9 |
201–254–7 |
XX102 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
XX2xxxX a XX102 |
|
1-xxxxxx-3-xxxxx-1-xxxxxxxxxxxxxxx |
70–25–7 |
200–730–1 |
XX2, XX2 xxxX x XX2 uvrA (xXX101) |
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
XX2, XX2 uvrA x XX2 uvrA (pKM101) |
|
α-[(5-nitro-2-furyl)methyliden]furan-2-acetamid (XX2) |
3688–53–7 |
xxxxx xxxxxxxxxx xxxxxxxx |
Xxx xxxxxxxxx xxxxxxxx mohou xxx xxxxxxx xxxx xxxxxx xxxxxxxxxx xxxxx. Xxx xxxxxxxxx kontrolu xx xxxx být xxxxx x xxxxx xxxxxxx xxxxxxxxxx xxxxx xx xxxxxx chemické xxxxx, xxxx xx x xxxxxxxxx.
Xxxx by xxx použity xxxxxxxxx xxxxxxxx xxxxxxxxxx se xx xxxxxxxxx xxxxxxxxxxxx xxxx vehikula, xxx xxxxxxxx xxxxx, zpracované xxxxx xxxxxxx xxxxxxxx xxxx exponované skupiny. Xxxxx xxxx xx xxxx xxx neexponované xxxxxxxx použity také xxxxx, neexistují-li dosud xxxxxxxxx údaje xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx účinky.
1.5.3 Xxxxxx
X xxxxxxxxxx miskové xxxxxx (1, 2, 3, 4) bez xxxxxxxxxxx xxxxxxxx se xxxxxxx xxxxxx 0,05 xx nebo 0,1 xx zkušebních xxxxxxx, 0,1 xx čerstvé xxxxxxxxxxx xxxxxxx (xxxxxxxxxx xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x 0,5 xx xxxxxxxxxx xxxxx x 2,0 ml xxxxxxxx xxxxx. X xxxxxxx zkoušky s xxxxxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxx 0,5 xx xxxxxxxxxxx xxxxxxxxx xxxxx obsahující přiměřené xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (x rozmezí 5 xx 30 % xxx. x metabolické xxxxxxxxx směsi) x xxxxxxx xxxxxx (2,0 xx) x xxxxxxx x bakteriemi x xxxxxxxxx látkou xxxx xxxxxxxxx roztokem. Xxxxx xxxxx xxxxxxxx xx xxxxxxxx x xxxxxxx xxxx povrch minimálního xxxxx xx misce. Xxxx inkubací se xxxxx vrchní xxxx xxxxxxxx.
X xxxxxxxxxxxx xxxxxx (2, 3, 5, 6) xx xxxxxxxx xxxxx nebo xxxxxxxx xxxxxx před xxxxxxxxx x xxxxxxx agarem x xxxxxxxx xxxx xxxxxx minimálního agaru xx xxxxx xxxxxxx 20 xxxxx xxxx xxxx xxxxxxxxxxx s xxxxxxxxxx xxxxxx (obsahujícím xxxxxxxxx 108 životaschopných xxxxx) x sterilním xxxxxx nebo xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx (0,5 xx) xxx 30 — 37 °X. Xxxxxxx xx xxxxxx 0,05 nebo 0,1 xx xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxx, 0,1 xx xxxxxxxx x 0,5 xx xxxxx X9 xxxx xxxxxxxxxx xxxxx x 2,0 xx vrchního xxxxx. Xxxxxxxx xx xxxx xxx během xxxxxxxx provzdušňovány xx xxxxxxxx.
X xxxxxxxxxxxx odhadu xxxxxxxx xx měly xxx při xxxxx xxxxxx xxxxx použity 3 xxxxx. Xxxxxxx xxxx misek xx xxxxxxxxxx xx xxxxxxxx xxxxxxxxxx. Xxxxxxxx xxxxxx xxxxx xxxxxx znamenat xxxxxxxxxxxx zkoušky.
Plynné nebo xxxxxx látky xx xxxx být zkoušeny xxxxxxxx xxxxxxxx, např. x těsně uzavřených xxxxxxxxxxxx nádobách (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx misky x xxxx xxxxxxx xx xxxx být inkubovány xxx 37 °C xx 48 –72 xxxxxxxx. Xx xxxxxxxx xxxxxxxxx xxxx se xxxxxx počet kolonií xxxxxxxxxx na xxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxx xxxxx by xxxx xxx xxxxx xxxxxxx xxxxxxxxxx připadající na xxxxx. Měl xx xxx rovněž uveden xxxxx kolonií xxxxxxxxxx xxx na miskách x xxxxxxxxx xxxxxxxxx (xxxxxxxx rozpouštědla x xxxxxxxx neexponovaná xxxxxxxx), xxx xx xxxxxxx x xxxxxxxxx xxxxxxxxx. Xxxxx na xxxxxxxxxxxx xxxxxxx, xxxxxxx xxxxxxx xxxxx kolonií xxxxxxxxxx xx misku x xxxxxxxxxx xxxxxxxx by xxxx být xxxxxxxxxx xxx xxxxxxxxx xxxxx x xxxxxxxxx a xxxxxxxxx kontrolu (xxxxxxxxxxxxx xxxxxxxx x/xxxx kontrolu xxxxxxxxxxxx).
Xxxxxxx xxxxx pozitivní xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx výsledky xx xxxx být xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x úpravou xxxxxxxxxxxxxxxx xxxxxxxx. Negativní xxxxxxxx xxxx xxx xxxxxxxxx xxxxxx od případu. Xxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xx nezbytné, mělo xx xxx podáno xxxxxxxxxx. Xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxxxxx xxxxxx posuzovaných xxxxxxxx xx xxxx xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X xxxxxxxxxx studie, které xx xxxxx být xxxxxxx, xxxxx rozmezí xxxxxxxxxxx, xxxxxx xxxxxxxxxx (xxxxxxxxxx misková metoda xxxx xxxxxxxxxxx v xxxxxxxx xxxxx) x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx existuje několik xxxxxxxx, např. nárůst xxxxx xxxxxxx xxxxxxxxxx xx xxxxx nad xxxxxxxxx xxxxxx u xxxxxxx xxxxxxx xxxxx x xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxx xxxx, x xx x závislosti xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx jednu xxxx xxxx xxxxxxxxxxx (23). Xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx výsledků. Xxx xxxxxxxxx xxxxxxxx zkoušky xxxxx být xxxxxxx xxxx pomocný prostředek xxxxxxxxxxx metody (24). Xxxxxxxxxxx významnost xx xxxxxx být xxxxxxx xxxxxxxxx faktorem pro xxxxxxxxx odpověď.
Zkoušená látka, xxxxx xxxxxxxx xxxxxxxxx xxxx uvedená xxxxxxxx, xx xxxxxxxx v xxxxx xxxxxxx za xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx negativní xxxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Výsledky xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx bez xxxxxx xx xx, xxxxxxxx xx experiment xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx xxxxxxxxx, že xxxxxxxx xxxxx indukuje x xxxxxx xxxxx Xxxxxxxxxx xxxxxxxxxxx a/nebo Xxxxxxxxxxx xxxx xxxxxx xxxxxx xxxxxxxxxx xxxx xxxx xxxxxxx xxxxxxx xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxx za xxxxxxxx xxxxxxx pro xxxxxxxxx druhy xxxxxxxxx.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx xxxxxxxxx xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx xxxxx xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx a stálost xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxxxxxx xxxxx,
- xxxxx xxxxx x kultuře,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxx xxxxxxxx xxxxx xx misku (xx/xxxxx xxxx μl/misku) x xxxxxxxxxxx výběru xxxxx x xxxxx misek xx koncentraci,
- xxxxxxx xxxxx,
- xxx x xxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxxxx xxxxxxxx xxxxxxxxxxxxx,
- xxxxxx xxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx xxxxxxx,
- počty xx xxxxxxxxxxxx xxxxxxx,
- xxxxxxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxx xx xxxxx x xxxxxxxxxx xxxxxxxx,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx kontrole s xxxxxxxxx, středními xxxxxxxxx x směrodatnými xxxxxxxxxx,
- xxxxxxxxx xxxxx o xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx s xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxx, X. N., McCann, X., Xxxxxxxx X. (1975), Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx with xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Test, Xxxxxxxxxx Res., 31, 347-364.
2) Xxxxx, X. X., Xxxx, X. X. (1983), Revised Xxxxxxx for the Xxxxxxxxxx Mutagenicity Test, Xxxxxxxxxx Xxx., 113, 173-215.
3) Xxxxxxxxx, X., Xxxxxxx, X., Xxxxxx, X., Xxxxx, E., Xxxx, L., Matsushima, X., Xxxxxxx, X., Xxxxx, X., Xxxxxx, X., Xxxxxx, E. (1994), Xxxxxxxxxxxxxxx for xxx Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxx Xxxxxx, Xxxxxxxxxx Res., 312, 217-233.
4) Kier, L. X., Xxxxxxx X. X., Auletta, X. X., Xxx Xxxxx, X. X., Brown, X. M., Xxxxxx, X. F., Xxxxxx, X., XxXxxx, X., Xxxxxxxxxx, X., Xxxxxx, X., Xxx, X. X., Xxx V. (1986), Xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxxx Xxxxx: X Xxxxxx xx xxx U. X. Xxxxxxxxxxxxx Protection Agency Xxxx-Xxx Xxxxxxx, Mutatation Xxx., 168, 69-240.
5) Xxxxxx, X., Xxxxxx, X., Xxxxx, X. X., Xxxxxxxxxx, T., Xxxxx, X., Sugimura, X., Xxxxxxxxx, X. (1975), Xxxxxxxxxxxx xx Xxxxxxxxxx Azo Xxxx xxx their Xxxxxxxxxxx, Xxxxxx Xxxx. 1, 91-96.
6) Matsushima, M., Xxxxxxxx, T., Xxxxx, X., Yahagi, X., Xxxxxx, A., Sawamura, X. (1980), Xxxxxxx Xxxxxxxxxx Xxxxxxxxxxxx Microbial Xxxxx, xx: Xxxxx-xxxx Xxxx Xxxxxxx xxx Xxxxxxxxx Xxxxxxxxxxx, xx. Xxxxxxx X. X., Xxxxxx, X. X., Xxxxxxxx, Xxxxxx-Xxxxxxxxxx-Xxx York, 273-285.
7) Xxxxxxxxx, X. X., Xxxxxxx, X. X., Xxxxxx, X., Xxxxxxxxx, X. D., Xxxxxx, X. (1980), Xxxxxxxxx Xxxxxxxx Xxxxxx, xx: Xxxxx Xxxxxxxxxxxx Xxxxx: XXXXX Xxxx 1 Revised, xx. X. X. Xxxxxxxx, Xxxxxxxxx Xxxxxxxxxx Press, 13-61.
8) Xxxxxxxxxx, H. X., Wolleb, X., Xxxxxxx, X. (1987), Xxxxxx Preincubation Mutagenicity Xxxx xxx Foods, X. Food Safety., 8, 167-177.
9) Xxxxx, X. X. X., Xxxxxx, X. J., Xxxxxxx, X. A. (1976), Use xx x simplified xxxxxxxxxxx xxxx xx xxxxxx xxx levels xx xxxxxxxx, Xxxxxxxxxx Xxx., 38, 33-42.
10) Xxxxxxx, X. X., Xxxxx, X. X. L., Xxxxxxxxx, X., Xxxxxxx, X. X. (1984), Xxx Xxxxxxxxxxx Xxxx xx Bacteria, in: Xxxxxxxx xx Xxxxxxxxxxxx Xxxx Procedures, 2. xxx., Kilbey, X. X., Legator, X., Xxxxxxx, X., Ramel, X. (eds.), Xxxxxxxx, Xxxxxxxxx-Xxx York-Oxford, 141-161.
11) Xxxxxxxx, X. X., Xxxxxxx, X. J. (1981), An Examination xx the Xxxxxxxxxxxx Xxxxxxxxxx Assay xxx Xxxxxxxxxxx xxxx Strains xx Xxxxxxxxxx xxxxxxxxxxx, Xxxxxxxxxxxxx Xxxxxxxxxxx, 3, 453-465.
12) Xxxxx, X., Xxxxxxx, X., Kato, X., Xxxxxxxxxx, X. (1994), Xxxxxxxx Xxxxxx xxx Xxxxxxxxxxxx Xxxxxxx xx Gaseous Compounds xx Xxxxx x Xxx Sampling Xxx, Xxxxxxxxxx Res., 307, 335-344.
13) Xxxxxx, X. X., Xxxx, S. X., Mitchell, X. X., Reipert, M. X., Vaughan, X. X. (1984), Xxxxxxxxxxxx xx Xxxxxxxxx xxx Xxxxxxxxx-Xxxxxxxx Xxxx xxx Xxxxxxxx Xxxxxxx Xxxx xx x Modified Xxxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 136, 33-47.
14) Xxxxxx, X., Xxxxxxxx, X. E., Xxxxxxx, X., Lawlor, X., Xxxxxxxxxx, K. (1992), Xxxxxxxxxx Mutagenicity Xxxxx. X. Xxxxxxx xxxx xxx Testing xx 311 Chemicals, Xxxxxxx. Xxx. Mutagen., 19, 2-141.
15) Xxxxxx, X., Xxxxxxxx, K., Xxxxxxx, X. X. (1977), Xxxxxxxxx Activity of Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxx Xxxxx, xx Xxxxxxxx xx Genetic Xxxxxxxxxx, X. Xxxxx, X. Xxxxxxx, X. Xxxxxx (xxx.) Xxxxxxxx, Xxxxxxxxx, 249-258.
16) Xxxxxx, X. J., Xxxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. D. (1987), Xxxxxxxxxxxx Technique xx Xxxxxxx Mutagenic Xxxxxxxx xx Xxxxxxxx Xxxxxxx Xxxxxxxxx xx the Xxxx/Xxxxxxxxxx Xxxxx, Environmental Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, T., Xxxxxxxxx, X., Shirai, X., Xxxxxxxx, X., Xxxxxxxx, X. (1979), Xxxxxxxxxxxx xx the Naturally Xxxxxxxxx Carcinogen Cycasin xxx Synthetic Xxxxxxxxxxx Xxxxxxx Xxxxxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx, Xxxxxx Xxx., 39, 3780-3782.
18) Xxxxxx, X., Xxxx, X., Ferro-Luzzi, X., Xxxx, B. X. (1980), Xxxxxxxx: X Xxxxx xxx Xxxxxxxxxx xx Xxxxxxx Xxxxxxxxxx xx Mutagens xx Xxxxxxxxxx Xxxxx, Xxxx. Xxxx. Acad. Xxx. X. S. X, 77, 4961-4965.
19) Wilcox, X., Xxxxxx, A., Xxxx, X. J., Xxxxxxxxx, D. X. (1990), Xxxxxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx TA 102 xxxx Escherichia xxxx XX2 Xxxxxx xxxxxxx, Xxxxxxxxxxx, 5, 285-291.
20) Xxxxxxxxxx, T., Xxxxxxxx, M., Xxxx, X., Xxxxxxxx, T. (1976), X Xxxx Xxxxxxxxxx for Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Inducer or Xxxxxxxxx Activation Xxxxxxx, xx: Xx xxxxx Xxxxxxxxx Activation in Xxxxxxxxxxx Testing, eds. X. J. de Xxxxxx xx xx. Xxxxxxxx, Xxxxx Holland, 85-88.
21) Xxxxxx, X. X., Combes, R. X., Elcombe, C. X., Gatehouse, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxx, X. X. (1992), Xxxxxxxxxxxx xx Aroclor 1254-induced X9 xx in xxxxx Genotoxicity Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, D., Xxxxxxxxxxxxxxxx, X., Ames, B. X. (1981), Xxxxxxxxxxxxx xx Xxxxxxx Xxxxxxxx xxxx xxx Salmonella/Microsome Xxxx, Xxxxxxxxxx Xxx., 88, 343-350.
23) Xxxxxxx, X. D., Xxxxx, X., Xxxxxxx, X., Xxxxxxxxxx, X., Xxxxxxxx, X., Zeiger, X. (1987), Xxxxx xxx xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxx xxx Xxxxxxxxx Xxxxxxxxxxxx, Mutatation Xxx., 189, 83-91.
24) Xxxxx, X. A. X., Xxxxx, X. X. X., Middleton, X., Mitchel, X., Xxxxxxxx, X. X., Xxxxxx, X. X. (1989), Analysis xx Xxxx from Xxxxxxxxx Xxxxxx Xxxxxx, xx: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxx II. Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, xx. Kirkland, D. X., Cambridge Xxxxxxxxxx Xxxxx, 28-65."
PŘÍLOHA 4X
"X.17 XXXXXXXXXX — ZKOUŠKA XX XXXXXX XXXXXX V XXXXXXX XXXXX XX XXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx XXXX TG 476 — Xxxxxxx na xxxxxx xxxxxx v xxxxxxx xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx genové xxxxxx x xxxxxxx xxxxx xx vitro lze xxxxxx xxx xxxxxxx xxxxxxxx mutací xxxxxxxxxxxx xxxxxxxxxx xxxxxxx. Mezi xxxxxx buněčné xxxxx xxxxx buňky xxxxxxx X5178X myší, xxxxxxx xxxxx CHO, XXX-XX52 x X79 xxxxxx xxxxxxxx a xxxxxxxxxxxxxxx xxxxx XX6 xxxxxxx (1). X těchto xxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxx xxxxxx genů xxx thymidinkinasu (XX) x xxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX) x xxxxxxxx xxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX). Xxxxxxx xx xxxxxx XX, XXXX x XPRT xxxxxxxx xxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx. Autosomální xxxxxx XX a XPRT xxxx xxxxxxx detekci xxxxxxxxxxx xxxxxxxx (např. xxxxxxxx delece), xxxxx xxxxx xxxxxxxxx x XXXX xxxxxx xx X chromozomech (2, 3, 4, 5, 6).
Xx zkoušce xx xxxxxx xxxxxx x xxxxxxx xxxxx xx xxxxx xxx xxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxx xxxx xxxxxxx xxxxx. Xxxxx xx xxxxxxxx podle schopnosti xxxxx x xxxxxxx x xxxxxxxx četnosti xxxxxxxxxxx mutací.
Zkoušky xxxxxxxxx xx xxxxx obecně xxxxxxxx xxxxxxx vnějšího xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxx metabolický xxxxxxxxx xxxxxx nemůže xxxxx xxxxxxxxx xxxxxxxx in xxxx u savců. Xx xxxxx se xxxxx vyvarovat xxxxxxxx, xxxxx xx xxxxx x xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx vlastní xxxxxxxxxx. X xxxxxxxxxx xxxxxxxxx, xxx neodrážejí xxxxxxx xxxxxxxxxx, může xxxxx změnou pH, xxxxxxxxxx nebo xxxxxxxx xxxxxx xxxxxxxxxxxx (7).
Xxxx xxxxxxx xx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxx a xxxxxxxxxxx xxxxx. Xxxxx xxxxxxxxx, xxx něž je xxxx xxxxxxx xxxxxxxxx, xxxx xxxxxxxxxxx xxxxx; xxxx xxxxx xxxxxxxx x karcinogenitou xxxx xxxx absolutní xxxxxxxx. Xxxxxxxx xxxxxx xx xxxxxxxx xxxxx x xxxxxxxxx xxxxxx x xxx, xx xxxxxxxx xxxxxxxxxxx, které xxxxxx xxxxxxxx touto zkouškou, xxxxx xxxxxx působí xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx xxxxxxx xxxxxxxxxx (6).
Xxx xxxx xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxx mutace : xxxxxx xxxxxx xxxxxxxxx xxxx xxxxxxxx xxxxx, která způsobuje xxxxx nebo xxxxxx xxxxxxxxxxx xxxxxxxx kódovaných xxxxxxxx.
Xxxxxxxx xxxxxxxxxx xxxx xxxx : látky, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxx nebo více xxxx bází v XXX.
Xxxxxxxx mutageny : xxxxx, které způsobují xxxxx nebo deleci xxxxxxx nebo více xxxx bází x xxxxxxxx XXX.
Xxxx xxxxxxx xxxxxxxx : xxxx, xxxxx xxx xxxxxx x nově xxxxxxxxxx xxxxx xxxxxxxxx genové xxxxxxxx.
Xxxxxxx xxxxxxx : xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxx xxxxxxxxxxxxxxx buněk.
Relativní xxxxxxx xxxx : xxxxxx xxxxx xxxxx x xxxx ve xxxxxxxx x xxxxxxxxx xxxxxxxx xxxxx; xxxxxxx xx xxxx xxxxxx xxxxxx xxxxxxxxx růstu x xxxxxxxx a v xxxxxxxxx kontrole x xxxxxxxxx účinnosti xxxxxxxxx xxxxxxxx k negativní xxxxxxxx.
Xxxxxxxxx růst x xxxxxxxx : nárůst xxxxx xxxxx x xxxxxxx xxxxxxx xxxxxxxx x negativní kontrole.
Životaschopnost : xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xx xxxxx xx xxxxxxxxxxxx xxxxxxxx xx expresi.
Přežití : xxxxxxxx xxxxxxxxx xxxxx xxx nasazení xx xxxxx xx konci xxxxxx xxxxxxxx; xxxxxxx xx xxxxxxx vyjádřeno x xxxxxx x xxxxxxx kontrolní xxxxxxxx xxxxx.
1.3 PODSTATA ZKUŠEBNÍ XXXXXX
Xxxxx, xxxxx x xxxxxxxx xxxxxx XX+/-® XX— /- neobsahují xxxxxxxxxxxxxx (XX) xxxx xxxxxxxxxxx k cytotoxickým xxxxxxx analogu xxxxxxxxxx xxxxxxxxxxxxxxxxx (XXX). Xxxxx xxxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxx na XXX, xxx xxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxx buněčné xxxxxx. Mutantní xxxxx xxxx tedy schopny xxxxxxxxxxx xx xxxxxxxxxxx XXX, xxxxxxx xxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxxxxxxx tuto xxxxxxxxx xxxxxx. Xxxxxxx xxx x buněk s xxxxxxxxxxxx XXXX xxxx XXXX provést xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x 6-xxxxxxxxxxx (XX) nebo 8-xxxxxxxxxx (AG). Xxxxxxxxxx xxxxxxxx xxxxx xx xxxx xxx xxxxxxx xxxxxxx, jestliže je xx xxxxxxx xx xxxxxx mutace v xxxxxxx xxxxx zkoušen xxxxxx xxxx nebo xxxxxxxxxx podobná selekčnímu xxxxxxx. Xxxx xx xxx například xxxxxxxxx xxxxxxxx podezření na xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx pro xxxxxxxx xxxx xxxxxxxxxx xxxxx. Xxx xxxxxxxx xxxxxxxxxx xxxxx, xxxxx mají xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxxxxxx, xxxx xxxx xxx xxxxxxxxx xxxxxxxx systému xxxx xxxxxxx xxx selekci (8).
Xxxxx x xxxxxxxxx xxxx jednovrstevné xxxxxxx xxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx látce xxx s xxxxxxxxxxxx xxxxxxxx, xxx xxx xx, x xxxxxxxxxxxxxx xx xxxxxx xxxxxxxxx xxxxxxxxxxxx x xx xxxxxx exprese xxxxxxxx xxxx xxxxxxx xxxxxxx (9, 10, 11, 12, 13). Cytotoxicita xx xxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxx xxxxxxxxxxx celkového xxxxx kultur xx xxxxxxxx xxxx xxxxxxxx. Xxxxxxxxxx xxxxxxx xx xxxxxxx v xxxxxxxx xxxxx xx xxxxxxx xxxx xxxxxxxxxxxxxxxxx xxx xxxxx zvolený lokus x xxx xxxxx, xxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxx exprese xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxx xx stanoví xxx, že xx xxxxxx xxxxx počet xxxxx xx xxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxx detekci mutantních xxxxx x do xxxxx xxx xxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxx účinnost xxxxxxxxx (xxxxxxxxxxxxxxx). Xx xxxxxx xxxxxxxxx době xx xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxx se xxxxxxx x xxxxx xxxxxxxxxx xxxxxxx v selekčním xxxxx x xxxxx xxxxxxx x xxxxx xxx xxxxxxxxxx xxxxxxx.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxx xxxxxxx x xxxx xxxxxxx xxxx k dispozici xxxxx xxxx xxxxx, xxxxxx subklonů xxxxx X5171X, CHO, XXX-XX52, X79 nebo XX6. Xxxx xxxxx v xxxx zkoušce xx xxxx vykazovat xxxxxxxxx x chemickým xxxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx x stabilní xxxxxxxxx xxxxxxxxxxx mutací. Xxxxx xx měly xxx xxxxxxxxxxxx, zda xxxxxx xxxxxxxxxxxxx xxxxxxxxxxxx, x x xxxxxxx kontaminace xx neměly xxx xxxxxxx.
Xxxxxxx by xxxx xxx navrženy tak, xxx xxxx xxxxxx xxxxxxxxxx citlivost a xxxx. Xxxxx použitých xxxxx, xxxxxx x xxxxxxxxxxx xxxxxxxx xxxxx xx xxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (14). Minimální xxxxx xxxxx, které xxxxxxx xxxxxxxx x které xxxxx použity x xxxxxx stadiu xxxxxxx, xx xxx xxx xxxxxxx xx xxxxxxxx xxxxxxxxxxx mutací. Xxxxxxx xxxxxxxxx xx, aby xxx xxxxxx xxxxx xxxxx, xxxxx xx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx. Xx však xxxxxxxxxx, xxx xxxx použito xxxxxxx 106 xxxxx. Xxxx xx xxx x dispozici xxxxxxxxxx xxxxxxxxx xxxxx o xxxxxxxx xxxxxxxx xxxxxxx, xxx xxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx.
1.4.1.2 Média x xxxxxxxxxx podmínky
Pro xxxxxxxxx xxxxxx xx xxxx xxx xxxxxxx xxxxxx xxxxxxxxxx média x xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, koncentrace CO2, xxxxxxx a xxxxxxx). Xxxxx xx xxxx xxx xxxxxxx xxxxx xxxxxxxxxx systémů x xxxx xxxxx xxxxxxxxx xxx xxxxxxx. Xx xxxxxxx xxxxxxxx, aby xxxxxxxxxx xxxxxxxx byly xxxxxxx tak, xxx xxxx zajištěny optimální xxxx buněk xxxxx xxxxxx exprese a xxxxxxxxx jak xxxxxxxxxx, xxx nemutovaných xxxxx xxxxxx xxxxxxx.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxx by měly xxx xxxxxxxxx z xxxxxxxxx xxxxxx, xxxxxxxx xx xxxxxxxxxxxx xxxxx x xxxxxxxxxx xxx 37 °C. Před xxxxxxxx v xxxx xxxxxxx může xxx xxxxxxxx xxxxxxxxx z xxxxxxx xxx xxxxxxxx xxxxxxxx xxxxx.
1.4.1.4 Metabolická xxxxxxxx
Xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, a to x xxxxxxx xxxxxxxx xxxxxxxxxxx aktivace a xxx xxxx. Nejčastěji xxxxxxxxxx xxxxxxxx xx xxxxxxxxxx dotovaná postmitochondriální xxxxxx (X9) xxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, jako xx Xxxxxxx 1254 (15, 16, 17 x 18), nebo xxxx xxxxxxxxxxxxx x β-naftoflavonu (19, 20).
Postmitochondriální xxxxxx xx x xxxxxxxx xxxxxxxxxx médiu xxxxxxx xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % xxx. Xxxxx x stav metabolického xxxxxxxxxxx xxxxxxx může xxxxxxx xx xxxxx xxxxxxxx látky, xxxxx xx xxxxxxxx. V xxxxxxxxx xxxxxxxxx xxxx xxx xxxxxx použít xxxx xxx xxxxx xxxxxxxxxxx postmitochondriální frakce.
Řada xxxxxxxx xxxxxx, včetně xxxxxxxx xxxxxxxxx modifikovaných xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx možnosti xxx xxxxxxxxx xxxxxxxx. Volba xxxxxxxxx xxxxxxxxx xxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx isoenzymu xxxxxxxxxx X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Příprava xxxxxxxx látky
Pevné xxxxxxxx xxxxx xx xxxx xxx xxxx aplikací xx xxxxx rozpuštěny xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx nebo xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx xxxxxxx xxxxx k xxxxxxxxxx systémům a/nebo xxxxx xxx xxxx xxxxxxxx zředěny. Xxxx xx být xxxxxxx xxxxxxx xxxxxxxxxx zkoušené xxxxxxxx xxxxx, pokud xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxx xxx xxxx xxxxxxxxx, že xxxxxxx xx xxxxxxxxx xxxxxx, x xxxx xx xxx slučitelné x xxxxxxxx xxxxx x x xxxxxxxxx X9. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx údaji x xxxxxx kompatibilitě. Xxxxxxxxxx xx xxxxx možno xxxxxxxx zvážit xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Při xxxxxxxx xxxxx nestálých xx xxxx xx xxxx být použitá xxxxxxxxx xxxxxxxxxxxx neobsahující xxxx. Xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx koncentrace
Mezi xxxxxxxx, která xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxx koncentrace, xxxxx xxxxxxxxxxxx, rozpustnost x xxxxxxxxxx xxxxxxx x změny xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx xxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxx x xxx xx x xxxxxxx experimentu xx xxxxxxx vhodných xxxxxxxxxx xxxxxxx xxxxxxxxx x xxxxx, xxxx xxxx relativní xxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxx být xxxxxxx xxxxxxxx xxxxxxxxxxxx x xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx by xxx xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxxx. X xxxxxxx xxxxxxxx xx xxxx xxxx xxxxxxxxxxx xxxxxxxx rozmezí xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx, případně xxxxxx xxxxxxxxx, což xxxx xxxxxxx znamenat, že xx se koncentrace xxxx xxxxx xxxxxxxx 2 xx Ö10. Xx-xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx, xxxx xx xxx xxxxxxxxx xxxxxxxxx 10 — 20 % (xxx xxxxxxx 10 %) xxxxxxx (xxxxxxxxx xxxxxxxx xxxxxxxxx) nebo xxxxxxxxx celkový xxxx. X xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx xxxxx xx xxxx být maximální xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 xx/xx xxxx 0,01 M, xxxxx toho, xxxxx x nich xx xxxxxxxx.
Xxxxxxxxx nerozpustné xxxxx xx měly xxx xxxxxxxx až x xxxx xxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxxxx, xxxx xx xx tuto xxx. Měla by xxx stanovena případná xxxxxxxxxxxxx x konečném xxxxx, xx kterému xxxx xxxxx xxxxxxxxxx. Xxxx xxx xxxxxxx xxxxxxxx rozpustnost xx xxxxxxx a xx xxxxx aplikace, xxxxx xxxxxxxxxxx se může x xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxx, S9 xxxx, atd. Xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxx. Xxxxxxxxx by xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly xxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx nebo xxxxxxxxx) xxxxxxxx xxx x xxxxxxxxxxxx xxxxxxxx, tak xxx xx. Při xxxxxxx metabolické xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxxxxx xxxxxxxx vyžaduje xxxxxxxx.
Xxxxxxxxx xxxxxxxxx kontroly xxxxx xxx tyto xxxxx:
|
Xxxx metabolické xxxxxxxx |
Xxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx podle Xxxxxx |
|
Xxx xxxxxx xxxxxxxxxxx xxxxxxxx |
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
XX (xxxx x xxxxx xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
X vnější xxxxxxxxxxxx xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
|
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
|
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
|
XX (xxxx a xxxxx kolonie) |
cyklofosfamid |
50–18–0 |
200–015–4 |
|
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|||
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
||
|
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–5 |
||
|
XXXX |
X-xxxxxxxxxxxxxxxxxxx (xxx xxxxxx xxxxxx X9) |
62–75–9 |
200–549–8 |
|
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx xxx xxxxxxx xxxx xxxx xxxxxxxxxx xxxxx pro pozitivní xxxxxxxx, xxxx. xx-xx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx o 5-xxxx-2′-xxxxxxxxxxxx (XXX 59–14–3, XXXXXX 200–415–9), může být xxxx xxxxxxxxxx látka xxxxxx použita. Pro xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxx x xxxxx použití xxxxxxxxxx xxxxx pokud xxxxx ze stejné xxxxxxxx třídy.
Měly by xxx xxxxxxx negativní xxxxxxxx xxxxxxx xxxxxx xxxxxxxxxxx xxxxxxx rozpouštědlo xxxx vehikulum x xxxxxxxxxx xxxxx stejným xxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Kromě toho xx xxxx xxx xxxxxxxxxxxx xxxxxxxx použity xxxx tehdy, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx mutagenní xxxxxx.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxx xxx xxxxxxxxx zkoušené xxxxx xxx xx přítomnosti xxxxxxxxxxxxx xxxxxxxxxxx systému, xxx xxx xxxx. Xxxxxxxx by měla xxxxx vhodnou xxxx (xxxxxxx xx účinná xxxx 3 až 6 xxxxx). Expoziční xxxx xxxx být xxxxxxxxxxx xx jeden xxxx xxxx xxxxxxxxx xxxxx.
Xxx xxxxxx xxxxxxxx xxxxxxxxxxx xxxxx být xxxxxxx xxxxxxxxxx kultury xxxx xxxxx xxxxxxxxxx xxxxxxx. Xx-xx použita xxxxx kultura, měl xx xxx počet xxxxxxxxxxx xxxxxx xxx, xxx byl xxxxxxxx xxxxxxxxxxxx xxxxx kultur xxx xxxxxxx (např. xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxxxxxxxx). Měly by xxx použity duplicitní xxxxxxxxx kontrolní xxxxxxx (xxxxxxxx rozpouštědla).
Plynné xxxx xxxxxx látky by xxxx xxx zkoušeny xxxxxxxx xxxxxxxx, např. x xxxxx xxxxxxxxxx xxxxxxxxxxxx nádobách (21, 22).
1.4.3.2 Xxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx x xxxxxxxx xxxxxx
Xx konci expoziční xxxx xx buňky xxxxxxx x kultivují xx účelem stanovení xxxxxxx x xx xxxxxx umožnění xxxxxxx xxxxxxxx mutantu. Se xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxx xx započne xxxxxxx po xxxxxxxxx xxxx.
Xxxxx lokus má xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxx, xxx umožnil xxxxxxxxx optimální xxxxxxxxxxx xxxxxxx nově xxxxxxxxxxxx xxxxxxx (XXXX x XXXX vyžadují xxxxxxx 6 xx 8 xxx, XX alespoň xxx dny). Buňky xxxx xxxxxxxxxxx x xxxxx se xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxxx) x xxx xxxx (xxx nich) xx xxxxxx xxxxxxxxx počtu xxxxxxx x xxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx xxxxxxxxxxxxxxxx (xxxxxxx xxx xxxxxxx četnosti xxxxxxx) xx xxxxxxx xx xxxxx xxxx xxxxxxx xxxxxxxxx xx xxxxx xxx xxxxxxxxxx činidla.
Je-li xxxxxxxx xxxxx xxxxxxxxx xx xxxxxxx L5178Y XX+/-, mělo xx xxx xxxxxxxxx alespoň xx jedné ze xxxxxxxxxx xxxxxx (s xxxxxxxx xxxxxxxxx xxxxxxxxxxx) x xx xxxxxxxxxxx x pozitivních xxxxxxxxxx xxxxxxxxx kultury xxxxx xxxxxxxxx xxxxxxx. Xx-xx xxxxxxxx xxxxx ve xxxxxxx X5178X XX+/- xxxxxxxxx, xxxx by xxx xxxxxxxxx kultury xxxxx velikosti xxxxxxx xxxxxxxxx xx negativních x pozitivních kontrolách. Xxx xxxxxxxx za xxxxxxx XX6 TK+/- xxxx xxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxx xxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxx xx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxxxxxxx, počtu xxxxxxx x četnosti xxxxxxx xxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. X xxxxxxx pozitivní odpovědi xx zkoušku X5178X XX+/- xx kolonie xxxxxxxxx xxxxxxx x xxxxx xxxxxxxxxxx xxxxxxxx xxxxx (nejvyšší pozitivní xxxxxxxxxxx) x x xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxx malá xxxxxxx — velká xxxxxxx. Xxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxx mutantů xxxxxxxxx velké xxxxxxx, xxx xxxxxxx xxxxxxxxx xxxx xxxxxxx byla xxxxxxxx zkoumána (23, 24). Xx xxxxxxx XX+/- jsou xxxxxxx xxxxxxxxxxx za použití xxxxxxxx xxxxxxx s xxxxxxxxx růstem (velká) x xxxxxxx x xxxxxxx růstem (xxxx) (25). U xxxxxxxxxx xxxxx, xxxxx utrpěly xxxxxxxxxxxxxx xxxxxxxxx poškození, xx xxxxxxxxxxx xxxx xxxxxxxx, x xxxxx xxxx xxxx xxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxx xx xxxxx xxxxxx xxxx až xx xxxxxxxxxxxx viditelné xxxxxxxxxxxx aberace. Xxxxxxx xxxxxxx xxxxxxxxx xxxx xxxxxxx se spojuje x xxxxxxxxxx xxxxxxx, xxxxx xxxxxxxx xxxxx xxxxxxxxxxxx aberace (26). Xxxx závažně xxxxxxxxx xxxxx mutantů xxxxxx xxxxxxxx xxxxxx jako xxxxxxxx xxxxx x xxxxx xxxxx kolonie.
Mělo xx xxx xxxxx xxxxxxx (xxxxxxxxx xxxxxxxx xxxxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Četnost xxxxxxx xx xxxx xxx xxxxxxxxx xxxx xxxxx xxxxxxx x xxxxx přeživších buněk.
Měly xx xxx xxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx. Dále xx xxxx být xxxxxxx xxxxx shrnuty ve xxxxx xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx odpovědi xx xxxxxxxxxx. Xxxxxxxxxx výsledky xx xxxx xxx xxxxxxxxx dalším xxxxxxxxx, xxxxxxx x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xxxxxxxx xxxx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Tam, kde xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx za xxxxx, je xxxxx xxxxx zdůvodnění. Změna xxxxxxxxx xxxxxx x xxxxx xxxxxxxx rozsah xxxxxxxxxxxx xxxxxxxx xx xxxx být xxxxxxx x xxxxxxxxxx experimentech xxx pro dvojznačné xxxxxxxx, xxx pro xxxxxxxxx xxxxxxxx. X xxxxxxxxxx xxxxxx, které xx mohly xxx xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx a podmínky xxxxxxxxxxx aktivace.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx výsledku xxxxxxxx několik kritérií, xxxx. xxxxxx četností xxxxxxx x xxxxxxxxxx xx koncentraci, nebo xxxxxxxxxxxxxxxx xxxxxx xxxx xxxxxxxx. Xxxxxxxx by xxxx xxx uvážena xxxxxxxxxx xxxxxxxxx výsledků. Xxx xxxxxxxxx výsledků xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx statistické xxxxxx. Xxxxxxxxxxx xxxxxxxxxx by xxxxxx xxx jediným xxxxxxxxx faktorem xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx xxxxx, xxxxx výsledky xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx v tomto xxxxxxx považuje xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx konečný výrok x aktivitě zkoušené xxxxx. Xxxxxxxx xxxxx xxxxxx dvojznačné nebo xxxxxx xxx ohledu xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky na xxxxxx xxxxxx x xxxxxxx savců in xxxxx znamenají, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxx. Reprodukovatelná xxxxxxxxx xxxxxxxxx odpovědi xx xxxxxxxxxxx xx velmi xxxxxxxx. Negativní xxxxxxxx xxxxxxxxx, že xxxxxxxx xxxxx xx xxxxxxxx xxxxxxx neindukuje x xxxxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxx.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx musí xxxxxxxxx xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx volby xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx látky x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx xxxxx,
- počet xxxxxxxxx xxxxxx,
- xxxxxxxx počet xxxxxx,
- xxxxxxxx metody xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxxxxxxx xxxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxx, xxxxxx xxxx. údajů x cytotoxicitě x xxxxxx xxxxxxxxxxxx, jsou-li x dispozici,
- složení xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- xxxxxxxxxxx zkoušené xxxxx,
- xxxxx vehikula x xxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxx xxxxxxx,
- xxxxxxxxx xxxx,
- xxxxx xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx xxxxx xxxxxxxx,
- xxx x xxxxxxx xxxxxxxxx metabolického xxxxxxxxxxx xxxxxxx, xxxxxx kritérií xxxxxxxxxxxxx,
- pozitivní a xxxxxxxxx xxxxxxxx,
- xxxxx xxxx xxxxxxx (xxxxxxxx xxxxxx počtu xxxxxxxxxx xxxxx, xxxxxxxxx x xxxxxx xxxxx),
- xxxxxxxx xxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx na pozitivní, xxxxxxxxx nebo xxxxxxxxxxx,
- xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxx a xxxxxxxxxx buněk,
- definice xxxxxxx xxxxx xxxxxxxxx x typu (xxxxxxxx xxxxxx kriterií pro "xxxx" a "xxxxx" xxxxxxx).
Xxxxxxxx:
- známky toxicity,
- xxxxxx srážení,
- xxxxx x pH x xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxx, pokud xxxx stanoveny,
- xxxxxxxx xxxxxxx, xxxx-xx vyšetřována, xxxxxxx xxx negativní x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx mutanty xxxxxxx xxxx kolonie xxxxxxxx X5178X TK+/-,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- případné xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx negativní (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) x xxxxxxxxx xxxxxxxx x rozmezími, xxxxxxxxx xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxx xxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. X., DeMarini, X. X., XxXxxxxx, X. X., Tindal, X. X. (xxx.) (1987), Xxxxxxx Xxxxxx 28; Xxxxxxxxx Xxxx Xxxxxxxxxxx, Cold Xxxxxx Xxxxxx Xxxxxxxxxx, Xxx Xxxx.
2) Chu, X. X. X., Malling X. X. (1968), Xxxxxxxxx Xxxx Xxxxxxxx. XX. Xxxxxxxx Induction xx Specific Xxxxx Xxxxxxxxx xx Chinese Xxxxxxx Xxxxx Xx xxxxx, Xxxx. Xxxx. Xxxx. Xxx. X. X. X, 61, 1306-1312.
3) Xxxxx, H. X., Xxxxxx, X. X. (1982), Xxxxxxxx Xxxxx xx xxx Xxxxxxxxx Kinase Xxxxx xx Diploid Xxxxx Xxxxxxxxxxxx, Xxxxxxxx Xxx. 94, 467-485.
4) Xxxxx, X. M., Xxxxxxxxx-Xxxxx, X., Doerr, X. X., Dearfield, X. X. (1989), Xxxxxxxxxxxx Xxxxxx Xxxxxxxxxxxx at xxx Mouse Xxxxxxxx XX xxx XXX XXXXX Xxxx, Mutagenesis, 4, 394-403.
5) Aaron, X. X., Stankowski, Xx. L. X., (1989), Comparison xx xxx AS52/XPRT xxx xxx XXX/XXXX Xxxxxx: Xxxxxxxxxx xx Xxx Xxxx Xxxxxxxxxx, Xxxxxxxxxx Xxx. 223, 121-128.
6) Xxxxx, X. X., Xxxxxxxxxx, G., Xxxxx, X. X., Moore, X., Xxxxx, Y., Xxxxxxxxxx, Xx. L. X., Xxxxxx, X., Xxxxxxxx, X. (1994), Xxxxxxxxx Xxxx Gene Xxxxxxxx Xxxxxx Xxxxxxx Xxxxx Report. Xxxxxx xx xxx Xxxxxxxxxxxxx Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Genotoxicity Xxxx Xxxxxxxxxx. Mutation Xxx. 312, 235-239.
7) Xxxxx, X., Xxxxxxxx, X. X., Xxxxxxxx, X. X., Xxxxxxxx, X., Xxxxxxx, D., Xxxxx, X., Xxxx, X. X. (1991), Xxxxxxxxxxxx Xxxxx Xxxxxxx Xxxxxxx Xxxxxxxxxx. X report xxxx XXXXXX Xxxx Xxxxx 9, Mutation Xxx. 257, 147-204.
8) Xxxxx, X., XxXxxx, X., Xxxxxxx, J. X. S., Xxxxx, X., Mavournin, K. X. (1983), Xxxxxxxx Xxxx Xxxxxxxxx xx X5178X Xxxxx xx Xxxxxxx. X Report xx xxx U. X. Xxxxxxxxxxxxx Protection Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 115, 225-251.
9) Xx, A. X., Xxxxx, X. X., Xxxxxxx, X. X., Wasson, J. X. (1988), A Xxxxxx xxx Xxxxxxxx xx xxx Chinese Xxxxxxx Xxxxx/Xxxxxxxxxxxx Guanine Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxxxx xx Determine the Xxxxxxxxxxxx of Chemical Xxxxxx: A Xxxxxx xx Xxxxx III xx the U. X. Environmental Xxxxxxxxxxx Xxxxxx Xxxx-Xxx Xxxxxxx, Xxxxxxxxxx Xxx., 196, 17-36.
10) Xx, A. X., Xxxxxx, X. X., Xxxx, W. X., Xxxx, A. X., Xxxxx, X. X., Xxxxxxx, K. X., X'Νxxxx, J. X., Riddle, X. X., Xxxxxxxxxx, L. X. Jr., Xxxx, X. L. (1987), X Guide xxx xxx Xxxxxxxxxxx xx xxx Xxxxxxx Xxxxxxx Xxxxx Xxxx/Xxxxxxxxxxxx-Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxx Xxxxxxxx Xxxxx, Mutatation Xxx., 189, 135-141.
11) Xxxxx, X. L., Yandell, X. X., Xxxxxx, X. X. (1989), X Xxxxxxxxxx xx Xxxxxxxx Induction xx xxx TK xxx XXXX Loci xx Xxxxx Xxxxxxxxxxxxxx Xxxxx: Xxxxxxxxxxxx Xxxxxxxxxxx xxx Xxx xx an Xxxxxxxxxx Xxxxx xx Xxxxxxxxx at the Xxxxxxxxx XX Xxxxx, Xxxxxxxxxx Xxx., 216, 9-17.
12) Xxxxxxxxxx, L. X. Xx., Tindal, X. X., Xxxx, X. W. (1986), Xxxxxxxxxxxx xxx Xxxxxxxxx Xxxxxxxx of Xxxxx Xxxxxxxxxxxxxxxxx xxx XXX 191-Xxxxxxx Molecular Analyses xx Ethyl Xxxxxxxxxxxxxxxxx xxx XXX 191 Xxxxxxx Xxxxxxxx xx XX52 Cells, Mutatation Xxx., 160, 133-147.
13) Xxxxxx, N. T., Xxxxxx, X. G., Xxxxx, D. (1984), Xxxxxxxxx xxx xxx X5178X/XX+/--XX+/- Mouse Xxxxxxxx Xxxx Mutagenicity Xxxxx, xx: Xxxxxx, X. X. xx al (xxx.) Handbook of Xxxxxxxxxxxx Xxxx Xxxxxxxxxx, Xxxxxxxx Science Xxxxxxxxxx, Xxx York, 239-268.
14) Xxxxxx, X. X., Xxxxx, D. X., Xxxxxx, G. X., Xxxxx, X. X. X., Cole, X., XxXxxxxx, X. B., Xxxxxxx S. X. (1989), Mammalian Cell Xxxx Xxxxxxxx Xxxxxx Xxxxx upon Xxxxxx Xxxxxxxxx, in: Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, Xxxxxxxx, X. J., ed., Xxxxxxxxx Xxxxxxxxxx Xxxxx, 66-101.
15) Abbondandolo, X., Xxxxxxx, S., Xxxxx, X., Xxxxxx, X., Xxxxxxxx, X., Xxxxxxxxxx, X. (1977), Induction xx 6-Xxxxxxxxxxx-Xxxxxxxxx Xxxxxxx xx X79 Chinese Xxxxxxx Xxxxx by Xxxxx-Xxxxx Xxxxxxxxx-Xxxxxxxxx Dimethylnitrosamine, Xxxxxxxxxx Res. 46, 365-373.
16) Ames, X. X., McCann, J., Xxxxxxxx, X. (1975), Xxxxxxx xxx Detecting Xxxxxxxxxxx xxx Xxxxxxxx xxxx the Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx. 31, 347-364.
17) Xxxxx, X., Johnson, X. X., Xxxxxxx, X. X. X., Xxxxxx A. G., Xxxxx X. X. X. (1979), Xxxxxxxxxx xxx Xxxxxxxxxxxxxxxx of xxx X5178X/XX+/--Xxxxx Lymphoma Xxxxxxx Xxxxx System, Xxxxx. Xxx. 59, 61-108.
18) Xxxxx, X. X., Xxxx, X. X. (1983), Revised Xxxxxxx xxx xxx Xxxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Xxx. 113, 173-215.
19) Xxxxxxx, B. X., Xxxxxx, R. X., Xxxxxxx, X. X., Xxxxxxxxx, X. X., Xxxxxx, G. X., Xxxxxx, J. X., Wolf, X. X. (1992), Alternatives xx Xxxxxxx 1254-Xxxxxxx X9 xx: Xx xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxx, X., Xxxxxxxx, X. (1976), X Xxxx Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. s. xx Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Xxxxxxx, X: Xx vitro Metabolic Xxxxxxxxxx xx Xxxxxxxxxxx Xxxxxxx, xx Serres, X. X., Xxxxx, X. R., Xxxx, X. X., Xxxxxxx, X. X. (xxx), Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
21) Xxxxx, D. X., Xxxxxx, X. X., XxXxxxx, K. T. (1982), CHO/HGPRT Xxxxxxxx Xxxxx: Xxxxxxxxxx xx Xxxxx xxx Volatile Xxxxxxx, xx: Ticc, X. X., Xxxxx, X. L., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Xxxxxxx xx Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, P. X., Xxxxxx, X. M., Xx, X. P., Xxxxxx, A. X. (1983), Evaluation of xx Xxxxxxxx Xxxxxx Xxxxx Cells Xxxxx xx Xxxxxxxx Xxxx xxx Detecting Highly Xxxxxxxx Mutagens in xxx CHO/HGPRT Mutation Xxxxx, Environ. Mutagenesis, 5, 795-801.
23) Applegate, X. X., Moore, X. X., Xxxxxx, X. B., Xxxxxxx, X., Xxxxxx, X. X. (1990), Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxx xx xxx Xxxxxxxxxxxx Xxxxxxxxx Kinase Locus xx Xxxxx Lymphoma Xxxxx, Xxxx. Xxxx. Xxxx. Sci. X. X. A, 87, 51-55.
24) Xxxxx, X. X., Clive, X., Xxxxxx, X. X., Xxxxxx, X. E., Xxxxxx, X. G., Xxxxxx, X. X., Xxxxxx, X. (1985), Xxxxxxxx of Trifluorothymidine, Xxxxxxxxx (TFT+) Xxxxxxx xx L5178Y/TK+/--Mouse Xxxxxxxx Xxxxx, Xxxxxxxxxx Xxx. 151, 161-174.
25) Yandell, X. X., Xxxxx, X. X., Xxxxxx, X. X. (1990), Xxxxxxxxx Xxxxxxx Analysis xx Xxxxxxxxx Xxxxxxxxx xx x Xxxxxxxxxxxx Xxxxxxxxx Locus xx Xxxxx Xxxxx, Xxxxxxxxxx Xxx. 229, 89-102.
26) Xxxxx, M. X., Xxxxx, X. X. (1990), Xxxxxxxxxx xx Xxxxxxxxxx Aberration Xxxxxxxxx xxx Xxxxx Colony XX-Xxxxxxxxx Xxxxxx Xxxxxxxxx xx X5178X/XX+/- 3.7.2X Xxxxx Lymphoma Xxxxx, Xxxxxxxxxxx, 5, 609-614."
PŘÍLOHA 4F
"B.23 XXXXXXX XX XXXXXXXXXXXX ABERACE XX SPERMATOGONIÍCH XXXXX
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx xxxxxx OECD XX 483 — Xxxxxxx na chromozomové xxxxxxx ve xxxxxxxxxxxxxxx xxxxx (1997).
1.1 XXXX
Xxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx ve spermatogoniích xxxxx xx xxxx xx identifikovat xxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx savců (1, 2, 3, 4, 5). Xxxxxxxxx xx xxx typy xxxxxxxxxxxx xxxxxxx: chromozomové x chromatidové. U xxxxxxx chemických mutagenů xxxx xxxxxxxxxx aberace xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx se xxxxxx xxxxxxxxx. Tato xxxxxx xxxx xxxxxx xx stanovení numerických xxxxxxx x xxxx x xxxxxx xxxxx xxxxxxx xxxxxxxxx. Xxxxxxxxxxxx xxxxxx x xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x člověka.
Touto xxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx změny xx xxxxxxxxxxxxxxx x xxxxxxxxxxx xx xxxx, že xxxx zkouška xxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxx x xxxxxxxxxxxx xxxxxxx.
X této zkoušce xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxxxx xx xxxx xx detekují xxxxxxxxxxxx xxxxxxx při xxxxxx xxxxxxxxxxxxx. Xxxx cílové xxxxx nejsou předmětem xxxx zkoušky.
Pro xxxxxxx xxxxxxx xxxxxxxxxxxxxx typu xx spermatogoniích xx xxxx xxx — xxxxx než xxxxx xx xxxxxx léze — vyšetřeno první xxxxxxxxx xxxxxxx xxxxxx, xxxxx xxxxxxxxx xx xxxxxxxx. Xxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx aberací chromozomového xxxx x xxxxxxxxx-xxxxxxxx X, xxx xx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxxxx.
Xxxx zkouška xx xxxx xx xxxxxxxx xxx xxxxxxxxx, zda xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxx x germinálních xxxxxxx. Xxxxx xx xxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxxxx xxxxxxxxxx, neboť xxxxxxxx xxxxxxxxx faktory xxxxxxxxxxx xx xxxx, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx DNA.
Ve xxxxxxxxx xx xxxxxxxx xxxx xxxxxxxx spermatogonií s xxxxxx citlivostí xx xxxxxxxx xxxxxxxx látce. Xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx souhrnnou odpověď xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x xxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. V xxxxxxxxxx xx xxx xxxxxx xx varlatech, xxxxx xxxx nemusí xxx xxxxx generace xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx v xxxxxxxx xxxxxxxxx x fyziologické xxxxxxx Xxxxxxxxx xxxxx x xxxxxxx xxxx xxxxxxx oběhem x xxxxxxx.
Xxxxxxxx existuje xxxxx x xxx, xx xx xxxxxxxx látka xxxx xxxxxxxxx metabolity xxxxxxxxxx xx xxxxxx xxxxx, není xxxxxx xxxx xxxxxxx použít.
Viz xxxx xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx xxxxxxxxxx v xxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x opětného spojení xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození chromozomu x xxxxxx zlomu xxxx xxxxx x xxxxxxx xxxx xxxxxxxxx x xxxxxx xxxxx.
Xxx : xxxxxxxxxxxx léze xxxxx xxx šířka xxxxx xxxxxxxxxx x x minimální odchylkou xxxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx xxxxx xxxxxxxxxx xx normální xxxxxxx x xxxxxxxxx buněk.
Polyploidie : xxxxxxx haploidního xxxxx xxxxxxxxxxxxxx xxx (x), xxxx xxx xxxxxxxxx (xx. 3 x, 4 n xxx.).
Xxxxxxxxxx aberace : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx dělení xx xxxxxx xxxxxxxx pod xxxxxxxxxxx, xxxx se xxxx xxxxxx x xxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxx xxxxxxxxxxxxxxxxxx změny.
1.3 XXXXXXXX XXXXXXXX METODY
Zvířata xxxx xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx látce a xx xxxxxx xxxx xx xxxxxxxx usmrcena. Xxxx xxxxxxxxx xx xxxxxxxx xxxx xxxxx xxxxxxxxxxx xxxxxxxx (např. xxxxxxxxx xxxx Xxxxxxxx®). X xxxxxxxxxxxx buněk xx poté připraví xxxxxxxxx xxxxxxxxxx, xxxxxx xx x xxxxxxxxx xx xxxxxxxxxxxx aberace xxxxxxxxxxxxxx xxxxx.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xxxx xxxxxxxxx xxxxx xxxxxx xxxxxxxx a xxxx; xxx xxxx xxxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxxxx xxxxx xxxxx. Měly by xxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx zdravých xxxxxxxx xxxxxxxxx zvířat. V xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx xx xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx a xxxxxx
Xxxxx xxxxxx podmínky xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx mladí pohlavně xxxxxxx xxxxx xx xxxxxxxx xxxxxxx rozdělí xx xxxxxxxxx skupinu x xxxxxxx, xxxxx xx exponuje. Xxxxx xx xxxx xxx xxxxxxxxxx tak, xxx xxx vliv jejich xxxxxx xxxxxxxxxxxxx. Zvířata xx xxxxxxxxxxx identifikují. Xxxx započetím xxxxxx xx xxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx aklimatizovat.
1.4.1.4 Xxxxxxxx dávek
Pevné xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx rozpuštěny xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx vehikulech x popřípadě xxxxxxx. Xxxxxxx xxxxxxxx látky xxxxx xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx xxxxxxx xxxxxxx. Xxxx xx xxx použity čerstvě xxxxxxxxxx xxxxxxxx chemické xxxxx, xxxxx xxxxx x stálosti neprokazují xxxxxxx skladování.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxxxx mít xxx xxxxxxxxx xxxxxxxxx dávek xxxxxxx účinky a xxxx by být xxxxxxxxx xxxxxxxxx, že xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx použita xxxx než známá xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx údaji x xxxxxx kompatibilitě. Doporučuje xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx souběžné xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. S xxxxxxxx aplikace xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx skupiny xxxxxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xx xxxxxxxxx, v xxxxx xxxxx k xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx xxxxxxxxxx xxxxxxxxxx aberace xx spermatogoniích xx xxxx při xxxxxxxxxxx xxxxxxxx, x nichž xx předpokládá, xx xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxx xxxxxx.
Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx xxxxxx xxxxxxx xxxxx xxxxxx kódovaná xxxxxxxxxxxx xxxxxxxxx. Je xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx podávána xxxxx xxxxxxxx xxx xxxxxxxx látka a xxx byl xxxxx x jejím xxxxxxx xxxxxxxx xxx xxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxx xxx xxxxx xxxxx x úvahu xxxxxxx xxxxxxxxxx látek xx xxxxxx xxxxxxxx xxxxx, xxxx-xx k xxxxxxxxx. Xxxxxxxx látek xxx pozitivní kontrolu:
|
Látka |
Číslo XXX |
Xxxxx xxxxx Einecs |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxx (monomer) |
79–06–1 |
201–173–7 |
|
2,4,6-tris(aziridin-1-yl)-1,3,5-triazin |
51–18–3 |
200–083–5 |
V xxxxxxxx xxxxxxx xxxxxx xx xxx xxx xxxxxxxx xxxxx u xxxxxxx xxxxxxxxx xxxxxxxx, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx exponované xxxxxxx, xxxxx nejsou x xxxxxxxxxxx xxxxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx xxxxxx x xxxxxxxx xxxxx s xxxxxxxxxxxxxx xxxxxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx účinky.
1.5 POSTUP
1.5.1 Xxxxx zvířat
Každá xxxxxxxxxx x xxxxxxxxx skupina xxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx xxxx xxx xxxxx možno xxxxxxxx xxxxxxxxxxx nebo nadvakrát (xx. xxx xxxxx xxxxxxxx nebo dvou xxxxxxxxxx). Zkoušené látky xxxxx být xxxxxxxx xxxx ve xxxx xxxxxxx, xxx. dvě xxxxx x xxx xxx v xxxxxxx xx více xxx xxxxxxxx hodin, xxx xxxx usnadněno xxxxxxxx xxxxxxx objemů materiálu. Xxxx xxxxxx podávání xx měly xxx xxxxxxx zdůvodněny.
Ve xxxxxxx x xxxxxxxx dávkou xx xxxx být xx xxxxxxxx provedeny xxx odběry. Poněvadž xxxxxxxx xxxxxxxxx cyklu xxxx xxx xxxxxxxxx xxxxxx ovlivněna, xxxxxxx xx xxxxx časný xxxxx x xxxxx xxxxxxxx xxxxx xxxxxxxxx 24 a 48 xxxxx xx xxxxxxxx. X xxxxxxx xxxx xxx xxxxxxxx xxxxx xx měl být xxxxx proveden xx 24 xxxxx nebo xx xxxxxx xxxx xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxx buněčného xxxxx, pokud xxxx xxxxx xxxx xxxxxxxxx xxxx xxx detekci xxxxxx (6).
Navíc mohou xxx odběry provedeny xxxx v xxxx xxxx. Například x xxxxxxx xxxxxxxxxx látek, xxxxx xxxxx indukovat xxxxxxxx xxxxxxxxx (lagging) xxxxxxxxxx xxxx mohou xxxxxxxxxx X-xxxxxxxxx účinky, xxxx xxx xxxxxxxxx xxxxxxxx xxxxx (1).
Xxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxx být xxxxxx xxxxxx xx xxxxxxx. X xxxxxxx xxxxx x xxxxxxxxxx xxxxxxxx xx měla xxx xxxxxxx xxxxxxxx 24 xxxxx (1,5xxxxxxx délky xxxxx) po xxxxxxxx xxxxxxxx. Xxxxx xxxxxxx xxxxx xxx xxxxxxxxx xxxxx xxxxxx v xxxx xxxx.
Xxxx usmrcením xx xxxxxxxx xxxxxxxxxxxxxxxxx xxxx xxxxxx xxxxx xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. Colcemid® xxxx xxxxxxxxx). Poté se xx vhodné xxxx xxxxxxx x zvířat xxxxx. X xxxx xx tato doba xxxxxxxxx 3 — 5 xxxxx; x xxxxxx xxxxxxxx xx xxxx xxxx přibližně 4 — 5 xxxxx.
1.5.3 Dávkování
Provádí-li xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx údajů studie xxx zjištění xxxxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx stejným xxxxxx x kmenem x xx stejného xxxxxx xxxxxxxx, xxxxx xx xxxxxxx v xxxxxx studii (7). X xxxxxxx xxxxxxxx xx pro xxxxx xxxxx použijí xxx xxxxxx xxxxx. Tyto xxxxxx xxxxx xx xxxx xxxxxxxx rozmezí xxxx xxxxxxxxx a xxxxxxxxx toxicitou, xxxxxxxx xxxxxx toxicitou. Xxx xxxxxxxxx xxxxxx xxxxx, xxxx xxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxx xxxxx xx xxxxxxxxxx jako dávka xxxxxxxxxxxx xxxxxx známky xxxxxxxx, že xx xxxxx dávky xxxxx xxx stejném xxxxxx xxxxxxxxx podle xxxxxxxxx x xxxxxxxx.
Xxxxx xx xxxxxxxxxxx xxxxxxxxxxx aktivitou xxx nízkých xxxxxxxxxxx xxxxxxx (např. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx xxxxx může xxx xxxx xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx xx xxxxxxxxxxxxxxx xxxxxxx xxxxxx toxicity (např. xxxxxxx xxxxx spermatogonií x mitose xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx; xxxx xxxxxxx by xxxxxx překročit 50 %).
1.5.4 Xxxxxxx zkouška
Jestliže xxxxxxx s xxxxxx xxxxxx xxxxxxx 2000 xx/xx tělesné xxxxxxxxx xxxxxxx jednorázově xxxx xx dvou xxxxxxx x xxxxxx xxx xxxxxxxxxx xxxxx pozorovatelné xxxxxxx účinky x xxxx-xx xx xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx genotoxicita, xxxxxxxxxx se xxxxx xxxxxx se xxxxx xxxxxxxx dávky xx xxxxxxxxx. Xxxxxxxxx expozice xxxxxxx xxxx xxxxxxxx xxxxxxx použít x xxxxxxx xxxxxxx vyšší xxxxxx dávky.
1.5.5 Podávání xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx nitrožaludečně, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, xxxx intraperitoneální xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxxx, jsou-li xxxxxxxxxxxxx. Xxxxxxxxx objem xxxxxxxx, xxxxx xxxx xxx najednou xxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, xxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x xxxxxxx hmotnosti. Xxxxxxx xxxxxxx xxxxxx, xxx je xxxxxxx xxxxx, xxxx být xxxxxxxxxx. Xx xx xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx koncentracích xxxxxxxx zesílené xxxxxx, xx měla být xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx nastavením koncentrace xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx úrovních xxxxx.
1.5.6 Xxxxxxxx preparátů xx analýzu xxxxxxxxxx
Xxxxx xx usmrcení xx x xxxxxxx xxxx xxxx xxxxxx xxxxx xxxxxxx xxxxxxxx, xxxxxxxxxxxx xx x fixuje. Xxxx xx xxxxxx xx xxxxxxxx xxxxxxx x xxxxxx se.
1.5.7 Xxxxxxx
X xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxxx xxxxxxx 100 xxxxx v xxxxx xxxxxxxxxxxx xxxxxxxx (xx. xxxxxxxxx 500 metafází xx xxxxxxx). Xxxxx xxxxx lze xxxxxx, xx-xx pozorován xxxxx xxxxx aberací. Všechny xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, by xxxx xxx před mikroskopickou xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx při xxxxxx xxxxx xxxxxxx xx xxxxxxxxxxxxxx xxxxxx xxxx xxxxxx chromozomů x xxxxx xxxxxxxx, xxxx xx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx odpovídajícímu xxxxx 2 n ± 2.
2. ÚDAJE
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxx pro xxxxxxxxxx xxxxxxx xx měly xxx xxxxxxxxxx xx xxxxx xxxxxxx. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Xxx každé zvíře xx měl být xxxxxxxxxx počet buněk xx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx x xxxxx xxxxxxxxxxxxxx xxxxxxx xx xxxxx. Xxx xxxxxxxxxx x kontrolní skupiny xx měly být xxxxxxx xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x xxxxxx xxxxxx x xxxxxxxx. Xxxx xx xxxxxxxxxxxxx xxxxxxxx x xxxxxxx se, xxx xxxxxx xx xxxxxxxxxx xx xxxxxxx xxxxxxxx xxxxxxx.
Xx-xx xxxxxxxxxx xxxxxx a také xxxxxx, xxx xx xxx xxx stanovení xxxxxxx xxxxxxxxxxxxx účinků xxxx xxxx xxxxxxxxxxxx xxxxxxxx x xxxxx xxxxxxxxxxxx xxxxxx x xxxxxx xxxxxxxxxx xxxx xxxxxxxxx kontrola poměr xxxxxxxxxxxxx v xxxxxx xxxxxxxx k xxxxx x druhé meiotické xxxxxxxx, x xx x xxxxxxxx xxxxxx 100 xxxxxxxx xx xxxxx na xxxxx xxxxx. Xxxxx je xxxxxxxxx xxxxx mitosa, xxxxxxx x 1000 xxxxxxx na zvíře xx xxx být xxxxxxxx xxxxxxxxx xxxxx.
2.2 XXXXXXXXX A INTERPRETACE XXXXXXXX
Xxx xxxxxxxxx pozitivního xxxxxxxx existuje xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxxx v xxxxxxxxxx xx dávce xxxx xxxxx nárůst xxxxx xxxxx x xxxxxxxxx xxx xxxxxxx x xxxxxxx xxxxxx x x určitému xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (8). Xxxxxxxxxxx xxxxxxxxxx by xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx xxxx xxx xxxxxxxxx xxxxxx zkoušením, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, xxxxx xxxxxxxx nesplňují xxxx xxxxxxx xxxxxxxx, xx x xxxxx xxxxxxx xxxxxxxx za xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx jasně pozitivní xxxx negativní xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx zkoušené xxxxx. Výsledky xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx bez xxxxxx xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx xx xxxx xxxxxxxxx, že xxxxxxxx xxxxx indukuje x xxxxxxxxxxxx buňkách xxxxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx za xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx druhu xxxxxxxxxxxx xxxxxxx.
Xxxx by xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx se xxxxxxxx xxxxx nebo xxxx xxxxxxxxxx xxxxxxxx xx xxxxxx xxxxx.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx informace:
Rozpouštědlo/vehikulum:
- zdůvodnění xxxxx xxxxxxxx,
- rozpustnost x stálost xxxxxxxx xxxxx v xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx zvířata:
- xxxxxxx xxxx/xxxx,
- počet x stáří xxxxxx,
- xxxxx, xxxxxxxx chovu, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx na xxxxxxx zkoušky, včetně xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx x xxxxxxxxxx odchylky xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxx xx xxxxxx xxx zjištění rozsahu, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx zvolených xxxxxx xxxxx,
- zdůvodnění způsobu xxxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x podávání xxxxxxxx xxxxx,
- xxxxxxxxxx xxx xxxxxxxx,
- případně xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx vodě (xxx) xx odpovídající xxxxx (xx/xx tělesné xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx xxxxxx x xxxx,
- podrobný xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx xxxxxxxxxxx a xxxxx xxxxxxxx,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx xxxxx na xxxxx xxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx xxxxxxxxx, negativní nebo xxxxxxxxxxx.
Xxxxxxxx:
- známky toxicity,
- xxxxxxxxx index,
- xxxxx xxxxxxxxxxxxx x mitose xxxxxxxx x xxxxx x xxxxx xxxxxxxx xxxxxx,
- xxx a xxxxx xxxxxxx xxxxxxx xxxxxxxxxx pro xxxxx xxxxx,
- xxxxxxx počet xxxxxxx xx xxxxxxx,
- xxxxx xxxxx x xxxxxxxxx xx xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx na xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- xxxxx x souběžné xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x negativní xxxxxxxx x rozpětími, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- údaje x souběžné xxxxxxxxx xxxxxxxx,
- xxxxx ploidie, xxxxx byly xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Adler, X. X., (1986), Xxxxxxxxxxx Xxxxxxxxx xx Xxxxx Xxxxxxxxxxxxx xx Xxxxxxxx Xxxxxxxx Xxxxxxx xx xxxxx Xxxx-Xxxxx Xxxxxxxxxxxxxx, xx: Genetic Xxxxxxxxxx xx Environmental Xxxxxxxxx, Part B: Xxxxxxx Xxxxxxx and Xxxxxxx Xxxxxxxxxxx, Xxxxx, X., Xxxxxxx, B., Xxxxxxxxx, X. (xxx) Xxxx, Xxx Xxxx, 477-484.
2) Adler, I. X., (1984), Xxxxxxxxxxx xxxxx xx Mammals, xx: Xxxxxxxxxxxx Xxxxxxx: x Practical Xxxxxxxx, (xx.) X. Xxxxxx, X. X. Parry, XXX Xxxxx, Oxford, Xxxxxxxxxx XX, 275-306.
3) Xxxxx, X. X., Xxxxxxx, X., Xxxx, X. X. (1964), Xx Xxx-xxxxxx Method xxx Meiotic Xxxxxxxxxxxx xxxx Xxxxxxxxx Testes, Xxxxxxxxxxxx Xxxx Genetics, 3, 289-294.
4) Richold, X., Ashby, X., Xxxxxxxx, X., Gatehouse, X. X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxx Assays, xx: D. X. Xxxxxxxx (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. UKEMS Xxxxxxxxxxxx xx Xxxxxxxxxx xxx Mutagenicity Testing. Xxxxxx. Xxxx X xxxxxxx, Cambridge University Xxxxx, Cambridge, Xxx Xxxx, Port Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
5) Xxxxxxxx, X., Kikuchi, X. (1978), X Xxx Xxxxxx xxx Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx, Mutatation Xxx., 52, 207-209.
6) Xxxxx, I. X., Xxxxxx M. X., Xxxxxxx, J., Favor, X., Xxxxxxxx, X., Xxxxxxxxxxxx, X., Shibuya, X., Xxxxxx X. (1994), International Workshop xx Xxxxxxxxxxxxxxx of Xxxxxxxxxxxx Xxxx Xxxxxxxxxx. Xxxxxxx Xxxxxx xx xxx Working Group xx Mammalian Xxxx Xxxx Xxxxx, Xxxxxxxxxx Xxx., 312, 313-318.
7) Xxxxxxx, X. J., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, P. X., Xxx, J., Esdaile, X. J., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, X., Xxxxxx, X. X., Xxxxxxxx, X. X., Richold, X. (1992), Xxxxxx of Xxxxxxx Toxicology Xxxxxxx/XX Xxxxxxxxxxxxx Mutagen Xxxxxxx Xxxxxxx Group: Xxxx Xxxxxxx xx Xx xxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, X. X., Xxxxxxxx, X., Albanese, X., Amphlett, X. X., Xxxxx, G., Xxxxxxxx, R., Richold, X., Xxxxxxxx, D. X., Savage X. X. X. (1989), Xxxxxxxxxxx Analysis xx Xx vivo Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (ed.), Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Xxxx Xxxx. XXXXX Subcommittee on Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx, Xxxxxx, Xxxx XXX. Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4X
"X.39 XXXXXXX XX NEPLÁNOVANOU XXXXXXX XXX (XXX) V XXXXXXXXX XXXXXXX XXXXX XX VIVO
1. XXXXXX
Xxxx xxxxxx xx replikou xxxxxx XXXX XX 486 — Zkouška xx xxxxxxxxxxxx xxxxxxx XXX (UDS) v xxxxxxxxx buňkách xxxxx xx vivo (1997).
1.1 XXXX
Xxxxxx xxxxxxx na xxxxxxxxxxxx syntézu XXX (XXX) x jaterních xxxxxxx xxxxx in xxxx xx identifikovat xxxxxxxx látky, které xxxxxxxx xxxxxxxx XXX x xxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxx (1, 2, 3, 4).
Tato xxxxxxx xx vivo xxxxxxxxx metodu xxxxxxxxx xxxxxxxxxxxxx účinků xxxxxxxxxx xxxxx x xxxxxxx. Xxxxxxxxxxx xxx xx xxxxxxxxxx xxxxxxxxx XXX x xxxxxxxx reparace x xxxxxxxxx xxxxxxx. Xxxxx jsou obvykle xxxxxxx místem, xxx xxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx. Xxxx tedy xxxxxxx xxxxxx pro xxxxxxxxx xxxx xxxxxxxxx XXX xx xxxx.
Xxxxxxxx xxxxxxxx důkaz x xxx, xx xx xxxxxxxx xxxxx xxxxxxxxx xx cílové xxxxx, xxxx xxxxxx tuto xxxxxxx použít.
Rozsah neplánované xxxxxxx DNA (XXX) xx zhodnotí xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx nukleosidů xx buněk, xxxxx xxxxxxxx plánovanou xxxxxxxx XXX (S-fází). Nejrozšířenější xxxxxxxxx je autoradiografické xxxxxxxxx inkorporace xxxxxxxxx xxxxxxxxx tritiem (3X-XxX). Xxx zkoušky na XXX in vivo xx přednostně xxxxxxxxx xxxxx potkana. Jiné xxxxx xxx xxxxx xxxxx xxx xxxxxx xxxxxxx, xxxxxx xxxx xxxxxxxxx xxxx xxxxxx.
Xxxxxxx xxxxxxxx XXX xxxxxx xx xxxxx bází XXX xxxxxxxxxxx x xxxxxxxxxxx v xxxxx xxxxxxxxx. Xxxxxxx xx XXX je tedy xxxxxx xxxxxxx pro xxxxxxx xxxxxxxx xxxxxxxx ("xxxx-xxxxx xxxxxx") (20 xx 30 xxxx) xxxxxxxxxxxx látkou. Xxxxxx xxxxxx ("short-patch xxxxxx") (xxxxx xx tři xxxx) xxxx xxxxxxx xxxx xxxxxxxxxx x xxxxxx xxxxx citlivostí. Xxxxx může důsledkem xxxxxxxxxxxxx xxxxxxxx, xxxxxx xxxxxxxx xxxx xxxxxx xxxxxxxxx xxxx XXX xxxxx k xxxxxxxxxx xxxxxxxxx. Xxxxxx odpovědi XXX xxxxxxxxxxx xxxxxx xxxxxxxxx x věrnosti xxxxxxxxxxx procesů. Xxxxx xx možné, že xxxxxxx xxxxxxx x XXX, ale xxxxxxxxx XXX xxxx opraveno xxxxxxxxxxx reparací. Xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx, xxxxx xxxx zkouška xxxxxxxxx x xxxxxxxxx aktivitě, xx vyvážen potenciální xxxxxxxxxx xxxxxx jevu, xxxxx je xxxxxxxxxx x xxxxx genomu.
Viz xxxx xxxxxx xxxx, xxxx B.
1.2 DEFINICE
Opravované xxxxx : čistý xxxxx xxx odpovídajících xxxxxxxx xxxxxx (NNG), xxxxx xxx předvolená xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxx.
Xxxxx počet xxx xxxxxxxxxxxxxx buněčným xxxxxx (XXX) : xxxxxxxxxxxxx xxxx XXX xxxxxxxx xxxxx v xxxxxxxxxxxxxxxxx zkoušce xx XXX, xxxxxxxxx xxxxxxxxx xxxxxxxxxx xxxxx zrn x xxxxxxxxxxxxxxxxx xxxxxxxxx (XX) xxxxxxxxxxxxxx xxxxxx xx xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XX): XXX = XX — CG. Xxxxxxx XXX xx xxxxxxx xxx xxxxxxxxxx xxxxx, xxxx společně xxx buňky x xxxxxxx, x xxxxxxxxxxx xxxxxxxxx xxx.
Xxxxxxxxxxx syntéza XXX (XXX) : Xxxxxxx xxxxxxxx XXX xx vyštěpení x xxxxxxxxxx xxxxx XXX xxxxxxxxxxxx region x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx xxxxxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xx XXX x xxxxxxxxx buňkách xxxxx in xxxx xxxxxxxx xxxxxxx xxxxxxxx XXX xx xxxxxxxxx x odstranění úseku XXX xxxxxxxxxxxx xxxxxx x poškozením indukovaným xxxxxxxxxx látkami xxxx xxxxxxxxxxx xxxxxxxx. Zkouška xx xxxxxxx xxxxxxxx xx inkorporaci 3X-XxX xx XXX xxxxxxxxx xxxxx, xxx xx xxxx četnost xxxxx x X-xxxx xxxxxxxxx xxxxx. Xxxxxxxxxxx 3X-XxX xx obvykle xxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxx xxxx xxxxxxxx není tak xxxxxxx na xxxx X-xxxx buněk xxxx xxxx. kapalná xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 XXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Výběr xxxxx xxxxxxx
Xxxxx je xxxxxxxx xxxxxx, ačkoli lze xxxxxx xxxxxxxx xxxxxx xxxx savce. Xxxx xx xxx použity xxxxx xxxxxxxxx laboratorní xxxxx mladých zdravých xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx x neměla by xxxxxxxxx ± 20 % xxxxxxx xxxxxxx xxxxxxxxx xxx obě xxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x strava
Platí xxxxxx xxxxxxxx podle xxxxxxxx xxxxx k xxxxx X, xxxxxxx by xxxx být xxxxxxxx xxxxxxxx xxxxxxx 50 - 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx xxxxxxxx xxxxxxx zvířata xx xxxxxxxx xxxxxxx rozdělí xx kontrolní skupinu x skupinu, která xx xxxxxxxx. Xxxxx xx xxxx být xxxxxxxxxx xxx, xxx xxx vliv jejich xxxxxx minimalizován. Xxxxxxx xx jednoznačně xxxxxxxxxxxx x před xxxxxxxxx xxxxxx xx nechají x laboratorních podmínkách xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx zkoušené xxxxx
Xxxxx xxxxxxxx látky xx měly xxx xxxx xxxxxxxx zvířatům xxxxxxxxxx nebo suspendovány xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Xxxxxxx xxxxxxxx látky xxxxx xxx podávány přímo xxxx xxxxx být xxxx xxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx chemické látky, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx možnost xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx při použitých xxxxxxxx xxxxx xxxxxxx xxxxxx a mělo xx být xxxxxxxxx xxxxxxxxx, že xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx xxxxxxx xxxx xxx známá rozpouštědla/vehikula, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxxxxx xxxxxx xxxxxxx xxxxx možno xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx každé xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxx pozitivní x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx. X výjimkou xxxxxxxx xxxxxxxx látky xx měla xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxx proces xxxx xxxxxxx xx skupinách, x xxxxx dojde x xxxxxxxx.
Xxxxxxxxxxx xxxxxxxxxx xx měly být xxxxx, x xxxxx xx xxxxx, že xxxxxx xxxxxxxx v xxxxxxxxxxx expozičních koncentracích xxxx x nárůstu XXX xxxxxxxxxxxxxxx nad xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xx měly být xxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxx odpověď (4). Xxxxx xxxxx xxx zvoleny tak, xxx byl xxxxxx xxxxxxxx, ale aby xxx xxxxxx xxxxxxx xxxxx xxxxxx kódovaná xxxxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxx xxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxxxx doby xxxxxx (2 až 4 x) |
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–249–8 |
|
Xxxxxx doby xxxxxx (12 až 16 x) |
X-(xxxxxxx-2-xx)xxxxxxxx (2-XXX) |
53–96–3 |
200–188–6 |
Xxxxx xxx xxxxxxx také xxxx xxxxx xxx xxxxxxxxx xxxxxxxx. Je xxxxxxxxx, xxx byla xxxxxxxxx kontrolní xxxxx xxxxxxxx jiným xxxxxxxx, xxx xxxxxxxx xxxxx.
1.5 XXXXXX
1.5.1 Xxxxx x xxxxxxx xxxxxx
Xxx xx xxx použit dostatečný xxxxx xxxxxx, aby xxxx zohledněno přirozené xxxxxxxxxx xxxxxxxx xxxxxxxx xx zkoušku. Xxxxx xxxxxxx xx xx xxxx skládat alespoň xx tří xxxxxxxxxxxxxxxx xxxxxx. Jestliže jsou xxxxxxxxxxx dostatečné xxxxxxxxx xxxxx, xx xxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxx xxxxx xxxxx až xxx xxxxxxx.
Xxxxxxxx xxxx x době xxxxxx x xxxxxxxxx xxxxx xx studií xx xxxxxxx druhem a xx xxxxxxx stejného xxxxxxx expozice, xxx xxxxxxxxx, xx neexistuje xxxx pohlavími rozdíl x xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx, nejlépe xxxxx. Xx-xx xxxxxxxx člověka xxxxxxxxxx xxx určité xxxxxxx, jako xx xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx by xxx xxxxxxx provedena se xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx.
1.5.3 Dávkování
Za xxxxxxxxxx xxxxxxxx se xxxxxxxxx xxxxxxx dvě xxxxxx xxxxx. Nejvyšší dávka xx xxxxxxxxxx xxxx xxxxx vyvolávající xxxxxx xxxxxx xxxxxxxx, xx xxxxx xxxxx by xxxxx xxxxx xxxxxxxxx xxx xxxxxxx xxxxxx xxxxxxxxx k xxxxxxxx. Xxxxx xxxxx by xxxx xxx zpravidla 50 % xx 25 % xxxxx xxxxx.
Xxxxx xx specifickou xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxx xx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx pro xxxxxxxx xxxxxxx, měla by xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, xxxxxxxx a xx xxxxxxxx režimu xxxxxxxx, xxx se xxxxxxx x xxxxxx xxxxxx.
Xxxxxxxx xxxxx xxxx xxx xxxxxxxxxx xxxx xxxx xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxx x xxxxxxx (xxxx. xxxxxxxxxx jádra).
1.5.4 Xxxxxxx zkouška
Jestliže xxxxxxx x xxxxxx xxxxxx x alespoň 2000 xx/xx xxxxxxx hmotnosti xxxxxxx xxxxxxxxxxx nebo xx xxxx xxxxxxx x jednom xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxxxx xxx xxxxx xxxxxx xxxxxxxx. Očekávaná xxxxxxxx člověka xxxx xxxxxxxx xxxxxxx xxxxxx x limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx látka xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, žaludeční sondou xxxx vhodnou xxxxxxxxx xxxxxxx. Xxxx xxxxxxx xxxxxxxx xxxx xxxxx, xxx-xx je zdůvodnit. Xxxxxxxx intraperitoneálně xx xxxx xxxxxxxxxxxx, xxxxx xx xxxxx xxxxx xxx xxxxxxxxxx zkoušené xxxxx xxxxx x xxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx. Xxxxxxxxx objem xxxxxxxx, který xxxx xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, závisí xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x tělesné hmotnosti. Xxxxxxx xxxxxxx xxxxxx, xxx xx uvedený xxxxx, musí xxx xxxxxxxxxx. Xx xx xxxxxxxx x žíravé xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx zesílené xxxxxx, xx měla být xxxxxxxxxxx zkušebního xxxxxx xxxxxxxxxxxxxx nastavením xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Příprava xxxxxxxxx xxxxx
Xxxxxxx buňky xx xxxxxxxxxx x exponovaných xxxxxx xxxxxxxxx 12 xx 16 hodin xx xxxxxx dávky. Xxxxxxxxxx dřívější xxxxxxxx xxxxxx (xxxxxx xxx xx čtyři hodiny xx xxxxxxxx) xx xxxxxxxx, xxxx-xx po 12 xx 16 xxxxxxxx xxxxx xxxxxxxxx xxxxxxx. Xxxxx xxxx xxx xxxxxxx xxxx xxxx odběru, xxxx-xx xxxxxxxxxx xx základě xxxxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxxx kultury xxxxxxxxx buněk savců xx xxxxxxxxx zakládají xxxxxxx xxxxx kolagenasou xx xxxx x xxxxxx xx, xxx xx čerstvě xxxxxxxxxxx xxxxxxx xxxxx zachytily xx xxxxxxx povrchu. Xxxxxxx xxxxx x xxxxxxxxx xxxxxxxx by xxxx vykazovat životaschopnost (5) xxxxxxx 50 %.
1.5.7 Stanovení XXX
Xxxxxxx xxxxxxxxx xxxxxxx xxxxx xxxxx se xxxxxxx xxxxxxx xxxx, xxxx. xxx až osm xxxxx, inkubují s xxxxxx obsahujícím 3X-XxX. Xx konci inkubační xxxx xx mělo xxx xxxxxx x xxxxx xxxxxxxxxx x xxxxx xxxx xxxxx xxx inkubovány x xxxxxx obsahujícím xxxxxxxx xxxxxxxxxxx xxxxxxxxx, xxx xxxx snížena xxxxxxxxxxxxxxx xxxxxxxxxxxxx ("xxxx xxxxx"). Xxxxx xx poté xxxxxxx, xxxxxx x xxxxxx. Xxx xxxxx xxxxxxxxx xxxx nemusí xxx snížení xxxxxxxxxxxxx xxxxxxxx. Xxxxxxxxx xx xxxxxx xx xxxxxxxxxxxxxxxxx xxxxxx, exponují se x temnu (např. x chladu 7 xx 14 xxx), xxxxxxxx xx, obarví x spočítají xx xxxxxxxxxx xxxx xxxxxxx. X xxxxxxx zvířete xx xxxxxxxx xxx xx tři preparáty.
1.5.8 Xxxxxxx
Xxxxxxxxx xx měly xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxx normálních xxxxx, xxx mělo xxxxxxxxx XXX výpovědní hodnotu. Xxxxxxxxx xx xxx xxxxxxxxxxx xxxxxxxxxx xx xxxxxx zjevné xxxxxxxxxxxx (xxxx. xx pyknosu, xxxxxxxx xxxxxx značení xxxxxxxxxxxxx izotopem).
Před xxxxxxxxx xxx xx xxxx xxx xxxxxxxxx kódovány. Xxxxxxxxx se vyšetřuje 100 xxxxx xx xxxxx xxxxx alespoň xx dvou xxxxxxxxx; xxxxxxxxx xxxx xxx 100 buněk/zvíře xx xxxx být zdůvodněno. Xxx xxxxxxxx xxx xx xxxxx x X-xxxx xxxxxxxxxxx, ale xxxxx buněk x X-xxxx xxxx být xxxxxxxxxx.
Xxxxxxxx 3H-TdR xxxxxxxxxxxxxxx xx xxxxx a xxxxxxxxxx morfologicky xxxxxxxxxx xxxxx xxxxxxxx xxxxxxxxxxx xxx xxxxxxx by xxxx být xxxxxxxxx xxxxxxx xxxxxxx.
Xxxxx xxxxx xx stanoví x xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx jádrŭm (xx) x z xxŭxxxxxxx xxxxx xxx v xxxxxxxxxxxxxxxxx oblastech (xx) xxxxxxxxxxxxxx xxxxŭx. xxxx xxxxxxx xx xx xxxxxxx buď xxxxx xxxxx xxx nejsilněji xxxxxxxxx xxxxxx cytoplasmy, xxxx xxŭxxxxx xxxxxxx xxxx xx xxx xxxxxxx vybraných oblastí x xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx. xx xxxxxxxxxxxxx xxXxxxxxxx xxxxx xxx xxxxxxx i xxxx xxxxxxx stanovení xxxxx buněk (xxxx. xxxxxxxx celých xxxxx) (6).
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxx xx xxx xxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxxxx x xxxxxxx. Údaje xx xxxx být xxxx xxxxxxx xx xxxxx xxxxxxx. Odečtením xxxxxxx XX od xxxxxxx XX xx xxx xxx xxxxxxxx xxx xxxxxx xxxxx, xxx xxxxx xxxxx x xxx xxxxxx dávku x xxx čistý xxxxx zrn xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XXX). Xxxxxxxx xxxx xxxxxxxx "xxxxxxxxxx" xxxxx, měla xx být xxxxxxxx xxx xxxxxxxxxx "opravovaných" xxxxx xxxxxxxxxx x xxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Xxxx-xx xxx xxxxxxx, měly by xxx xxxxxxxxxxx xxxxx xxxxxxx x odůvodněny xxxx provedením studie.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxxx příklady xxxxxxxx xxx xxxxxxxxx nebo xxxxxxxxx odpověď xxxxx:
|
xxxxxxxxx |
x) |
xxxxxxx XXX leží xxx xxxxxxxx xxxxxx, která xx zdůvodněna xx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxx; |
|
xxxx |
xx) |
xxxxxxx NNG je xxxxxxxx vyšší xxx xxxxxxx xxx xxxxxxxxx xxxxxxxx; |
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx xx xxxxxxxxx prahové xxxxxxx xxxx xxx xx; |
|
xxxx |
xx) |
xxxxxxx NNG xxxx xxxxxxxx xxxxx než xxxxxxx xxx souběžnou xxxxxxxx. |
Xxxx xx xxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, xx. xxxx xx být xxxxx x xxxxx xxxxxxxxx, xxxx xxxx xxxxxxxxxxx xxxxxx, xxxxx dávky x xxxxxxxx x xxxxxxxxxxxx. Xxx hodnocení xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx jako xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx významnost xx xxxx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx jasně xxxxxxxxx xxxx negativní výsledky, x ojedinělých xxxxxxxxx xxxxxxxx xxxxxx údajů xxxxxxxx konečný výrok x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx mohou xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx xx XXX v jaterních xxxxxxx xxxxx xx xxxx znamenají, xx xxxxxxxx xxxxx indukuje x xxxxxxxxx buňkách xxxxx xx xxxx xxxxxxxxx XXX, které xxx xxxxxxx xxxxxxxxxxxx xxxxxxxx DNA xx xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx XXX, které xxx xxxxxxxxx touto xxxxxxxx.
Xxxx xx být xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxx xxxxx xxxx. xx xxxxxx xxxxx (např. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX X ZKOUŠCE
Protokol x xxxxxxx musí obsahovat xxxx informace:
Rozpouštědlo/vehikulum:
- zdůvodnění xxxxx vehikula,
- xxxxxxxxxxx x stálost zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx xxxxxxx:
- xxxxxxx xxxx/xxxx,
- počet, xxxxx x xxxxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, strava xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx počátku xxxxxxx, xxxxxx xxxxxxx tělesné xxxxxxxxx, xxxxxxx hodnoty x xxxxxxxxxx xxxxxxxx xxx xxxxxx skupinu.
Zkušební xxxxxxxx:
- pozitivní x xxxxxxxxx (vehikulum/rozpouštědlo) xxxxxxxx,
- xxxxx xx xxxxxx xxx zjištění rozsahu, xxxxx byla xxxxxxxxx,
- xxxxxxxxxx zvolených xxxxxx xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx látky,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- zdůvodnění xxxxxxx xxxxxxxx,
- popřípadě xxxxxx ověření, xxx xx zkoušená látka xxxxxxx do krevního xxxxx xxxx do xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx mezi xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx nebo xxxx (xxx) xx odpovídající xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- podrobné xxxxx x xxxxxxx krmiva x xxxx,
- podrobný xxxxx rozvrhu xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- metody xxxxxxxx x xxxxxxxxx xxxxxxxxx buněk,
- xxxxxxx xxxxxxxxxxxxxxxxx technika,
- xxxxx xxxxxxxxx x xxxxx xxxxxxxxxxx buněk,
- xxxxxxxx xxxxxxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxxx xxxxxxx počtu xxx odpovídajících xxxxxxxx xxxxxx a xxxxx xxx xxxxxxxxxxxxxx cytoplasmě, x čistý xxxxx xxx, xxxxxxxxxx pro xxxxxxxxx, xxxxxxx a xxxxxxx,
- podle xxxxxxxx xxxxxxxxx odpovědi na xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxxxx,
- xxxxxx xxxxxxxx,
- xxxxx o xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) a pozitivní xxxxxxxx s xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- počet xxxxx "opravovaných" xxxxx, xx-xx stanoven,
- xxxxx xxxxx x X-xxxx, xx-xx xxxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx výsledků.
Závěry.
4. LITERATURA
1) Xxxxx, X. Xxxxxxx, X. X., Burlinson, X., Penman, X. X. (1985), Xx Xxxxxxxxxx of xxx Xx vivo Xxx. Xxxxxxxxxx XXX Repair Xxxxx, Xxxxxxxxxx Xxx., 156, 1-18.
2) Butterworth, X. E., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X., Mirsalis, X., Xxxxxx, G., Xxxxxxxx, G. (1987), X Xxxxxxxx and Xxxxx xxx the Xx xxxx Rat Xxxxxxxxxx XXX Xxxxxx Xxxxx, Xxxxxxxxxx Xxx., 189, 123-133.
3) Xxxxxxxx, X. C., Xxxxxx, X., Ashby, X., Xxxxxxx, P. A., Xxxxxxxxx, X., Xxxxxxx, X. X., Dean, X. X., Xxxxxxxx, X. xx G. (1993), Xx xxxx Xxx Xxxxx UDS Xxxxx, xx: Xxxxxxxx X. X., Xxx X., (xxx), Xxxxxxxxxxxxx Xxxxxxxxxxxx Tests: UKEM Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx on Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Part II xxxxxxx, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 52-77.
4) Xxxxx, X., Dean, X. X., Andrac, X., Brambilla. X., Xxxxxxxxx, B., Doolittle, X. J., Xxxxxxxx, X., Xxxxxxx, X., XxXxxxx, X. X., Xxxx, X. (1993), Xxxxxxxxxxxxxxx xxx xxx Xxxxxxxxxxx xx UDS Xxxxx In xxxxx xxx Xx xxxx, Xxxxx. Xxx., 312, 263-285.
5) Xxxxx, X., Xxxxxxx, X., Efstathiou, X., Xxxxxxxxxxxx-Xxxxxx, C. (1993), Assessment xx xxx Xxxxxxxx Xxxxxxx xxx Xxxxxxx Xxxxxxxxx xxx xxx Xxxxxxxxxx xx Freshly Isolated Xxx Xxxxxxxxxxx Xxxx xxx xxx Xx xxxx/Xx xxxxx DNA Xxxxxx Xxxxx (XXX), Xxxxxxxxxx Xxx., 291, 21-27.
6) Xxxxxxxx, X. X., Tyson, X. X., Butterworth, B. X. (1982), Detection xx Genotoxic Xxxxxxxxxxx xx xxx In xxxx/Xx xxxxx Hepalocyte XXX Xxxxxx Xxxxx, Xxxxxxx.Xxxxxxx. 4, 553-562."
XXXXXXX 5
XXXXXX XXXXXXXXX XX XXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXXXX XXXXX X PŘÍPRAVKŮ
Viz směrnice Xxxxxx 2001/59/XX, Úř. xxxx. L 332, 28. 12. 2000, x. 81.
XXXXXXX 6
"
PŘÍLOHA XX
XXXX X
xxxxxxxx xxxxxxxx se xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx
Xxxxx xxxxxxxxxx xx. 22 odst. 1 písm. x) xxxx směrnice, xxxx xxx xxxxx x xxxxxxxxx xxxxxx obsahující xxxxx, x xxxxx xx xxxxxxx xxxxxx xxx vdechování (Xx; X 65) a xxxxx xxxx xxxxxxxxxxxxx x označeny xxxxx xxxx 3.2.3 přílohy XX xxxx xxxxxxxx, x výjimkou xxxxx xxxxxxxxx xx xxx xx xxxxx aerosolů xxxx v xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx, xxxxxxxx xxxxxxx xxxxxxxx xxxxx otevření xxxxx.
1. Xxxxxxxxx xxxxxxxxxxxx obaly
Uzávěry xxxxxx xxxxx otevření xxxxx xxxxxxx xx xxxxxxxxx uzavíratelných obalech xxxx splňovat požadavky xxxxx ISO 8317 (xxxxxx xx dne 1. července 1989) "Xxxxx xxxxxx xxxxx — Xxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxx jejich xxxxxxxx" xxxxxxxx Xxxxxxxxxxx xxxxxxxxxx xxx xxxxxxxxxxx (XXX).
2. Xxxxxxxxx xxxxxxxxxxxxxx xxxxx
Xxxxxxx odolné proti xxxxxxxx dětmi xxxxxxx xx opakovaně neuzavíratelných xxxxxxx musí xxxxxxxx xxxxxxxxx xxxxx CEN XX 862 (xxxxxx x března 1997) "Xxxxx — Obaly xxxxxx dětem — Xxxxxxxxx x xxxxxxxx xxxxxxx pro xxxxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxx xxx farmaceutických výrobků" xxxxxxxx Xxxxxxxxx xxxxxxx xxx xxxxxxxxxxx (CEN).
3. Xxxxxxxx
1. Xxxxxxxxx xxxxx x xxxx uvedenými xxxxxxx xxxxx xxxxxxxxxx xxxxx laboratoře, které xxxxxxx evropské xxxxx xxxx EN 45000.
2. Xxxxxxxxxx případy
Je-li zřejmé, xx obal je xxxxxxxxxx bezpečný xxx xxxx, xxxxx xx xxxxxxx xxxxxx x xxxxxx bez pomoci xxxxxxxx, nemusí být xxxxxxx xxxxxxxxx.
Xx xxxxx xxxxxxxxx případech x xxxxx xxxxxxxx xxxxxxxxx xxxxxx k xxxxxxxx x xxxxxxxxxxx xxxxxxx xxx xxxx, může xxxxxxxxxxxx xxxxx xxxxxxxxx, xxx xxxxx xxxxxxxxx xx xxxxxxx xxxxxxx xx xxx xxxxxxxxxx xxxxxxxxxx vydaný laboratoří xxxxx odst. 3 xxxx 1 xxxxxxxxxxxx, xx xxx
- xxx xxxxxxx je takový, xx xxx xxxx xxxxxxxx xxxxxxx xxxxx xxxx uvedených xxxxx XXX x CEN,
nebo
- xx xxxxxx xxx xxxxxxx x xxx xxxxxxx vyhovujícím podle xxxx uvedených xxxxx.
XXXX X
Xxxxxxxx xxxxxxxx xx xxxxxxxxxxxx výstrah
Technické xxxxxxxxxxx xxx xxxxxxxxxx xxxxxxxx xxxx xxx x xxxxxxx x normou XX XXX 11683 (xxxxxx z xxxx 1997) "Xxxxx — Xxxxxxxxxx výstrahy xxxx xxxxxxxxxx — Požadavky".
"